netFormulary
 Report : A-Z of formulary items 20/11/2019 07:40:11
[Back]
 
Section Name Details
08.01.05 Arsenic Trioxide Trisenox®

Use in line with NICE 

07.03.04 Rubber contraceptive diaphragms - Type A Diaphragm with Flat Metal Spring  Flat spring diaphragm sizes 55–95mm (rising in 5mm)
10.02.01 3,4,diaminopyridine (3,4-DAP) 

Hospital use only 

10.01.03 Abatacept Orencia® Hospital Use Only
02.09 Abciximab  Hospital Use Only
08.03.04.02 Abiraterone Tablets Zytiga®
04.10.01 Acamprosate Campral EC®
02.08.02 Acenocoumarol Sinthrome®
02.02.07 Acetazolamide  Intracranial hypertension
Unlicensed indication
11.06 Acetazolamide  Amber Formulary Status Specialist ophthalmologist recommendation - Acetazolamide M/R capsules and tablets
Red Hospital OnlyAcetazolamide 500mg injection
12.01.01 Acetic Acid 2% Earcalm ® As per Antibiotic Formulary
03.07 Acetylcysteine  Tablets
Sachets
11.08.01 Acetylcysteine 10% eye drops 
11.08.01 Acetylcysteine 5% & hypromellose 0.35%. Ilube
13.10.03 Aciclovir Zovirax®
11.03.03 Aciclovir 3% eye ointment Zovirax®
13.05.02 Acitretin Neotigason®
03.01.02 Aclidinium Eklira Genuair® For COPD only
16.08.07 Actico®  Cohesive inelastic high compression bandage. Short stretch bandage
Rationale (developed by TV Team)
Type of wound product is suitable for
Venous leg ulceration
Lymphoedema
Management of chronic oedema
Duration dressing remains on wound before changing
Daily to 7 days
Frequency of dressing change
Dependant on exudate levels if wound present or oedema management.
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Not recommended on those patients with an ABPI lower than 0.8.
Caution in diabetic patients
Caution when cardiac overload or renal failure present or suspected.
Rationale for inclusion in formulary
Only cohesive short stretch bandage. Nurses competent in its usage.
16.02.01 ActiForm Cool  Hydrogel Sheet
Rationale (developed by TV Team)
Type of wound product is suitable for
Necrotic or sloughy wounds that require hydration and cooling pain relief
Can be used on dry wounds with the backing left in place
Cut to shape of the wound
Requires a secondary dressing
Duration dressing remains on wound before changing
1-3 days if dressings become discoloured or opaque or at first signs of exudate strike through
Frequency of dressing change
If dressing becomes discoloured or opaque or at first signs of exudate strike through. Do not allow to dry out
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Should not be used as a covering for deep narrow cavities or sinuses.
Do not use on infected wounds.
Not suitable for heavily exuding wounds
Known product or component sensitivity
Not for application on ischaemic wounds
Rationale for inclusion in formulary
Dry necrotic, sloughy or painful wounds
For ease of application - sheet gel rather than liquid
Primary dressing
Can be used prior to larval therapy to maintain moisture levels
16.03.01 Actilite (Honey Dressing)  Specialist recommendation
Non-adherent viscose net dressing 99% Manuka honey and 1% Manuka oil.
Type of wound product is suitable for
A primary dressing for low to moderate shallow exuding wound with light slough. Granulating or
epithelialising wounds with clinical signs of infection. Requires a secondary dressing.
Max Duration dressing remains on wound before changing
3-7 Days
Frequency of dressing change
3 to 7 days depending on exudate
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Known allergy to Bee Venom and Honey products
Blood sugars should be monitored in patients with diabetes
Stinging sensation may be experienced. If unacceptable for patient then discontinue.
Rationale for inclusion in formulary
For antimicrobial and de-sloughing properties
Ease of application
Can be cut to size
Easy removal in one piece
Availability of different sizes
Not found to be harmful to peri-wound skin
Malodour
Cost effective
16.02.05 ActivHeal Foam  Podiatry only
Specialist recommendation
Two layer dressing consisting of a polyurethane bacterial barrier membrane with a centrally located hydrophilic pad +/- acrylic adhesive border.
Rationale (developed by TV Team)
Type of wound product is suitable for
Moderately exuding wounds with signs of granulation, epithelialisation or slough.
Can be used as primary or secondary
Duration dressing remains on wound before changing
1-7 days
Frequency of dressing change
Up to 7 days dependent on exudate levels
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Full thickness burns
Surgical implantations
Rationale for inclusion in formulary
Cost effective
Simple to use on the foot and digits
Can be cut to shape
16.02.05 ActivHeal Foam Tracheostomy  Specialist recommendation
Tracheostomy foam dressing
Rationale (developed by TV Team)
Type of wound product is suitable for
ActivHeal Foam Tracheostomy dressing has a fenestration, which allows the dressing to fit neatly around a tracheostomy tube. The dressing can also be used around intubation and cannula insertion procedures, external bone fixators and appropriately-sized wound drainage tubes.
Duration dressing remains on wound before changing
Dependant on clinical need and soiling
Frequency of dressing change
Up to 7 days, dependant on clinical need and soiling
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Do not use if reaction to any of its components
Rationale for inclusion in formulary
Specific dressing shaped and able to cut for tracheostomies.
Cost effective
16.03.01 Activon Tube (Honey)  Specialist recommendation
100% medical grade Manuka Honey.
Type of wound product is suitable for
Use as topical treatment for infected sloughy shallow or cavity wounds. Primary or addition to other Activon products. Requires secondary dressing.
Max Duration dressing remains on wound before changing
Up to 4 days
Frequency of dressing change
Daily in acute infection
Up to 4 days in chronic infection dependant on exudate
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Wounds with active blood loss
Known allergies to bee Venom and Honey products
Blood sugars should be monitored in diabetic patients
Stinging sensation may be experienced – discontinue if not tolerant.
Rationale for inclusion in formulary
Anti-microbial and de-sloughing properties
Control of odours
Benefit of adding to other action products and increasing honey
Suitable for use in cavities
Cost effective
16.03.01 Activon Tulle (Honey Dressing)   Specialist recommendation
Knitted viscose mesh impregnated with 100% Manuka Honey.
Type of wound product is suitable for
Creates a moist healing environment effectively eliminates odour. Provides anti-microbial action.
Debrides and de-sloughs shallow wounds where the exudate level has started to decrease. Requires secondary dressing
Max Duration dressing remains on wound before changing
Up to 4 days
Frequency of dressing change
Daily in acute infection
Up to 4 days for chronic infection depending on exudate
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Wounds with active blood loss
Known allergies to bee Venom and Honey products
Blood sugars should be monitored in diabetic patients
Stinging sensation may be experienced – discontinue if not tolerant.
Rationale for inclusion in formulary
Anti-microbial and de-sloughing properties for wounds with reduced levels of exudate.
Control of odours
Ease of application and removal in one piece
Can be cut to size
Available to various size
Cost effective
10.01.03 Adalimumab Humira® Hospital Use Only
11.08.02 Adalimumab Humira®

Use in line with NICE

13.05.03 Adalimumab Humira® Use in line with NICE TA146
13.06.01 Adapalene Differin® Avoid in pregnancy
13.06.01 Adapalene with benzoyl peroxide Epiduo® 1st line topical therapy for mild to moderate acne vulgaris.
Used in preference to antimicrobial agents.
09.05.02.01 Addiphos ®  
02.03.02 Adenosine Injection 
02.07.03 Adrenaline / Epinephrine  Hospital Use Only
03.04.03 Adrenaline / Epinephrine   Jext ® and Epipen®
08.01.05 Afatinib Giotrif®

Use in line with NICE

08.01 Aflibercept Zaltrap®
11.08.02 Aflibercept Eylea® Use in line with NICE
09.08.01 Agalsidase Alpha Infusion  NHSE commissioned
04.03.04 Agomelatine Valdoxan® Supported with a RICaD
09.02.02.02 Albumin Solution 
08.02.03 Alemtuzumab 

In line with NICE 

06.06.02 Alendronic Acid 70mg effervescent tablets Binosto® £££
Third line option in individuals who have not tolerated first line alendronate tablets and second line risedronate tablets and in whom a bone-sparing agent is still considered clinically necessary.
06.06.02 Alendronic Acid Tablets 
09.06.04 Alfacalcidol One-Alpha®
09.06.04 Alfacalcidol Injection 
15.01.04.03 Alfentanil  Injection
Intensive care - High strength - Palliative Care Team recommendation during end of life care only.
Nasal spray (unlicensed)- Palliative Care Team during end of life care for the relief of incident pain
07.04.01 Alfuzosin 
07.04.01 Alfuzosin Hydrochloride MR tablets 
16.03.01 Algivon (Honey Dressing)  Specialist recommendation
Alginate dressing impregnated with 100% Manuka Honey.
Type of wound product is suitable for
Primary dressing for infected, shallow cavity wounds, particularly if necrotic or malodorous with
moderate exudate. Requires secondary dressing.
Max Duration dressing remains on wound before changing
Up to 4 days for chronic infection
Frequency of dressing change
Daily for acute infection
Up to 4 days for chronic infection/depending upon exudate
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Wounds with active blood loss
Known allergy to be venom and honey products
Blood sugars should be monitored in diabetic patients
Stinging sensation may be experienced – discontinue if not tolerated
Rationale for inclusion in formulary
Antimicrobial and de sloughing properties
Absorbent
Malodour
Ease of application and removal in one piece
Can be cut to size
Available in various sizes
Can be shaped to wound size and depth
Cost effective
09.08.01 Alglucosidase Alfa Myozyme® NHSE commissioned
03.04.01 Alimemazine (trimeprazine)   For children as per guidance
02.12 Alirocumab Praluent® To be used in line with NICE TA 393
02.05.05.03 Aliskiren Rasilez® Supported by RICaD
13.05.01 Alitretinoin Toctino® Use in line with NICE TA 177
16.03.03 Allevyn Ag  Specialist use- dressing for pin sites only - HOSPITAL USE ONLY
A non adherent foam dressing impregnated with silver sulphadiazine that can be cut to suit the patient
Rationale (developed by TV Team)
Type of wound product is suitable for
For use around infected pin sites
Duration dressing remains on wound before changing
Daily or as directed
Frequency of dressing change
Daily
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Patients who have a known sensitivity to Silver Sulphadiazine or Sulphonamides
Females who are at or near full term pregnancy or lactating
Not for use on neonates or new born infants during the first month of life
Rationale for inclusion in formulary
Used around infected pin sites in patients with external metalwork to help reduce bacterial load
HOSPITAL USE ONLY
16.02.05 Allevyn Cavity  Specialist recommendation
Foam dressing
Available in adhesive, non adhesive and gentle

Rationale (developed by TV Team)
Type of wound product is suitable for
Wound management by secondary intention on acute, chronic, full thickness or partial thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds surgical wounds, malignant wounds donor sites and fungating ulcers
Can be used as a primary or secondary dressing
Duration dressing remains on wound before changing
Can stay in place up to 3-7 days
Frequency of dressing change
Dependent on exudate levels
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
In common with all adhesive products, some cases of irritation and/or maceration of the skin may occur.
It should be noted that inappropriate use or too frequent dressing changes, particularly in patients with fragile skin, can result in skin stripping. If this occurs change to the Allevyn gentle border range.
If redness or sensitisation occur, discontinue use
Caution under compression when exudate levels are moderate to high.
Rationale for inclusion in formulary
Can be used for low to moderate exudate levels
Different sizes and shapes available
Cost effective
16.02.05 Allevyn Non-adhesive  Foam dressing
Available in adhesive, non adhesive and gentle

Rationale (developed by TV Team)
Type of wound product is suitable for
Wound management by secondary intention on acute, chronic, full thickness or partial thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds surgical wounds, malignant wounds donor sites and fungating ulcers
Can be used as a primary or secondary dressing
Duration dressing remains on wound before changing
Can stay in place up to 3-7 days
Frequency of dressing change
Dependent on exudate levels
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
In common with all adhesive products, some cases of irritation and/or maceration of the skin may occur.
It should be noted that inappropriate use or too frequent dressing changes, particularly in patients with fragile skin, can result in skin stripping. If this occurs change to the Allevyn gentle border range.
If redness or sensitisation occur, discontinue use
Caution under compression when exudate levels are moderate to high.
Rationale for inclusion in formulary
Can be used for low to moderate exudate levels
Different sizes and shapes available
Cost effective
16.02.05 Allevyn range (excluding Silver)   **As per local procurement contracts**
Foam dressing
Available in adhesive, non adhesive and gentle
Rationale (developed by TV Team)
Type of wound product is suitable for
Wound management by secondary intention on acute, chronic, full thickness or partial thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds surgical wounds, malignant wounds donor sites and fungating ulcers
Can be used as a primary or secondary dressing
Duration dressing remains on wound before changing
Can stay in place up to 3-7 days
Frequency of dressing change
Dependent on exudate levels
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
In common with all adhesive products, some cases of irritation and/or maceration of the skin may occur.
It should be noted that inappropriate use or too frequent dressing changes, particularly in patients with fragile skin, can result in skin stripping. If this occurs change to the Allevyn gentle border range.
If redness or sensitisation occur, discontinue use
Caution under compression when exudate levels are moderate to high.
Rationale for inclusion in formulary
Can be used for low to moderate exudate levels
Different sizes and shapes available
Cost effective
16.02.03 Allevyn®Life  Specialist recommendation
Hydrocellular foam dressing
Rationale (developed by TV Team)
Type of wound product is suitable for
Shallow granulating wounds, acute and chronic exuding wounds, full and partial thickness wounds
such as leg ulcer, malignant wound, surgical wound.
Primary dressing
Silicone adhesive
Duration dressing remains on wound before changing
Up to 7 days dependent on dressing indicators
Frequency of dressing change
Up to 3 times a week maximum
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Do not use with oxidising agents such as hypochlorite solutions or hydrogen peroxide
Discontinue if reddening or sensitivity occurs.
Do not cut
Caution under compression where exudate levels are moderate to high
Rationale for inclusion in formulary
Fragile skin with absorbency and conformability, problematic healing wounds. Odour control.
09.05.01.01 Alliance Calcium Syrup  Calcium sandoz is discontinued
10.01.04 Allopurinol 
06.01.02.03 Alogliptin Vipidia® 1st line choice
07.01.01.01 Alprostadil Prostin VR®
07.04.05 Alprostadil cream  Vitaros® Specialist initiation
For patients who would otherwise use alprostadil injection.
07.04.05 Alprostadil Intracavernosal injection  
02.10.02 Alteplase  Hospital Use Only
13.12 Aluminimum Salts 
09.05.02.02 Aluminium Hydroxide  Specialist recommendation
04.09.01 Amantadine Hydrochloride Symmetrel® Capsules
Syrup - for patients with swallowing difficulties
02.02.03 Amiloride Hydrochloride  Tablets
Oral solution
Caution with ACE inhibitors. A weak diuretic
03.01.03 Aminophylline Phyllocontin Continus®
03.01.03 Aminophylline Injection Phyllocontin Continus® Hospital only
02.03.02 Amiodarone Hydrochloride Tablets 
  • Specialist initiation
  • 02.03.02 Amiodarone Injection 
    04.02.01 Amisulpride  Supported by ESCA
    Tablets
    Solution
    04.03.01 Amitriptyline  Tablets
    SF Solution - £££
    04.07.03 Amitriptyline  1st line
    Off label use
    Low abuse Low cost
    04.07.04.02 Amitriptyline 
    02.06.02 Amlodipine Maleate 
    13.10.02 Amorolfine 5% nail lacquer  ££
    03.12 Amoxicillin nebulised  Hospital only
    03.12 Amphotericin Fungizone® Hospital only
    11.03.02 Amphotericin (eye) 
    16.20 Anabact (metronidazole gel)  Specialist recommendation
    Pale yellow, clear gel containing 0.75% metronidazole
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Malodourous fungating wounds
    Requires a secondary dressing
    Duration dressing remains on wound before changing
    Apply 1-2 times daily following cleansing
    Frequency of dressing change
    1-2 times daily for a maximum of 8 weeks.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Avoid exposure to strong sunlight or UV light
    Not to be used on a patient with known sensitivity to any components
    Avoid contact with eyes
    Not for use of any other aetiology of wound as odour control.
    Rationale for inclusion in formulary
    Odour control for fungating tumours
    09.01.04 Anagrelide Capsules Xagrid®
    10.01.03 Anakinra Kineret® Hospital Use Only
    08.03.04.01 Anastrozole 
    03.01.04 Anoro® Ellipta® 55/22mcg (multi dose dry powder inhaler device)  In line with COPD Guidance
    13.08.01 Anthelios XL cream Melt- in cream SPF 50+

    ACBS Criteria:
    Protection from UV radiation in abnormal cutaneous photosensitivity resulting from genetic disorders or photodermatoses, including those resulting from radiotherapy and chronic or recurrent herpes simplex labialis. 

    Preparations with SPF less than 30 should not normally be prescribed

    14.05.03 Anti-D (Rh0) Immunoglobulin 
    08.02.02 Anti-human thymocyte immunoglobulin (rabbit)  Thymoglobuline®
    02.08.02 Apixaban Eliquis BSSE APC preferred agent
    This recommendation must only be taken into account after a patient and prescriber have discussed all treatment options (including warfarin) and only if they have no preference about which medicine they want to use.

    RedUse following Hip and Knee surgery – Full course of treatment supplied on discharge
    Amber Formulary StatusFollowing diagnosis of AF – use in line NICE and toolkit, initiation/recommendation by haematologist, transfer to GP with RICaD
    Amber Formulary StatusFor the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/recommendation by haematologist, transfer to GP with RICaD
    04.09.01 Apomorphine  Supported with a ESCA
    Pen & Injection
    16.21 Appeel Adhesive Remover  Adhesive remover available in 4 different applications
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Adhesive dressing or appliance removal where skin stripping, loss of skin integrity and pain is a concern
    Sachet – suitable for larger dressing removal
    Wipes – ideal for adhesive around tubes
    Foam applicator – ideal for infants or use of the face
    Spray, single patient, multiple use product for all dressings and/or urinary sheath removal
    Duration dressing remains on wound before changing
    Use at each dressing change
    Frequency of dressing change
    N/A
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Should not be used when there is a known sensitivity to any of the ingredients
    If in doubt, patch test a small area, prior to use
    The product is flammable and should be used in a well ventilated area
    Avoid use around, flames and sources of ignition
    Rationale for inclusion in formulary
    For pain free removal of dressings where fragile skin is a concern
    11.08.02 Apraclonidine  Apraclonidine 0.5% eye drops
    Apraclonidine 1% eye drops (preserv-free) - only PF sympathomimetic
    10.01.03 Apremilast Otezla® Use in line with NICE TA 433
    13.05.03 Apremilast 

    Use in line with NICE Use in adults is commissioned by CCGs

    04.06 Aprepitant Emend® For use with chemotherapy only
    16.03.03 Aquacel Ag Plus Extra range   Specialist recommendation
    Hydrofibre with silver
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Management of clinically infected, sloughy, necrotic or granulating wounds with moderate to heavy exudate.
    Moderate to highly exuding wounds.
    Aquacel Ag Plus Extra can be used to break down biofilms
    Requires a secondary dressing
    Duration dressing remains on wound before changing
    Dependent upon exudate 1 - 7 days
    Frequency of dressing change
    Dependent upon level of exudate and clinical presentation
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Should not be used on individuals who are sensitive to or have had an allergic reaction to the dressing or its components.
    Not suitable for dry wounds.
    No haemostatic properties.
    Rationale for inclusion in formulary
    Specialist antimicrobial product
    Moderate to high exudate levels
    Can be used to break down biofilms
    Remains intact on wound bed and easily removable in one piece (non dispersible)
    16.02.04 Aquacel range (excluding Silver)   Hydrofibre
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Moderate to heavy exudate, sloughy, necrotic or granulating wounds. Available in rope for cavities
    b>Duration dressing remains on wound before changing
    Maximum 7 days
    Frequency of dressing change
    1-7 days depends on clinical need
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not suitable for dry wounds. Non dissolvable.
    Known product or component sensitivity
    Do not cut
    Rationale for inclusion in formulary
    Aids debridement of slough or necrotic tissue
    Remains intact so easily removed in one piece
    Absorbs exudate which aids most wound healing facilitating atraumatic dressing change,
    Cost effective
    16.02.06 Aquacel range (excluding Silver)  Rationale (developed by TV Team)
    Type of wound product is suitable for
    Moderate to heavy exudate, sloughy, necrotic or granulating wounds. Available in rope for cavities
    Duration dressing remains on wound before changing
    Maximum 7 days
    Frequency of dressing change
    1-7 days depends on clinical need
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not suitable for dry wounds. Non dissolvable.
    Known product or component sensitivity
    Do not cut
    Rationale for inclusion in formulary
    Aids debridement of slough or necrotic tissue
    Remains intact so easily removed in one piece
    Absorbs exudate which aids most wound healing facilitating atraumatic dressing change,
    Cost effective
    13.02.01 Aquadrate® 
    16.02.01 Aquaform Hydrogel  Alternative to Granugel
    Hydrogel: Clear viscose sterile gel
    Aids autolytic debridement and removal of devitalised tissue.
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Low exuding, necrotic or sloughy wounds
    Duration dressing remains on wound before changing
    Up to 3 days
    Frequency of dressing change
    1-3 days
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not suitable for heavily exuding wounds. Caution known product or component sensitivity.
    Full thickness burns or infected wounds
    Not for application to ischaemic wounds
    Rationale for inclusion in formulary
    Required for wound beds that need donation of moisture to rehydrate the wound bed and debride. Cost effective
    04.02.01 Aripiprazole Abilify® Supported by ESCA
    The GP should be given a rationale for prescribing rather than first line antipsychotics
    Approved for use in Tourette's syndrome
    15.02 Articaine Hydrochloride with Adrenaline Septanest® For dental use only.
    09.06.03 Ascorbic Acid 
    04.02.03 Asenapine 
    09.08.01 Asfotase alfa 

    Use in line with NICE

    Highly Specialised

    02.09 Aspirin (antiplatelet) 
    04.07.01 Aspirin 300mg dispersible tablets   Topical analgesia - for gargling
    02.04 Atenolol 
    04.04 Atomoxetine Strattera® Please note that commissioning discussion is underway. However the present status is as follows:-
    Red Birmingham CrossCity CCG, Birmingham South Central CCG, Sandwell & West Birmingham CCG
    Amber Traffic Light Supported with an ESCA - Solihull CCG.
    02.12 Atorvastatin Tablets 
    07.01.03 Atosiban Tractocile®
    15.01.05 Atracurium Besilate Injection 
    16.01.01 Atrauman   First line
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For flat granulating and epithelising wound for non to heavy exudate where adherence may occur. To be used as a primary dressing with a secondary for absorption.
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    1-7 days, depending on levels of exudate
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known product or component sensitivity
    Rationale for inclusion in formulary
    Used to reduce adherence to wound bed. Most cost effective non adherent dressing.
    Dressing impregnated with neutral triglycerides to prevent penetration of granulation tissue.
    Petroleum free.
    16.03.03 Atrauman Ag  Specialist recommendation
    Non adherent Primary Dressing containing metallic silver
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For clinically infected shallow, granulating wounds with low exudate. To be used as a primary dressing with a secondary for absorption.
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    1-7 days, depending on levels of exudate
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known product or component sensitivity
    Must be removed prior to x-ray, ultrasound, diathermy and MRI
    Rationale for inclusion in formulary
    Used to reduce adherence to wound bed with clinical signs of infection
    Most cost effective non adherent dressing containing silver.
    Dressing impregnated with neutral triglycerides to prevent penetration of granulation tissue.
    Petroleum free.
    Specialist Use Only
    15.01.03 Atropine  Amber Formulary StatusSF Solution
    Amber Formulary StatusTablets - For Myaesthenia Gravis only
    Red Hospital OnlyInjection
    11.05 Atropine Sulphate  0.5% & 1% eye drops
    1% Single Use Drops - Specialist ophthalmologist recommendation - use by glaucoma surgeons for neovascular glaucoma
    13.02.01 Aveeno Cream®  Green £££ - Paediatrics Only
    Amber Formulary Status £££ - Recommended by specialist for oncology use only
    10.01.03 Avelumab Bavencio®

    Hospital Use Only Use in line with NICE

    07.04.05 Aviptadil 25mcg / Phentolamine 2mg intracavernosal injection Invicorp®

     

    • Approved on formulary December 2017
    • Specialist initiation. 
    • 3rd line after oral PDE-5 inhibitors failed and patient not responding to or intolerant of alprostadil. 
    • To be reviewed within 12 months to assess alprostadil supply issues and patent expiry 
    06.01.06 Aviva testing strips  

    Glucose test strips to be used with the Accu-Chek Aviva Expert

    Meter for initiation by specialist centres only GP can Prescribe strips in line with specialist recommendations

    08.01.05 Axitinib Inlyta® This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Red Formulary Status
    Red Formulary Status

    Not Present on this Formulary

    Amber Formulary Status
    Amber Formulary Status
    08.01.03 Azacitidine Injection 
    03.12 Azathioprine  To be administered in conjunction with prednisolone (plain tablets)
    Supported by ESCA
    08.02.01 Azathioprine  Red Tablets & Suspension (Unlicensed special - £££)
    Red Hospital Only Injection
    10.01.03 Azathioprine  Supported with an ESCA
    13.05.03 Azathioprine  Specialist initiation and stabilisation
    Supported with an ESCA (under development)
    13.06.01 Azelaic Acid 15% gel Finacae®
    13.06.01 Azelaic Acid 20% cream  Skinoren®
    11.04.02 Azelastine Optilast® 3rd line
    12.02.01 Azelastine and fluticasone Dymista Third line option for adults and children over 12 years with moderate to severe allergic rhinitis if treatment with oral antihistamine, nasal antihistamine or nasal corticosteroid alone or in combination has failed

    Follow treatment algorithm (to follow)
    11.03.01 Azithromycin Azyter® 1st line for Ophthalmic Chlamydia
    17.05 B. Braun Medical Actreen Lite Male  Gender - Actreen Lite Male
    Order code - 228208E – 228218E
    Gauge/CH size - 8 to 18
    Usual quantity - 30 every month (1 pack per month)
    Review period – Every 3 months
    17.05 B. Braun Medical Actreen Mini Female  Gender - Actreen Mini Female
    Order code - 228010E to 228014E
    Gauge/CH size - 10 to 14
    Usual quantity - 30 every month (1 pack per month)
    Review period – Every 3 months
    10.02.02 Baclofen  Tablets
    SF liquid
    10.02.02 Baclofen Injection  Hospital Only
    11.08.01 Balanced Salt Solution   Theatre use
    13.02.01.01 Balneum Plus ® Bath Oil  £££
    13.02.01 Balneum® Plus cream 
    03.01.01.01 Bambuterol Bambec® Specialist initiation for severe brittle asthma / CF
    17.03 Bard Biocath Hydrogel coated Foley catheter  Gender - Male
    Order code - D2265 – D2266
    Gauge/CH size - 12 - 26
    Usual quantity - One every 12 weeks
    Review period - Before each Rx or if catheter life less than 4 weeks
    Gender - Female
    Order code - D2269
    Gauge/CH size - 12 - 22
    Usual quantity - One every 12 weeks
    Review period - Before each Rx or if catheter life less than 4 weeks
    17.06 Bard Flip Flo catheter Valve  Order code - BFF5
    Pack size - 5
    Usual quantity - 5 valves (1 pack) per month
    Review period – Weekly (at every catheter change)
    17.03 Bard Lubri-sil Aquafil Hydrogel Coated Silicone   With pre-filled syringe of sterile water; suitable for patients with latex allergy.
    Gender - Standard/Male
    Order code - D175812-22E
    Gauge/CH size - 12 to 22
    Usual quantity - One every 12 weeks
    Review period - Before each Rx or if catheter life less than 4 weeks
    Gender - Female
    Order code - D176112-16E
    Gauge/CH size - 12 – 16
    Usual quantity - One every 12 weeks
    Review period - Before each Rx or if catheter life less than 4 weeks
    10.01.03 Baricitinib Olumiant®

    Hospital Use Only

    Use in line with NICE

    08.02.02 Basiliximab Injection 
    08.02.04 BCG bladder instillation 
    14.04 BCG vaccine diagnostic agent 
    14.04 BCG vaccine Intradermal 
    07.04.04 BCG-medac bladder instillation 
    03.02 Beclometasone and formoterol Fostair® Fostair Aerosol inhalation - Beclometasone dipropionate 100 micrograms & Formoterol fumarate 6 micrograms
    Fostair Aerosol inhalation - Beclometasone dipropionate 200 micrograms & Formoterol fumarate 6 micrograms
    Fostair NEXThaler® (= dry powder inhalation) - Beclometasone dipropionate 100 micrograms & Formoterol fumarate 6 micrograms
    Fostair NEXThaler® (= dry powder inhalation) - Beclometasone dipropionate 200 micrograms & Formoterol fumarate 6 micrograms
    03.02 Beclometasone Dipropionate Clenil Modulite®
    12.02.01 Beclometasone Dipropionate  First Line
    03.02 Beclometasone/formoterol/glycopyrronium Trimbow®®

    TRIPLE COMBINATION INHALER

    Beclometasone/formoterol/glycopyrronium inhaler

    (Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution)

    Use inline with COPD guidnace - Criteria for triple therapy and for triple inhaler use in COPD

    03.04.02 Bee and Wasp Allergen Extracts Pharmalgen® Hospital only
    08.02.02 Belatacept Infusion 
    08.01.01 Bendamustine 
    02.02.01 Bendroflumethiazide  2.5mg dose (higher doses not indicated in hypertension)
    Most patients do not develop hypokalaemia. Suggest check potassium level one month after initiation and annually thereafter. (MeReC 10/94)
    15.02 Benzocaine 20% Gel Ultracare® Bubble Gum
    13.06.01 Benzoyl Peroxide 
    13.06.01 Benzoyl Peroxide 5% with Clindamycin 1% Duac® Once Daily
    12.03.01 Benzydamine  Benzydamine 0.15% oral rinse
    Benzydamine 0.15% oral spray
    04.06 Betahistine Dihydrochloride 
    09.08.01 Betaine anhydrous powder  NHSE commissioned
    06.03.02 Betamethasone 
    13.04 Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic® Potency: potent
    Ointment
    Scalp application
    13.04 Betamethasone (as Valerate) 0.025% Betnovate-RD® Potency: moderate
    Cream
    Ointment
    13.04 Betamethasone (as Valerate) 0.1% Betnovate® Potency: potent
    Cream
    Ointment
    Scalp application
    13.04 Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet® Steroid potency: potent
    11.04.01 Betamethasone 0.1%  Eye drops
    Eye ointment
    12.01.01 Betamethasone 0.1% with Neomycin 0.5% ear drops 
    11.04.01 Betamethasone 0.1% with Neomycin 0.5% eye drops  Short term use only
    13.04 Betamethasone Dipropionate 0.064% with Clotrimazole 1% Lotriderm® Potency: potent
    12.01.01 Betamethasone ear drops 
    12.02.01 Betamethasone Sodium Phosphate 
    11.06 Betaxolol Betoptic® Specialist ophthalmologist recommendation
    0.25% ophthalmic suspension
    0.5% eye drops
    0.5% unit dose eye drops

    07.04.01 Bethanechol Chloride Myotonine®
    08.01.05 Bevacizumab Infusion Avastin®
    11.08.02 Bevacizumab intravitreal injection Avastin®
    08.01.05 Bexarotene Capsules 
    02.12 Bezafibrate  Immediate release formulation
    Modified release formulation
    16.02.05 Biatain dressings  Podiatry use only
    Specialist recommendation
    Polyurethane foam dressing with bevelled edges
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Moderately exuding wounds with signs of granulation, epithelialisation or slough.
    Can be used as primary or secondary
    Duration dressing remains on wound before changing
    1-7 days
    Frequency of dressing change
    Up to 7 days dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use with oxidising solutions such as hydrogen peroxide
    Full thickness burns
    Surgical implantations
    Rationale for inclusion in formulary
    Simple to use on the foot and digits
    Can be cut to shape
    08.03.04.02 Bicalutamide Tablets 
    11.06 Bimatoprost Lumigan® Specialist Ophthalmologist Recommendation.
    11.06 Bimatoprost with Timolol Ganfort® Specialist Ophthalmologist Recommendation
    12.03.05 Biotene Oralbalance®  Approved for ACBS condition
    Dry mouth (xerostomia)
    For patients suffering from dry mouth as a result of having (or having undergone) radiotherapy, or sicca syndrome.
    Palliative Care
    Dental practitioners
    06.01.01.02 Biphasic Insulin Aspart NovoMix® 30 Prescribe by BRAND name
    06.01.01.02 Biphasic Insulin Lispro Humalog® Mix 25 & 50 Prescribe by BRAND name
    06.01.01.02 Biphasic Isophane Insulin Humulin® M3 Prescribe by BRAND name
    06.01.01.02 Biphasic Isophane Insulin Insuman® Comb Comb 15
    Comb 25
    Comb 50
    Prescribe by BRAND name
    12.04 Bismuth Iodine Paraffin Paste BIPP ®
    12.02.03 Bismuth subnitrate and iodoform  
    12.04 Bismuth Subnitrate and Iodoform Paste for Gauze  
    02.04 Bisoprolol 
    02.08.01 Bivalirudin Angiox® Hospital Use Only
    07.04.04 Bladder cocktail urological solution 
    08.01.02 Bleomycin Injection 
    13.07 Bleomycin intra-lesional 
    08.02.03 Blinatumomab Blincyto®

    In line with NICE 

    06.01.06 Blood Glucose Meter (Accu-Chek Aviva Expert)® 

    ££

    Meter for initiation by specialist centres only.  

    Category 3 meter

    For patients using insulin pumps or those who have been taught carbohydrate counting

    Training on the correct use, storage and recording of the readings should be provided by the issuing clinician

    06.01.06 Blood Glucose Meter (Accu-Chek Mobile)® 

    Category 2 meter

    Restricted use: Meter restricted for use in patients with needle phobia, paediatrics, visual impairments, and physical impairments requiring single- handed use.  

    For patients with type 2 diabetes or with gestational diabetes

    Training on the correct use, storage and recording of the readings should be provided by the issuing clinician

    06.01.06 Blood Glucose Meter (CareSens Dual) ®

    Category 1 meter

    For patients with type 1 diabetes who need to monitor their blood glucose and blood ketone levels.

    Training on the correct use, storage and recording of the readings should be provided by the issuing clinician

    06.01.06 Blood Glucose Meter (Freestyle Optium Neo)® 

    ££

    Restricted use: Meter restricted for use on the advice of specialist care only.

    Category 1 meter

    For patients with type 1 diabetes who need to monitor their blood glucose and blood ketone levels.

    Training on the correct use, storage and recording of the readings should be provided by the issuing clinician

    06.01.06 Blood Glucose Meter (GlucoMen Areo 2K) ®

    PREFERRED FIRST LINE Category 1 meter

    For patients with type 1 diabetes who need to monitor their blood glucose and blood ketone levels.

    Training on the correct use, storage and recording of the readings should be provided by the issuing clinician

    06.01.06 Blood Glucose Meter (Tee2+)® 

    PREFERRED FIRST LINE Category 2 meter

    For patients with type 2 diabetes or with gestational diabetes

    Training on the correct use, storage and recording of the readings should be provided by the issuing clinician

    06.01.06 Blood Glucose Meter (Wavesense Jazz Wireless meter)® 

    FOR SMARTPHONE USERS Category 2 meter

    For patients with type 2 diabetes or with gestational diabetes

    Training on the correct use, storage and recording of the readings should be provided by the issuing clinician

    08.01.05 Bortezomib Injection Velcade®
    02.05.01 Bosentan Tracleer® Hospital Use Only
    NHS England commissioned
    08.01.05 Bosutinib Bosulif®

    In line with NICE Hospital only- NHSE commissioned

    04.07.04.02 Botulinum Toxin Type A botox® Use in line with NICE
    07.04.02 Botulinum toxin Type A 
    13.12 Botulinum toxin type A   For hyperhidrosis
    04.09.03 Botulinum Toxin Type A Injection Botox® To be prescribed by brand.
    14.04 Botulism antitoxin 
    08.01.05 Brentuximab Injection 
    13.06.03 Brimonidine 3mg/g gel (Mirvaso ®)  Approved by BSSE APC - Nov 14
    One application per 24 hours, at any time suitable for the patient
    11.06 Brimonidine Tartrate  Specialist ophthalmologist recommendation
    11.06 Brimonidine Tartrate 0.2% with Timolol 0.5% Combigan® Specialist ophthalmologist recommendation
    11.06 Brinzolamide Azopt® Specialist ophthalmologist recommendation
    11.06 Brinzolamide 1% and brimonidine 0.2% Eye drops Simbrinza® Specialist ophthalmologist recommendation
    11.06 Brinzolamide 1% with Timolol 0.5%  Azarga® Specialist ophthalmologist recommendation
    04.08.01 Brivaracetam Briviact®

    Amber Traffic Light Brivaracetam Tablets and 10 mg/ml oral solution

    • Initiation by Tertiary Epilepsy Specialist only. 
    • Supported with ESCA
    • For adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with severe refractory epilepsy warranting tertiary specialist input for patients who have tried three or more AEDs. The patient has used levetiracetam and has documentation of intolerance and patient is using a third line agent (perampanel, zonisamide, lacosamide, eslicarbazepine) which would be replaced by brivaracetam.


    Red Hospital Only Brivaracetam 10 mg/ml solution for injection/infusion

    10.01.03 Brodalumab Kyntheum ®

    Hospital Use Only Use in line with NICE

    06.07.01 Bromocriptine 
    03.02 Budesonide  Budesonide Inhaler
    Budesonide Nebulised Solution
    03.02 Budesonide and formoterol DuoResp Spiromax®® DuoResp Spiromax 160/4.5 is therapeutically equivalent to Symbicort Turbohaler 200/6
    DuoResp Spiromax 320/9 is therapeutically equivalent to Symbicort Turbohaler 400/12
    03.02 Budesonide and formoterol Symbicort®
  • For asthma only

  • Non-Formulary for COPD
  • 17.14 Bullen Actibrief Plus Male with 10 pouches  Order code - ABPlus/18/20 to ABPlus/18/40
    Usual quantity - 2 pairs per 6 months
    Pouches 1 per 5-7 days (30 pouches per 6 months)
    02.02.02 Bumetanide  Monitor potassium level. Indicated in pulmonary oedema. Need large doses in renal failure
    15.02 Bupivacaine and Adrenaline 
    15.02 Bupivacaine Hydrochloride  Injection
    Infusion (epidural)
    15.02 Bupivacaine Hydrochloride with Glucose Marcain Heavy®
    15.02 Bupivacaine with Fentanyl 
    04.07.02 Buprenorphine Temgesic®
    04.07.02 Buprenorphine patch  Specialist initiation - specialist pain clinics, palliative care and for patients with swallowing difficulties.
    Supported with a RICaD (under development)
    Patches must be prescribed by BRAND
    04.10.03 Buprenorphine S/L tablets 
    04.10.02 Bupropion Hydrochloride  Tier 2
    06.07.02 Buserelin  For assisted conception
    Nasal Spray & Injection
    08.03.04.02 Buserelin nasal spray 
    04.01.02 Buspirone Hydrochloride  Tier 2 - £
    08.01.01 Busulfan  Red Tablets
    Red Hospital Only Infusion
    16.02.02 C View   Vapour-permeable adhesive film
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Dry non infected wounds, retention of lines, fixation of secondary dressings, protection of intact skin, protection of skin against friction, protection of newly epithelialised wounds
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    Up to 7 days
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Clinically infected wounds, bleeding or exuding wounds
    Rationale for inclusion in formulary
    Retention of lines, protection of intact skin, fixation of other dressings.
    Waterproof
    16.02.02 C- View post op  Vapour-permeable adhesive film with absorbent pad
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Dry non infected wounds, low exuding wounds, minor burns, protection of intact skin, protection of newly epithelialized wounds
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    Up to 7 days
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Clinically infected wounds, bleeding or exuding wounds
    Rationale for inclusion in formulary
    Protection of intact skin, low exuding wounds.
    Waterproof
    03.04.03 C1 Esterase Inhibitor Cinryze ®, Berinert® Hospital only
    NHS England commissioned
    08.01.05 Cabazitaxel Infusion 
    06.07.01 Cabergoline 
    08.01.05 Cabozantinib Cabometyx®

    Use in line with NICE

    13.14.03 Cade oil 12% w/w and salicylic acid 6% w/w in emulsifying ointment  BAD recommended quantity = 100g
    03.05.01 Caffeine  Hospital only
    13.03 Calamine aqueous cream 
    13.03 Calamine Lotion 
    13.05.02 Calcipotriol 
    Ointment
    Scalp solution - £££
    13.05.02 Calcipotriol 50micrograms/g with Betamethasone 0.05% Dovobet® Gel
    Ointment
    Step down to Calcipotriol oint as per NICE CG153

    Maximum 15g per day or 100g per week.
    Use for four weeks and then assess.
    Subsequent courses repeated after an interval of at least 4 weeks.
    13.05.02 Calcipotriol 50micrograms/g with Betamethasone 0.05mg/g Enstilar® Alternative option, 1st line
    Excipients include liquid paraffin and butane-
    Extremely flammable aerosol
    06.06.01 Calcitonin (salmon) / Salcatonin  Calcitonin injection (salmon)
    Calcitonin nasal spray (salmon)
    09.06.04 Calcitriol 
    13.05.02 Calcitriol 3micrograms/g ointment Silkis Specialist recommendation for delicate areas, face and flexures
    09.06.04 Calcium Carbonate with Colecalciferol   theiCalD3 - BCC CCG local choice. Agreed at August 2016 MMG
    Adcal-D3 - ALL preparations
    Cacit® D3
    09.05.01.01 Calcium Chloride Injection 
    08.01 Calcium Folinate  This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Red Formulary Status
    Red Formulary Status

    Red Formulary Status
    Red Formulary Status

    Amber Formulary Status
    Amber Formulary Status
    09.05.01.01 Calcium Gluconate Injection 
    09.05.01.01 Calcium Salts Adcal®
    09.05.01.01 Calcium Salts  Calcichew®
    09.05.02.02 Calcium Salts Calcium-500 Phosex® Specialist recommendation
    09.05.02.02 Calcium Salts Osvaren® Specialist recommendation
    06.01.02.03 Canagliflozin  To be used in line with NICE guidance
    02.05.05.02 Candesartan 
    13.09 Capasal® 
    08.01.03 Capecitabine Tablets 
    12.03.05 Caphosol®  Oncology & haematology use
    10.03.02 Capsaicin Zacin®, Axsain® Tier 2
    £££
    04.07.03 Capsaicin cream 0.075%  Only strength licensed for post-herpetic neuralgia and diabetic peripheral polyneuropathy.
    02.05.05.01 Captopril  For existing patients only
    04.07.03 Carbamazepine  Trigeminal neuralgia only
    04.08.01 Carbamazepine  Tablets
    MR tablets
    SF liquid
    APC Preferred Brand = Tegretol
    MHRA Category 1 - Doctors are advised to ensure that their patient is maintained on a specific manufacturer’s product
    06.02.02 Carbimazole Neo-Mercazole® Neutropenia and agranulocytosis
    Doctors are reminded of the importance of recognising bone marrow suppression induced by carbimazole and the need to stop treatment promptly.
    Patient should be asked to report symptoms and signs suggestive of infection, especially sore throat.
    A white blood cell count should be performed if there is any clinical evidence of infection.
    Carbimazole should be stopped promptly if there is clinical or laboratory evidence of neutropenia.
    03.07 Carbocisteine 
    16.02.08 CarboFLEX  Specialist recommendation
    Odour absorbent wound contact dressings containing activated charcoal
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For the management of moderate to heavily exuding malodorous wounds including fungating
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    As exudate level determines
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to the dressing or its components
    As soon as CarboFlex becomes contaminated with exudate, odour control diminishes
    The underlying cause of wound odour should be identified prior to commencement of product
    Rationale for inclusion in formulary
    CarboFLEX is a layered dressing to provide higher levels of fluid handling
    On shallow or cavity wounds with moderate to heavy levels of exudate
    11.08.01 Carbomers Clinitas® Non BAK
    11.08.01 Carbomers Xailin Gel®
    11.08.01 Carbomers Viscotears® Liquid gel
    Single dose units - £££
    08.01.05 Carboplatin Injection 
    07.01.01 Carboprost 
    06.01.06 CareSens PRO blood glucose test strips 

    Glucose test strips to be used with the CareSens Dual meter

    08.01.05 Carfilzomib Kyprolis®

    Use in line with NICE

    09.08.01 Carglumic Acid Carbaglu® NHSE commissioned
    11.08.01 Carmellose Xailin Fresh
    11.08.01 Carmellose 1% MULTI (Moorfields)  
    12.03.01 Carmellose Sodium Orabase®
    12.03.01 Carmellose Sodium Orahesive®
    08.01.01 Carmustine 
    09.08.01 Carnitine  NHSE commissioned
    L-carnitine Chewable tablet & Liquid
    L-carnitine Injection
    02.04 Carvedilol  Second Line
    07.04.04 Catheter Patency Solutions - Chlorhexidine 
    07.04.04 Catheter Patency Solutions - Sodium chloride 0.9% 
    17 Cath-It (Richardson HC)  Order code - 908420
    13.02.02 Cavilon Durable Barrier Cream  Skin protectant
    When used in the context of wound management
    Type of wound product is suitable for
    Intact skin
    As a barrier against bodily fluids, prevention of skin damage associated with incontinence
    Can be used alongside containment products
    Can be used to prevent friction to vulnerable areas of skin
    Duration dressing remains on wound before changing
    Reapply Twice daily
    Frequency of dressing change
    Reapply sparingly twice daily
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use on infected skin
    Not be used as an emollient
    Not to be used around the peri wound
    Can increase adherence of some dressing products and therefore care should be taken when adhesive products are being used in conjunction with the cream on people with fragile skin
    Rationale for inclusion in formulary
    The only barrier cream that can be used in conjunction with containment products without blocking the absorption of the pad
    Cost effective, does not require reapplication at every episode of hygiene
    16.15 Cavilon Durable Barrier Cream   Skin protectant
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Intact skin
    As a barrier against bodily fluids, prevention of skin damage associated with incontinence
    Can be used alongside containment products
    Can be used to prevent friction to vulnerable areas of skin
    Duration dressing remains on wound before changing
    Reapply Twice daily
    Frequency of dressing change
    Reapply sparingly twice daily
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use on infected skin
    Not be used as an emollient
    Not to be used around the peri wound
    Can increase adherence of some dressing products and therefore care should be taken when adhesive products are being used in conjunction with the cream on people with fragile skin
    Rationale for inclusion in formulary
    The only barrier cream that can be used in conjunction with containment products without blocking the absorption of the pad
    Cost effective, does not require reapplication at every episode of hygiene
    13.02.02 Cavilon No Sting Barrier Film Pump Spray and applicators  Protective transparent barrier film
    When used in the context of wound management
    Type of wound product is suitable for
    Superficial broken skin and abrasions
    As a barrier against bodily fluids, prevention of skin damage associated with incontinence
    Can be used alongside containment products
    Can be used to prevent friction to vulnerable areas of skin
    Can be used on superficial abrasions caused by incontinence
    Can be used to protect peri wound from exudate
    Can be used to protect against aggressive adhesive products
    Can be used to protect the skin surrounding stoma sites
    Duration dressing remains on wound before changing
    Up to 72 hours
    Frequency of dressing change
    Every 72 hours
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use on infected skin
    Allow product to dry before applying the containment products, dressings or clothing (30 seconds)
    Too many layers can make the area of skin feel stiff
    Can affect electrode readings in the treated area
    Rationale for inclusion in formulary
    Available in a foam applicator and spray to aid application
    Non sticky after use
    Can be used on broken areas of skin
    Cost effective, does not require reapplication at every episode of hygiene
    16.15 Cavilon No Sting Barrier Film Pump Spray and applicators   Protective transparent barrier film
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Superficial broken skin and abrasions
    As a barrier against bodily fluids, prevention of skin damage associated with incontinence
    Can be used alongside containment products
    Can be used to prevent friction to vulnerable areas of skin
    Can be used on superficial abrasions caused by incontinence
    Can be used to protect peri wound from exudate
    Can be used to protect against aggressive adhesive products
    Can be used to protect the skin surrounding stoma sites
    Duration dressing remains on wound before changing
    Up to 72 hours
    Frequency of dressing change
    Every 72 hours
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use on infected skin
    Allow product to dry before applying the containment products, dressings or clothing (30 seconds)
    Too many layers can make the area of skin feel stiff
    Can affect electrode readings in the treated area
    Rationale for inclusion in formulary
    Available in a foam applicator and spray to aid application
    Non sticky after use
    Can be used on broken areas of skin
    Cost effective, does not require reapplication at every episode of hygiene
    17.15 Cavilon spray/foam applicator  Order code - 3346P
    Usual quantity - Start with 1 pack; check patient tolerance, usage and prescribe as appropriate.
    03.12 Ceftazidime nebulised  Hospital only
    11.03.01 Cefuroxime 5% eye Drops and Powder  Unlicensed
    Ophthalmologists only
    03.12 Cefuroxime nebulised  Hospital only
    10.01.01 Celecoxib Celebrex® CVD risk assessment required
    Supported by RICaD (in development)
    16.08.07 Cellona  Specialist recommendation
    Sub compression wadding bandage to pad and shape a limb prior to compression therapy

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Provides padding for larger limbs under compression.
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    Daily up to weekly dependant on exudate and oedema management.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Advised not to apply directly to skin as can cause irritation.
    Rationale for inclusion in formulary
    Cost effective for use in larger quantities when used in lymphoedema management.
    08.01.05 Ceritinib Zykadia®

    Use in line with NICE

    10.01.03 Certolizumab Pegol Cimzia® Hospital Use Only
    12.01.03 Cerumol® 
    03.04.01 Cetirizine 
    13.02.01 Cetraben emollient cream ® 
    16.14 Cetraben Pump Cream  Rationale to support use in the context of wound management.
    Emollient containing white soft paraffin and light liquid paraffin
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For inflamed, dry, chapped skin
    Duration dressing remains on wound before changing
    Reapply daily
    Frequency of dressing change
    Daily
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or hypersensitivity to any of the ingredients
    Rationale for inclusion in formulary
    Treatment of dry skin
    Dermatology approved
    06.07.02 Cetrorelix Cetrotide®
    08.01.05 Cetuximab Injection Erbitux®
    04.01.01 Chloral Hydrate 
    08.01.01 Chlorambucil Tablets 
    11.03.01 Chloramphenicol  0.5% eye drops - 1st line
    1% eye ointment
    0.5% Eye Drops (Minims- Preservative free)
    12.01.01 Chloramphenicol EAR drops  Only with positive culture/sensitivity data
    13.11 Chlor-clean Tablets  This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Green Formulary Status
    Green Formulary Status

    Not Present on this Formulary

    Not Present on this Formulary
    04.01.02 Chlordiazepoxide  For alcohol withdrawal.
    Chlordiazepoxide hydrochloride capsules
    Chlordiazepoxide hydrochloride tablets - £££
    04.10.01 Chlordiazepoxide  Adjunct in acute alcohol withdrawal
    12.03.04 Chlorhexidine Gluconate  Green Chlorhexidine gluconate 0.2% mouthwash
    Red Chlorhexidine gluconate 1% dental gel
    13.11.02 Chlorhexidine Gluconate   Chlorhexidine gluconate preparations
    13.11.02 Chlorhexidine Gluconate 0.015% with Cetrimide 0.15% Travasept 100®
    12.02.03 Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin®
    03.04.01 Chlorphenamine 
    04.02.01 Chlorpromazine  Supported by ESCA
    Tablets
    Syrup
    Injection
    04.06 Chlorpromazine Hydrochloride  Nausea, hyperemesis in pregnancy (off label)
    02.02.01 Chlortalidone Tablets 
    09.06.04 Cholecalciferol and calcium phosphate sachets Calfovit D3®
    14.04 Cholera vaccine Dukoral® via travel vaccine service
    12.03.01 Choline Salicylate Bonjela® Adult
    07.04.04 Chondroitin sulphate  Chondroitin sulfate urological solution
    06.05.01 Choriogonadotropin Alfa Ovitrelle® Hospital use only
    06.05.01 Chorionic Gonadotrophin  Hospital use only
    16.04.02 Cica care   Specialist recommendation (burns)
    Silicone sheet for scar treatment
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Not for use on open wounds- to be applied on healed scar only.
    This is not a dressing but a scar treatment
    Duration dressing remains on wound before changing
    23 hours
    Frequency of dressing change
    Daily
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use on open or infected wounds
    Do not use on skin affected by acne
    Discontinue use if a rash or itching occur
    Rationale for inclusion in formulary
    Scar therapy
    Silicone sheets have been shown to soften, flatten scarring aiding movement, nerve sensations and function.
    Self adherent, Re-usable
    03.02 Ciclesonide Alvesco® For specialist use in Birmingham Region Severe Asthma Service sites initiation and continuation only.
    08.02.02 Ciclosporin  Red Capsules & Solution - Neoral - New post transplant
    Amber Formulary Status Capsules & Solution - Neoral - Post transplant pre 2013
    Red Hospital Only Infusion
    10.01.03 Ciclosporin  Supported with an ESCA
    11.08 Ciclosporin  Amber Formulary Status Ikervis® (Ciclosporin 1 mg/mL eye drops, emulsion) - Specialist initiation in line with NICE TA369
    Red Optimmune® (Ciclosporin 2mg/g eye ointment)
    13.05.03 Ciclosporin  Specialist initiation and stabilisation
    Supported with an ESCA (under development)
    09.05.01.02 Cinacalcet Mimpara® NHSE Funded for dialysis only
    04.06 Cinnarizine 
    12.01.01 Ciprofloxacin 0.3% drops  Specialist recommendation
    Off label of eye drops
    11.03.01 Ciprofloxacin 0.3% Eye Drops  Specialist ophthalmologist recommendation (Corneal consultants)
    15.01.05 Cisatracurium Nimbex®
    08.01.05 Cisplatin 
    04.03.03 Citalopram 

    Tier 2 

    Tablets
    Oral drops

    08.01.03 Cladribine Injection 
    08.02.04 Cladribine tablets Mavenclad®

    In line with NICE

    Hospital only- NHSE commissioned

    13.06.02 Clindamycin  Specialist initiation
    07.02.02 Clindamycin 1% gel  Zindaclin®

    To be reviewed in 12 months to assess clindamycin 1% solution supply issues.

    13.06.01 Clindamycin 1% gel Zindaclin®

    To be reviewed in 12 months to assess clindamycin 1% solution supply issues.

    07.02.02 Clindamycin 1% topical solution Dalacin T®
    13.06.01 Clindamycin 1% topical solution 
    16.08.03 CliniFast  Elasticated Sub bandage lining

    Rationale (developed by TV Team)
    Type of wound product is suitable for:
    To be used under retention and compression bandages when conformity is required
    Can be used for wet/dry wrapping.
    Duration dressing remains on wound before changing
    As required
    Frequency of dressing change
    As required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Ensure the correct size for a limb is selected
    Rationale for inclusion in formulary
    Cost effective choice when conformity to a limb is required
    17.09 Clinifix Tube Holder   Order code - 40-310
    Gauge/CH size - 10
    Usual quantity - 1 per week (1 box every 10 weeks)
    Review period – Before each Rx
    17.11 Clinimed Bioderm XLS (oval)  Has drainable plug which will fit most leg/night bags; remains for 3 days (alt to sheaths))
    Order code - 20026-10
    Usual quantity - 10 every month
    Review period – Before each Rx or if more than 30 used per month
    16.07.03 Clinipore  Permeable non woven, synthetic adhesive tape
    For securing bandages
    Rationale (developed by TV Team)
    Frequency of dressing change
    Determined by wound type and dressing change
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None listed
    Rationale for inclusion in formulary
    Available on drug tariff, cost effective and evaluated as meeting the requirements of a tape including adherence.
    16.02.08 Clinisorb   Specialist recommendation
    Odour absorbent charcoal dressing
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Malodourous wounds such as fungating wounds
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    1-7 days dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not indicated as a primary dressing in dry wounds
    Store at room temperature
    Exudate levels will reduce the effectiveness of the charcoal
    Rationale for inclusion in formulary
    Clinisorb is an activated charcoal dressing which adsorb toxins removing malodour from the wound
    Can be cut to size
    Cost effective
    04.08.01 Clobazam  MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history
    13.04 Clobetasol Propionate 0.05% Dermovate® Potency: very potent
    Cream
    Ointment
    Scalp application
    13.04 Clobetasone Butyrate 0.05% Eumovate® Potency: moderate
    Cream
    Ointment
    08.01.03 Clofarabine Injection 
    06.05.01 Clomifene Citrate  Specialiest recommendation - ovulation induction
    04.03.01 Clomipramine  Capsules
    MR tablets
    04.08.01 Clonazepam Injection  MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history
    04.08.01 Clonazepam Tablets  MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history
    02.05.02 Clonidine Hydrochloride Injection  Hospital Use Only
    02.05.02 Clonidine Hydrochloride Tablets 
    02.09 Clopidogrel 75mg Tablets 
    12.01.01 Clotrimazole Canesten® Only with positive culture/sensitivity data
    13.10.02 Clotrimazole  1% cream
    1% powder - groin and feet
    1% solution - hirsute “hairy” patients
    07.02.02 Clotrimazole - All formulations 
    04.02.01 Clozapine Clozaril® Only for emergency use in existing patients when inpatient at UHB.
    13.14.03 Coal tar BP 10% w/w in YSP  BAD recommended quantity = 100g
    13.14.03 Coal tar BP 2% w/w in YSP  BAD recommended quantity = 100g
    13.14.03 Coal tar BP 5% w/w in YSP  BAD recommended quantity = 100g
    13.09 Coal Tar Extract 5% (Alcoholic) Alphosyl 2 in 1®
    13.14.03 Coal tar scalp pomade  BAD recommended quantity = 100g
    Coal tar solution BP 6% w/w / salicylic acid 2% w/w in emulsifying ointment
    13.05.02 Coal Tar Solution 2.5%, Arachis (peanut) Oil extract of Coal Tar 7.5%, Tar 7.5%, Cade Oil 7.5%, Liqiud Paraffin 35% Polytar Emollient® Contains peanut oil
    13.05.02 Coal Tar Solution 5% Exorex®
    13.14.02 Coal tar solution BP 3.3% w/w and propylene glycol 20% w/w in Synalar® gel  BAD recommended quantity = 100g
    Use for very inflamed hyperkeratotic scalp psoriasis. Massage it into the affected scalp, leave for
    1-3 hours then shampoo out. Best done in the evenings.
    13.14.02 Coal tar solution BP 5% w/w in betamethasone valerate 0.025% w/w ointment  BAD recommended quantity = 100g
    Use for moderate to severe psoriasis of the trunk and limbs when other treatments such as Vitamin D analogues have been ineffective. Apply directly to affected skin once or twice daily (often as a night-time treatment) for 2-4 weeks then decrease the frequency of application.
    Use with caution if the skin is very inflamed or if there are pustules, as tar can be an irritant.
    13.14.03 Coal tar solution BP 6% w/w and salicylic acid 6% w/w in Ung. Merck  BAD recommended quantity = 100g
    02.02.04 Co-amilofruse (furosemide and amiloride)  Combination products should be avoided, unless compliance is an issue
    16.08.08 Coban
    Coban Lite
     
    Two layer compression system available in full and reduced compression (Coban Lite).
    Comprises of a latex free foam padding and cohesive bandage.

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Treatment of venous and mixed aetiology leg ulcers
    Duration dressing remains on wound before changing
    1 to 7 days
    Frequency of dressing change
    Daily up to weekly dependant on exudate and oedema management.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Arterial disease
    Not to be used with other padding or wadding
    Rationale for inclusion in formulary
    Two layer compression kit, Once applied the two layers form a band to become a single layer bandage.
    Bandage technique can be adapted to reduce forefoot oedema (Extra training required)
    04.09.01 Co-Beneldopa  Capsules
    MR Capsules
    Dispersible tablets
    15.02 Cocaine  Cocaine 10% solution
    Cocaine 25% paste
    Cocaine 5% nasal solution
    15.02 Cocaine with Adrenaline 
    04.09.01 Co-Careldopa  Tablets
    MR tablets
    04.09.01 Co-Careldopa and Entacapone Stalevo® Supported with a ESCA
    13.14.06 Coconut oil 25% w/w in emulsifying ointment  BAD recommended quantity = 100g
    Use as a scalp moisturiser and anti-inflammatory for the removal of thick scales in psoriasis, seborrhoeic dermatitis, pityriasis amiantacea and scalp atopic dermatitis, where commercial preparations such as Cocois® (40 g, £6.22) or SebcoTM (40 g, £4.54) have been inadequately effective. Rub firmly into scalp skin, leave overnight under a shower cap, and wash out next morning.
    13.06.02 Co-Cyprindiol 2000/35
    (Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms)
     
    Prescribe generically
    04.07.02 Codeine Phosphate Injection 
    04.07.02 Codeine Phosphate tablets  Tablets & Syrup 25mg/5ml
    10.01.04 Colchicine 
    09.06.04 Colecalciferol  Please see guidance listed below to support prescribing.
    Please prescribe generically as listed below
    Oral Capsules or Tablets
    Colecalciferol 800 unit capsules
    Colecalciferol 800 unit tablets
    Colecalciferol 1,000unit capsules
    Colecalciferol 1,000unit tablets
    Colecalciferol 3,200unit capsules
    Colecalciferol 4,000unit tablets
    Colecalciferol 20,000unit capsules
    Colecalciferol 25,000unit tablets
    Colecalciferol 40,000unit capsules
    Oral Solution
    Colecalciferol 2,740units/ml oral drops sugar free
    Colecalciferol 10,000units/ml oral drops sugar free
    Colecalciferol 10,000units/ml oral solution sugar free
    Colecalciferol 15,000units/5ml oral solution
    Colecalciferol 25,000units/1ml oral solution unit dose ampoules sugar free
    Colecalciferol 50,000units/1ml oral solution unit dose ampoules sugar free

    Licensed brands currently available (updated March 2017)
    Aviticol 800 IU Capsules
    Aviticol 1,000 IU Capsules (Listed in the Drug Tariff)
    Aviticol 20,000 IU Capsules
    Desunin 800 IU Tablets (Listed in the Drug Tariff)
    Desunin 4,000 IU Tablets (Listed in the Drug Tariff)
    Fultium-D3 800 IU Capsules (Listed in the Drug Tariff)
    Fultium-D3 3,200 IU Capsules (Listed in the Drug Tariff)
    Fultium-D3 20,000 IU Capsules (Listed in the Drug Tariff)
    Fultium-D3 2740 IU/ml oral drops, solution (Listed in the Drug Tariff)
    InVita D3 800 IU soft capsules
    InVita D3 2,400 IU/ml oral drops, solution
    InVita D3 25,000 IU oral solution (Listed in the Drug Tariff)
    InVita D3 50,000 IU oral solution (Listed in the Drug Tariff)
    Plenachol 20,000 IU Capsules
    Plenachol 40,000 IU Capsules (Listed in the Drug Tariff)
    Stexerol-D3 1,000 IU Tablets (Listed in the Drug Tariff)
    Stexerol-D3 25,000 IU Tablets (Listed in the Drug Tariff)
    STRIVIT-D3 800 IU Capsules
    THORENS 10 000 I.U. /ml oral drops, solution (Listed in the Drug Tariff)
    THORENS 25 000 I.U. /2.5 ml oral solution 
    09.05.02.02 Colestilan BindRen®

    NHSE Funded adult renal dialysis

    02.12 Colestyramine  Jaundice and Primary biliary cirrhosis (PBC)
    03.12 Colistimethate sodium   NHS England Commissioned for Cystic Fibrosis only
    Red New Patients

    Amber Formulary Status Existing patients (initiated prior to April 2013)
    Promixin® - Powder for nebuliser solution
    Colomycin® Injection may be used for nebulisation; administer required dose in 2-4 mL of sodium chloride 0.9%, (or water for injections) or a 1:1 mixture of sodium chloride 0.9% and water for injection
    Colobreathe® - Dry powder for inhalation, hard capsule (NICE TA276)
    10.03.01 Collagenase Xiapex® Await NICE Verdict
    17.09 Coloplast Aquasleeve   Small (leg circum. 24-33cms)
    Order code - 783678
    Gauge/CH size - 4
    Usual quantity - 4 every 6 months (1 pack per 6 months)
    Review period – Before each Rx
    Standard (34 -39cms)
    Order code - 783680
    Gauge/CH size - 4
    Usual quantity - 4 every 6 months (1 pack per 6 months)
    Review period – Before each Rx
    Medium (40-46cms)
    Order code - 783686
    Gauge/CH size - 4
    Usual quantity - 4 every 6 months (1 pack per 6 months)
    Review period – Before each Rx
    Large (47-64cms)
    Order code - 783694
    Gauge/CH size - 4
    Usual quantity - 4 every 6 months (1 pack per 6 months)
    Review period – Before each Rx
    Extra large (65cms+)
    Order code - 783708
    Gauge/CH size - 4
    Usual quantity - 4 every 6 months (1 pack per 6 months)
    Review period – Before each Rx
    17.06 Coloplast catheter valve  Order code - CV3808
    Pack size - 10
    Usual quantity - 10 valves (1 pack) every 2 months
    Review period – Weekly (at every catheter change)
    17.13 Coloplast Conveen Sheath liners  Order code - 5100
    17.03 Coloplast Folysil X-Tra Silicone Open Ended catheter   With pre-filled syringe for balloon inflation and empty syringe for balloon deflation pack of 1 (Male)
    Product - Standard/Male
    Order code - AA8C12/4/6/8
    Gauge/CH size - 12/14/16/18
    Usual quantity - One every 12 weeks
    Review period - Before each Rx or if catheter life less than 4 weeks
    17.05 Coloplast Speedicath Compact Plus Female catheter  Gender - Female
    Order code - 28810 – 28814
    Gauge/CH size - 10 to 14
    Usual quantity - 30 every month (1 pack per month)
    Review period – Every 3 months
    17.05 Coloplast Speedicath Sterile Pre-Hydrated Polyurethane catheter  Gender - Standard/Male
    Order code - 28408 to 28418
    Gauge/CH size - 8 to 18
    Usual quantity - 30 every month (1 pack per month)
    Review period – Every 3 months
    Gender - Female
    Order code - 28506 to 28516
    Gauge/CH size - 6 to 16
    Usual quantity - 30 every month (1 pack per month)
    Review period – Every 3 months
    06.04.01.01 Combined continuous HRT tablet Premique, Premique low dose, Indivina, Angelique, Climesse, Elleste Duet Conti, Kliofem, Kliovance, This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Present on this Formulary
    UHB does not commence oestrogens or HRT but will continue treatment for patients adimtted on these products in line with the Birmingham Women's Hospital Formulary.

    Green Formulary Status
    Green Formulary Status
    Suitable for post menopausal, non-hysterectomised women who have not had natural period for at least one year
    Premique ®
    Premique low dose ®
    Femoston-Conti ®
    Kliovance ®

    Amber Formulary Status
    Amber Formulary Status
    OESTROGENS FOR HRT

     

    BWHFT Formulary

    GREENAMBER                                    RED                                  
    Oral Period-Free Continuous Combined preparations
    Premique
    Premique low dose
    Femoston-Conti
    Kliovance
    Kliofem
    Femoston-conti 0.5mg/2.5mg
    Indivina® 1mg, 2mg,  1mg/2.5mg; 1mg/5mg and 2mg/5mg
    Angelique
    Climesse 
    Elleste Duet Conti
     
    Prescribing Advice
    Indivina® may be used when an estradiol and medroxyprogesterone acetate combination is required. Angelique may be used when an alternative progestogen is required contains Drospirinone
    Prescribed for postmenopausal women with intact uterus. Twelve months since LMP or aged 53 -54yrs
    06.04.01.01 Combined cyclical HRT tablet Elleste-Duet®, Femoston, Prempak-C, Premique cycle, Cycloprogynova, Trisequins, Tridestra This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Present on this Formulary
    But
    UHB does not commence oestrogens or HRT but will continue treatment for patients adimtted on these products in line with the Birmingham Women's Hospital Formulary.

    Green Formulary Status
    Green Formulary Status
    Prempak C ®
    Start with one month to ensure patient suitability, discussion of risks vs benefits essential
    Premique ® cycle
    Elleste-Duet ®
    Femoston ®

    Amber Formulary Status
    Amber Formulary Status
    Prempak C ®

     

    BWHFT Formulary

    GREENAMBER                                    RED                                  
    Oral Cyclical Combination Preparations
    Prempak C 0.625mg & 1.25mg
    Elleste- Duet 1mg & 2mg
    Femoston 1/10 & 2/10
    Cycloprogynova 2mg
    Trisequins
    Tridestra
     
    Prescribing Advice
    Cycloprognova and Tridestra have placebo Tablets or pill free days at the end of each 28 day cycle which can give return of symptomsaa
    07.03.01 Combined Hormonal Contraceptives NuvaRing® This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Amber Formulary Status
    Amber Formulary Status
    As per BWHFT Formulary.

    Present on this Formulary
    At HeFT this is not considered appropriate for initiation. HOWEVER if patients are stable on these medications there is no requirement to change them to an alternative.

    Amber Formulary Status
    Amber Formulary Status
    07.03.01 Combined Hormonal Contraceptives Qlaira® Only for Trinovum failure
    07.03.01 Combined Hormonal Contraceptives Evra Restricted to patients with compliance problems and metabolic problems
    07.03.01 Combined Hormonal Contraceptives Synphase®

    Phasic 21-day preparation

    Added to formulary May 2017 as alternative to Trinovum which was discontinued in 2016.  

    06.04.01.01 Combined HRT patch Evorel® Conti, Evorel® Sequi, Evra, FemSeven Conti, FemSeven Sequi This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Present on this Formulary
    UHB does not commence oestrogens or HRT but will continue treatment for patients adimtted on these products in line with the Birmingham Women's Hospital Formulary.

    Amber Formulary Status
    Amber Formulary Status
    When oral therapy inappropriate
    Evorel ® Sequi
    Evorel ® Conti


    Double Amber Formulary Status
    Double Amber Formulary Status
    Evra® - Double yellow £££– for women for whom neither an oral preparation nor a long acting reversible contraceptive technology is appropriate

    Amber Formulary Status
    Amber Formulary Status
    Oestrogens & HRT

     

    BWHFT Formulary

    GREEN                                        AMBER                             RED                                                                                         
    Transdermal Cyclical Combination Preparations
    Evorel Sequi
    Femseven Sequi
    Evra For women in whom neither an oral preparation or long acting reversible 
    contraceptive technology is appropriate
     
    Prescribing Advice
    Femseven Sequi may be considered if Evorel Sequi is not tolerated.
     
    Transdermal Period- Free Continuous Combined Preparations
    Evorel ContiFemseven Conti 
    Prescribing Advice
    Evorel® first line, may consider FemSeven ® if Evorel® not tolerated
    Prescribed for postmenopausal women with intact uterus. Twelve months since LMP or aged 53 -54yrs
    09.02.02.01 Compound Sodium Lactate Intravenous Infusion 
    16.08.07 Comprilan  Specialist recommendation
    100 % cotton short stretch compression bandage
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Venous leg ulceration
    Varicosis
    Management of chronic oedema
    Management of primary and secondary lymphoedema
    Deep venous thrombosis
    Thrombophlebitis

    Duration dressing remains on wound before changing
    1 to 7 days
    Frequency of dressing change
    Dependant on exudate levels if wound present or oedema management.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Advanced Peripheral arterial occlusive disease
    Decompensated cardiac insufficiency
    Septic phlebitis
    Phlegmasia coerula doleris
    Rationale for inclusion in formulary
    Cotton short stretch bandage. Used by lymphoedema nurse specialists
    03.04.03 Conestat Alfa Ruconest® Hospital only
    NHS England commissioned
    16.15 Conotrane cream  Barrier cream
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Intact skin, not to be applied to a wound.
    To protect the skin from moisture, irritation and chafing.
    Frequency of dressing change
    Application at every episode of hygiene. Apply a thin layer sparingly
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used in conjunction with containment products for incontinence due to the inclusion of liquid paraffin in the ingredients, this will repel urine/faeces back onto the skin.
    Any allergy to the listed ingredients
    Rationale for inclusion in formulary
    Dermatology approved
    13.02.02 Conotrane® Cream  Barrier cream
    When used in the context of wound management
    Type of wound product is suitable for:
    Intact skin, not to be applied to a wound.
    To protect the skin from moisture, irritation and chafing.
    Frequency of change
    Application at every episode of hygiene. Apply a thin layer sparingly
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used in conjunction with containment products for incontinence due to the inclusion of liquid paraffin in the ingredients, which will repel urine/faeces back onto the skin.
    Any allergy to the listed ingredients
    Rationale for inclusion in formulary
    Dermatology approved
    17.11 Conveen Optima (non-latex) self sealing Urisheath (standard length)  Short length is available
    Order code - 22025/28/30/35/40
    Gauge/CH size - 25/28/30/35/40mm
    Usual quantity - 30 every month
    Review period – Before each Rx or if more than 30 used per month
    17.12 Conveen Prep Wipes  Single use protective film wipes
    Order code - 62042
    Pack size - 54
    Usual quantity - 30 every month (1 pack per month)
    Review period – Before each Rx or if more than 30 used per month
    Note: If the above product is unsuitable please contact your local Continence Service for samples of alternative products.
    09.06.07 Copper (chelated) capsules 
    06.05.01 Corticorelin  Hospital use only
    16.08.03 Cotton Stockinette BP  Sub bandage lining

    Rationale (developed by TV Team)
    Type of wound product is suitable for:
    To be used under retention and compression bandages
    Duration dressing remains on wound before changing
    As required
    Frequency of dressing change
    As required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used under Coban compression therapy
    Not to be used under compression hosiery
    Does not conform to a limb shape. If conformity is required, choose Clinifast
    Rationale for inclusion in formulary
    Cost effective choice when conformity to a limb is not required
    08.01.05 Crisantaspase Injection 
    08.01.05 Crizotinib Capsules 
    13.03 Crotamiton Eurax®
    16.03.04 Cutimed Sorbact  Specialist recommendation
    DACC coated dressings providing antimicrobial properties, available in a pad, gel, gel sheet, ribbon, round swab and rectangular swab
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Colonised or clinically infected moist wound, suitable for any wound type
    Duration dressing remains on wound before changing
    1-3 days
    Frequency of dressing change
    1-3 days dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use in combination with oils and creams
    Known hypersensitivity to ingredients
    Not for dry wound
    Not for heavily exuding wounds
    Rationale for inclusion in formulary
    Alternative to available antimicrobials
    04.06 Cyclizine Valoid®
    04.06 Cyclizine injection  For palliative care use.
    11.05 Cyclopentolate Hydrochloride  0.5% and 1% eye drops
    0.5% and 1% Single Dose Units - Specialist ophthalmologist recommendation
    08.01.01 Cyclophosphamide 
    Red Tablets for oncology
    Red Hospital Only Injection
    06.04.02 Cyproterone Acetate 
    08.03.04.02 Cyproterone Acetate 
    08.01.03 Cytarabine  Injection
    Liposomal Injection
    02.08.02 Dabigatran Pradaxa® RedUse following Hip and Knee surgery – Full course of treatment supplied on discharge
    Amber Formulary StatusFollowing diagnosis of AF – use in line NICE and toolkit, initiation/recommendation by haematologist, transfer to GP with RICaD
    Amber Formulary StatusFor the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/recommendation by haematologist, transfer to GP with RICaD
    08.01.05 Dacarbazine Injection 
    08.02 Daclizumab Zinbryta® Use in line with NICE TA 441
    08.01.02 Dactinomycin Injection Cosmegen Lyovac®
    02.08.01 Danaparoid Orgaran® Hospital Use Only
    06.07.02 Danazol  Benign fibrocystic breast disease
    06.07.02 Danazol  Hereditary angiodema (off label)
    10.02.02 Dantrolene 
    15.01.08 Dantrolene Sodium Dantrium Intravenous®
    06.01.02.03 Dapagliflozin  To be used in line with NICE guidance
    08.01.05 Daratumumab Darzalex ®

    Use in line with NICE

    09.01.03 Darbepoetin Alfa Aranesp® NHSE commissioned Renal dialysis
    CCG Commissioned for use in cancer - NICE TA 323
    08.01.05 Dasatinib Tablets 
    08.01.02 Daunorubicin  Injection
    Liposomal Injection
    16.05 Debrisoft 

    £££
    Specialist recommendation
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Acute or chronic wounds with surface debris eg pressure ulcers, leg ulcers, diabetic foot ulcers
    Hyperkeratosis
    Duration dressing remains on wound before changing
    Not applicable
    Frequency of dressing change
    At each dressing change or as required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to polyester
    Heavy slough and necrotic tissue may require autolytic debridement to soften prior to use
    Thick hyperkeratosis may take more than one treatment
    Must be wet with clean warm water prior to use
    Do not get an emollient on the pad as this blocks the monofilaments
    Rationale for inclusion in formulary
    Lifts debris, superficial slough and exudate without damaging new granulation or epithelial cells
    Removes biofilms
    Lifts hyperkeratosis and dry flaking skin peri-wound
    Recommended by NICE
    Treatment well tolerated
    Convenient, easy to use, disposable single use pad

    08.01.03 Decitabine Injection 
    09.01.03 Deferasirox Exjade® NHSE commissioned
    09.01.03 Deferiprone Tablets Ferriprox® NHSE commissioned NICE NG8
    08.03.04.02 Degarelix Firmagon® Commissioned by CCGs, in line with NICE TA 404
    Supported with an ESCA
    06.05.02 Demeclocycline Capsules   For the treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone. UNLICENSED
    06.06.02 Denosumab XGEVA®
    06.06.02 Denosumab Prolia® Supported with an ESCA
    13.08.02 Dermablend  Specialist recommendation
    13.08.02 Dermacolor®  1st line
    Specialist recommendation
    FP10 prescriptions should be endorsed 'ACBS'
    16.14 Dermatonics Heel Balm  Rationale to support use in the context of wound management.
    Cream containing 25% urea
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    To moisturise dry skin on the soles of feet
    For use on adults and children over 12 years of age
    Duration dressing remains on wound before changing
    Reapply daily
    Frequency of dressing change
    Daily
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or hypersensitivity to any of the ingredients, contains beeswax and lanolin
    Not to be used on children under 12
    Rationale for inclusion in formulary
    Treatment of dry skin conditions of the foot.
    Dermatology approved
    13.02.01 Dermatonics Heel Balm®  Specialist recommendation for epidermolysis bullosa
    15.02 Dermogesic spray 
    16.14 Dermol 500 Lotion  Rationale to support use in the context of wound management
    Emollient lotion containing an antimicrobial
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For dry and pruritic skin conditions including eczema and dermatitis.
    Can be applied to skin as an emollient or used as a soap substitute
    Duration dressing remains on wound before changing
    Reapply daily
    Frequency of dressing change
    Daily
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or hypersensitivity to any of the ingredients contains benzalkonium chloride, 0.1%, chlorhexidine hydrochloride 0.1%, liquid paraffin, isopropyl myristate.
    Should not be used unless infection is present or is a frequent complication
    Rationale for inclusion in formulary
    Treatment of dry skin requiring antimicrobial properties
    Dermatology approved
    13.02.01 Dermol 500 lotion ®  Short term use only
    13.02.01.01 Dermol® (Bath Additive with Anitmicrobial) Dermol 600®
    09.01.03 Desferrioxamine Mesilate Injection  NHSE commissioned NICE NG8
    15.01.02 Desflurane Suprane®
    06.05.02 Desmopressin  Tablets
    Nasal solution
    Nasal Spray 10 mcg/ dose - Not high strength for haemophilia
    Melts - £££
    06.05.02 Desmopressin injection  Hospital use only
    07.03.02.01 Desogestrel 75mcg  Prescribe generically
    06.03.02 Dexamethasone  Tablets - £££
    Oral solution - £££
    06.03.02 Dexamethasone  Injection
    11.04.01 Dexamethasone 0.1%  Eye drops
    Single dose unit drops - for post corneal transplants or OSD - Use the agent with the lowest acquisition cost.

    04.06 Dexamethasone injection 

    Palliative care only 

    11.04.01 Dexamethasone intravitreal implant Ozurdex®
    04.06 Dexamethasone tablets 

    ££££

    For resistant nausea and vomitting

    12.01.01 Dexamethasone with Antibacterial Otomize® Second Line
    12.01.01 Dexamethasone with Antibacterial Sofradex®
    11.04.01 Dexamethasone with Antibacterials Tobradex®
    11.04.01 Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol® Specialist ophthalmologist recommendation
    Eye drops
    Eye ointment
    04.04 Dexamfetamine  Please note that commissioning discussion is underway. However the present status is as follows:-
    Red Birmingham CrossCity CCG, Birmingham South Central CCG, Sandwell & West Birmingham CCG
    Amber Traffic Light Supported with an ESCA - Solihull CCG.
    08.01 Dexrazoxane Savene® This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Red Formulary Status
    Red Formulary Status

    Red Formulary Status
    Red Formulary Status

    Amber Formulary Status
    Amber Formulary Status
    04.07.02 Diamorphine 
    04.01.02 Diazepam 
    04.08.02 Diazepam  Emulsion Injection
    Injection
    10.02.02 Diazepam 
    04.01.02 Diazepam Injection 
    15.01.04.01 Diazepam Injection 
    04.08.02 Diazepam Rectal tubes 
    02.05.01 Diazoxide Eudemine® Hospital Use Only
    13.08.01 Diclofenac Solaraze® £££
    15.01.04.02 Diclofenac Injection  Post operative use.
    Consider switch to oral Ibuprofen or Naproxen
    10.01.01 Diclofenac Sodium  CVD risk assessment required
    Not 1st line NSAID
    Renal Colic and acute sever pain full condition
    E/C tablets - short term use
    Dispersible tablets - £££- short term use. Swallowing difficulties
    Suppositories - short term use
    Injection - short term use
    11.08.02 Diclofenac Sodium  Voltarol® Ophtha Multidose
    08.03.01 Diethylstilbestrol Tablets  ££££
    13.04 Diflucortolone valerate 0.3% oily cream Nerisone Forte® Potency: very potent
    02.01.01 Digoxin Elixir Lanoxin-PG®
    02.01.01 Digoxin Injection 
    02.01.01 Digoxin specific antibody fragments  Hospital Only - Obtained from regional poisons unit
    02.01.01 Digoxin Tablets 
    04.07.02 Dihydrocodeine  Tablets
    Oral solution- for patients with swallowing difficulties
    02.06.02 Diltiazem  Tablets - FIRST LINE
    Brand Rationalisation – APC preferred brands:-
    Adizem SR Capsules and Tablets
    Adizem XL Capsules
    Angitil SR Capsules
    Angitil XL Capsules
    Tildiem LA Capsules
    Tildiem Retard Tablets
    13.05.03 Dimethyl fumarate Skilarence®

    Use in line with NICE. For use in moderate to severe plaque psoriasis- CCG commissioned

    07.04.04 DIMETHYL SULPHOXIDE Bladder Instillation 50% 
    13.10.04 Dimeticone Hedrin®
    07.01.01 Dinoprostone 
    13.14.07 Diphenylcyclopropenone in acetone 0.00001-6.0% w/v  BAD recommended quantity = 10ml
    Diphenylcyclopropenone (DCP) is a highly sensitising agent used to treat alopecia areata and resistant viral warts as topical immunotherapy. It should be applied only in Dermatology departments by a trained professional. Applying it to the patient’s skin carries a risk of sensitising the person carrying out the treatment. Bottles should be handled wearing protective gloves.
    02.09 Dipyridamole Persantin®, Persantin Retard® Tablets
    Modified release capsules
    06.06.02 Disodium Etidronate Didronel®
    06.06.02 Disodium Pamidronate 
    02.03.02 Disopyramide Capsules 
    02.03.02 Disopyramide Injection Rythmodan®
    04.10.01 Disulfiram Antabuse®
    13.05.02 Dithranol Dithrocream® All strengths - specialist recommendation
    13.14.05 Dithranol in Lassar’s paste 0.1% w/w  BAD recommended quantity = 100g
    13.14.05 Dithranol in Lassar’s paste 0.5% w/w  BAD recommended quantity = 100g
    13.14.05 Dithranol in Lassar’s paste 1% w/w  BAD recommended quantity = 100g
    13.14.05 Dithranol in Lassar’s paste 10% w/w  BAD recommended quantity = 100g
    13.14.05 Dithranol in Lassar’s paste 15% w/w  BAD recommended quantity = 100g
    13.14.05 Dithranol in Lassar’s paste 2% w/w  BAD recommended quantity = 100g
    13.14.05 Dithranol in Lassar’s paste 4% w/w  BAD recommended quantity = 100g
    13.14.05 Dithranol in Lassar’s paste 8% w/w  BAD recommended quantity = 100g
    13.14.05 Dithranol pomade 0.4% w/w   BAD recommended quantity = 100g
    Dithranol 0.4% w/w, salicylic acid 2% w/w, emulsifying wax BP 25% w/w, liquid paraffin to 100%
    02.07.01 Dobutamine  Hospital Use Only
    08.01.05 Docetaxel Infusion Taxotere®
    04.06 Domperidone  Tablets - short term use only
    Suppositories
    SF suspension - £££ - swallowing difficulties only
    04.11 Donepezil Aricept® Tablets
    Orodispersible
    APC verdict - present status = RED
    Future status = AMBER with a framework in primary care before transfer - commissioning discussion
    02.07.01 Dopamine  Hospital Use Only
    03.07 Dornase Alfa Pulmozyme® NHS England Commissioned for Cystic Fibrosis only
    Red New Patients

    Amber Formulary Status Existing patients (initiated prior to April 2013)
    11.06 Dorzolomide Trusopt® Specialist ophthalmologist recommendation
    2% eye drops
    2% single use eye drops (SDU)
    11.06 Dorzolomide 2% with Timolol 0.5% Cosopt® Specialist ophthalmologist recommendation
    Eye drops
    Single use eye drops (SDU)
    13.02.01 DoubleBase® 
    03.05.01 Doxapram Dopram® Hospital only
    15.01.07 Doxapram Dopram®
    07.04.01 Doxazosin 
    02.05.04 Doxazosin Tablets 
    13.03 Doxepin 5% cream Xepin® Supported with a RICaD (in development)
    08.01.02 Doxorubicin Hydrochloride  Injection
    Liposomal Injection
    13.06.02 Doxycycline  In line with Antibiotic guide
    02.03.02 Dronedarone Multaq® To be used in line with NICE guidance
    04.06 Droperidol Xomolix® Fo hospital use only
    03.01.04 Duaklir Genuair  Aclidinium bromide + formoterol fumarate (Fixed Dose Combination)
    To be used in in-line with COPD Guidance
    06.01.02.03 Dulaglutide Trulicity® In line with NICE Exenatide prolonged-release and NICE NG28.  
    Not for monotherapy
    Not in combination with insulin
    04.03.04 Duloxetine Cymbalta® AMBER - Accompanied by rationale for use/restricted medicines form
    07.04.02 Duloxetine Yentreve®
    04.07.03 Duloxetine (Cymbalta®)   £££
    3rd line after gabapentin
    Low abuse - high cost
    Advice of specialist
    16.02.04 Duoderm range   Hydrocolloid dressing
    The adhesive layer forms a cohesive gel when in contact with wound exudate
    Available as Extra thin or Signal (Bordered)
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Dry to lightly exuding wounds
    Non infected
    Acute or Chronic wounds
    Duration dressing remains on wound before changing
    Up to 7 days maximum
    Frequency of dressing change
    3-7 days
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not suitable for infected wounds, full thickness burns or wounds with exposed bone, muscle or tendon or wounds that are likely to macerate, particularly on plantar surface of foot
    Not for diabetic foot ulcers
    Not for ischaemic wounds
    Known product or component sensitivity
    Rationale for inclusion in formulary
    Conformable, waterproof, aids autolysis. Protect surrounding skin , reduced risk of blistering. Cost effective
    06.04.02 Dutasteride Avodart® £££
    Supported with a RICaD
    When finasteride has failed or is contraindicated/not tolerated
    16.11 EasY-Slide (application aid for open toe stockings)  Compression hosiery garments applicator for open toe
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Application of open toe compression garments
    Duration dressing remains on wound before changing
    N/A
    Frequency of dressing change
    N/A
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    N/A
    Rationale for inclusion in formulary
    Applicator for open toe hosiery
    16.01.02 Eclypse 

    Approved June 2018 to replace Flivasorb

    Superabsorbent dressing (can be used under compression)

    Rationale (developed by TV Team)

    Type of wound product is suitable for

    Moderate -> heavily exuding wounds and under compression

    Duration dressing remains on wound before changing

    1-3 days

    Frequency of dressing change

    1-3 days

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)

    Arterial bleeds or heavily bleeding wounds.

    Wounds with low exudate level.

    Known sensitivity to product.

    Rationale for inclusion in formulary

    Evaluated better than Flivasorb and more cost effective.

    11.03.02 Econazole 1% eye drops 
    07.02.02 Econazole pessaries Gyno-Pevaryl®
    02.08.02 Edoxaban Lixiana ® Amber Formulary StatusFollowing diagnosis of AF – use in line NICE and toolkit, initiation/recommendation by haematologist, transfer to GP with RICaD
    Amber Formulary StatusFor the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/recommendation by haematologist, transfer to GP with RICaD
    15.01.06 Edrophonium 
    10.02.01 Edrophonium Chloride  Hospital only
    09.08.01 Eliglustat Cerdelga®

    NHSE commissioned

    Use in line with NICE

    Highly Specialised

    09.01.04 Eltrombopag Tablets Revolade®
    06.01.02.03 Empagliflozin  To be used in line with NICE guidance
    16.13 Emulsifying Ointment  Rationale to support use in the context of wound management.
    Emollient ointment containing emulsifying wax, white soft paraffin and liquid paraffin
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For treatment of dry skin conditions
    Duration dressing remains on wound before changing
    Reapply daily
    Frequency of dressing change
    Daily
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or hypersensitivity to any of the ingredients
    Rationale for inclusion in formulary
    Treatment of dry skin
    Dermatology approved
    13.02.01 Emulsifying Ointment BP 
    02.05.05.01 Enalapril   For existing patients only
    02.08.01 Enoxaparin  For all other indications.

    The APC's view is that on clinical grounds, the status for certain indications approved by APC should be amber, supported by an ESCA.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.(ESCAs to be developed).
    02.08.01 Enoxaparin  Single use in DVT
    02.01.02 Enoximone Perfan® Hospital Only
    04.09.01 Entacapone Comtess® Supported with a ESCA
    08.03.04.02 Enzalutamide Xtandi® Use in line with NICE
    Hospital only - NHSE commissioned
    13.14.07 Eosin solution 2% w/v  BAD recommended quantity = 100ml
    Used for erosive dermatitis, especially around stomas, appliances and intertrigo. Apply when dressing or device changed.
    13.02.01 Epaderm ointment Epaderm®
    16.13 Epaderm Ointment  Rationale to support use in the context of wound management
    Emollient ointment containing liquid paraffin, yellow soft paraffin and emulsifying wax
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For use on all dry skin conditions and with dry or wet wrapping techniques
    Duration dressing remains on wound before changing
    NA
    Frequency of dressing change
    Daily or more frequently if required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Non listed
    Rationale for inclusion in formulary
    Treatment of dry skin conditions.
    Dermatology approved
    02.07.02 Ephedrine  Hospital Use Only
    12.02.02 Ephedrine hydrochloride nose drops 0.5% and 1% drops  Short term use only
    13.02.01 Epimax®  
    08.01.02 Epirubicin Injection 
    02.02.03 Eplerenone  Supported by RICaD
    09.01.03 Epoetin   This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Not Present on this Formulary

    Red Formulary Status
    Red Formulary Status

    Not Present on this Formulary
    09.01.03 Epoetin beta NeoRecormon® NHSE commissioned Renal dialysis
    CCG Commissioned for use in cancer - NICE TA 323
    09.01.03 Epoetin Theta Eporatio® This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Not Present on this Formulary

    Not Present on this Formulary

    Amber Formulary Status
    Amber Formulary Status
    09.01.03 Epoetin Zeta  This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Not Present on this Formulary

    Not Present on this Formulary

    Amber Formulary Status
    Amber Formulary Status
    02.08.01 Epoprostenol Flolan® Hospital Use Only
    02.09 Eptifibatide Integrilin® Hospital Use Only
    03.07 Erdosteine Erdotin® Hospital only
    09.06.04 Ergocalciferol  Red20,000 units solution & capsules (osto D2)
    Red Hospital OnlyInjection
    07.01.01 Ergometrine Maleate 
    07.01.01 Ergometrine Maleate and Oxytocin Syntometrine®
    08.01.05 Eribulin Injection 
    08.01.05 Erlotinib Tablets 
    04.08.01 Eslicarbazepine Zebinix® Supported with a ESCA
    MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history
    02.04 Esmolol injection  Hospital Use Only
    07.02.01 Estradiol 10micrograms  Vagifem®
    07.02.01 Estradiol 500microgram pessaries  Ortho-Gynest®
    07.02.01 Estradiol 7.5micrograms/24 hours vaginal ring  Estring®
    08.01.01 Estramustine Phosphate Estracyt®
    07.02.01 Estriol 0.01% cream  Gynest®
    07.02.01 Estriol 0.1% cream  Ovestin®
    02.11 Etamsylate Dicynene® Hospital Use Only
    10.01.03 Etanercept Enbrel® Hospital Use Only
    13.05.03 Etanercept Enbrel® Use in line with NICE TA103
    09.05.01.02 Etelcalcetide  Parsabiv®

    Use in line with NICE

    NHSE commissioned

    02.13 Ethanolamine Oleate  Hospital Use Only
    06.04.01.01 Ethinylestradiol  Ethinylestradiol tablets
    2microgram
    and
    10 microgram

    For induction of puberty in female patients who cannot tolerate or are allergic to first-line patches.
    08.03.01 Ethinylestradiol  This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Not Present on this Formulary

    Not Present on this Formulary

    Amber Formulary Status
    Amber Formulary Status
    07.03.01 Ethinylestradiol / levonorgestrel phased pill  TriRegol®
    07.03.01 Ethinylestradiol 150mcg / Levonorgestrel 30mcg  Microgynon 30 ED®
    07.03.01 Ethinylestradiol 20 mcg / norethisterone 1mg Loestrin 20® Induction of puberty
    07.03.01 Ethinylestradiol 20mcg / desogestrel 150mcg 

    Monophasic low strength (21-day preparation)

    Gedarel®20/150

    Lestramyl®20/150

     

    07.03.01 Ethinylestradiol 20mcg / gestodene 75 mcg Millinette 20®
    07.03.01 Ethinylestradiol 30 mcg / drospirenone 3 mg 

    Monophasic standard strength (21-day preparation)

    Brands approved by APC:

    Yacella

    Acondro

    Dretine

    07.03.01 Ethinylestradiol 30mcg / desogestrel 150mcg 

    Monophasic standard strength (21-day preparation)

    Gedarel®30/150

    Lestramyl®30/150

    07.03.01 Ethinylestradiol 30mcg / gestodene 75 mcg Millinette 30 ®
    07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg Rigevidon®
    07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg Levest®
    07.03.01 Ethinylestradiol 35 mcg / noresthisterone 500mcg Brevinor®
    07.03.01 Ethinylestradiol 35 mcg / norgestimate 250 mcg Lizinna®
    04.08.01 Ethosuximide  MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors
    15.02 Ethyl Chloride Cryogesic® Spray
    11.99.99.99 Ethylenediaminetetraacetic acid (EDTA) 0.37% drops  This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Not Present on this Formulary

    Red Formulary Status
    Red Formulary Status

    Not Present on this Formulary
    15.01.01 Etomidate Injection Etomidate-Lipuro®
    07.03.02.02 Etonorgestrel Nexplanon®
    08.01.04 Etoposide Injection 
    15.01.04.02 Etoralac Injection 
    13.02.01 Eucerin intensive lotion ®   10% urea
    08.01.05 Everolimus Tablets 
    02.11 Evicel®  Hospital Use Only
    02.12 Evolocumab Repatha® To be used in line with NICE TA394.
    08.03.04.01 Exemestane 
    06.01.02.03 Exenatide Byetta® To be used in line with NICE guidance
    06.01.02.03 Exenatide MR Bydureon® To be used in line with NICE guidance
    02.12 Ezetimibe Ezetrol® Use in NICE TA 385

    02.11 Factor VIIa (Recombinant) - [Eptacog alfa (activated) injection] Novo 7® Hospital Use Only
    10.01.04 Febuxostat Adenuric®
    02.06.02 Felodipine  Brand Rationalisation – APC preferred brands:-
    Cardioplen XL
    Felotens XL
    02.12 Fenofibrate  Tablets
    Capsules
    15.01.04.03 Fentanyl Injection 
    04.07.02 Fentanyl lozenges  Palliative care only
    04.07.02 Fentanyl Nasal Spray 
    04.07.02 Fentanyl Patches  Birmingham CrossCity CCG patch choice = Fencino or Matrifen
    04.07.02 Fentanyl sublingual tablets  Palliative care only
    09.01.01.02 Ferric Carboxymaltose Ferinject®
    09.01.01.01 Ferric Maltol Feraccru®
    • In adults for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD).
    • Specialist initiation, and transfer of prescribing to GP using RICaD (in development) 
    09.01.01.01 Ferrous Fumarate  Tablets
    Liquid
    09.01.01.01 Ferrous Gluconate  If patient intolerant of sulphate
    09.01.01.01 Ferrous Sulphate  ££££
    03.04.01 Fexofenadine  ££
    09.01.06 Filgrastim Injection 
    13.09 Finasteride Propecia® For hyperandrogenism in women
    Not NHS Not NHS
    06.04.02 Finasteride 1mg  Hyperandrogenism in women
    06.04.02 Finasteride 5mg 
    08.02.04 Fingolimod 
    16.16 First consider clients own footwear options.  First consider clients own footwear options.
    16.18 Flamazine  Burns Specialist recommendation
    1% silver sulfadiazine
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Partial thickness & full thickness burn injuries. Sloughy burn wounds or areas of graft loss
    Duration dressing remains on wound before changing
    24-48 hours
    Frequency of dressing change
    Daily- occasionally alternate day
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy to any ingredients.
    Not to use in pregnancy or breast feeding
    Take care if: suffer kidney or liver problems, deficiency of the enzyme known as glucose 6- phosphate dehydrogenase. Taking tablets prescribed for epilepsy
    Rationale for inclusion in formulary
    Prevent and treat bacterial infections in burns, skin graft donor sites.
    16.03.04 Flaminal Forte Gel  Alginate gel. Moderate to heavily exuding wounds. Contains antimicrobial enzymes
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Colonised wound bed. More suited to sloughy wounds. Can be used on all wound types
    Useful for cavity wounds and sinus’s
    Requires a secondary dressing
    Duration dressing remains on wound before changing
    1-7 days
    Frequency of dressing change
    1-7 days dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Sensitivity to alginate dressings or polyethylene glycol
    Full thickness burns
    Rationale for inclusion in formulary
    1st line antimicrobial in paediatrics
    Consider as first line product if signs of colonisation or clinical infection
    Does not cause cellular damage
    16.03.04 Flaminal Hydro Gel   Alginate gel.
    Low to moderate exuding wounds. Contains antimicrobial enzymes.
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Colonised wound bed. More suited to sloughy wounds. Can be used on all wound types
    Useful for cavity wounds and sinus’s
    Requires a secondary dressing
    Duration dressing remains on wound before changing
    1-7 days
    Frequency of dressing change
    1-7 days dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Sensitivity to alginate dressings or polyethylene glycol
    Full thickness burns
    Rationale for inclusion in formulary
    1st line antimicrobial in paediatrics
    Consider as first line product if signs of colonisation or clinical infection
    Does not cause cellular damage
    16.22 Flammercerium  Silver sulfadiazine 1.0g & Cerium nitrate 2.2g
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Partial thickness & full thickness burn injuries.
    Duration dressing remains on wound before changing
    24-48 hours
    Frequency of dressing change
    Daily- occasionally alternate day
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy to any ingredients.
    Not to use in pregnancy or breast feeding, infants or babies under the age of 2 years.
    Take care if: suffer kidney or liver problems, deficiency of the enzyme known as glucose 6- phosphate dehydrogenase. Taking tablets prescribed for epilepsy
    Rationale for inclusion in formulary
    Prevent and treat bacterial infections in burns
    02.03.02 Flecainide Acetate Injection Tambocor®
    02.03.02 Flecainide Acetate Tablets 
    17.06 Flexicare E-Z Flow  Order code - 00-0060
    Pack size - 5
    Usual quantity - 5 valves (1 pack) per month
    Review period – Weekly (at every catheter change)
    13.04 Flucinolone Acetonide 0.0025% Synalar 1 in 10 Dilution® Potency: mild
    Paediatric use only
    07.02.02 Fluconazole Oral 150mg 
    08.01.03 Fludarabine Phosphate Fludara® Red Tablets
    Red Hospital Only Injection
    06.03.01 Fludrocortisone Acetate Florinef®
    13.04 Fludroxycortide 7.5cm x 200cm tape Haelan® ££
    15.01.07 Flumazenil Injection Anexate®
    12.01.01 Flumetasone 0.02% with Clioquinol 1% Locorten-Vioform®
    04.07.04.01 Flunarizine Tablets 

    Not licenced in the UK

    Licenced in Europe and Ireland:- Preventative management in primary headache

    13.04 Fluocinolone Acetonide 0.0025% Gel Synalar Gel Potency: potent
    £££
    13.04 fluocinolone acetonide 0.025% with clioquinol 3% Synalar C® Potency:Potent
    Cream
    Ointment
    11.04.01 Fluocinolone intravitreal implant Iluvien®
    09.05.03 Fluoride 

    Dental prescribing only


    Sodium Fluoride Mouthwash, BP
    Sodium Fluoride Toothpaste 0.619%, DPF
    Sodium Fluoride Toothpaste 1.1%, DPF
    11.04.01 Fluorometholone Drops FML® Specialist ophthalmologist recommendation
    11.99.99.99 Fluorouracil 

    Hospital Use Only

    (5FU drops)

    13.08.01 Fluorouracil Efudix®
    13.08.01 Fluorouracil 0.5%, salicylic acid 10% Actikerall® For hyperkeratotic lesions
    08.01.03 Fluorouracil Injection 
    04.03.03 Fluoxetine 

    Tier 1 -

    Capsules
    Liquid

    04.02.02 Flupentixol Decanoate Injection (oily) Depixol® Hospital ONLY
    APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion)
    04.02.01 Flupentixol Tablets Depixol® Supported by ESCA
    04.02.02 Fluphenazine Decanoate Injection (oily)  APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion)
    08.03.04.02 Flutamide 
    03.02 Fluticasone and formoterol Flutiform®
    03.02 Fluticasone and salmeterol Sirdupla® For exisiting patients
    Sirdupla (salmeterol/fluticasone) is a bioequivalent alternative to Seretide Evohaler
    25/125 (salmeterol 25 microgram, fluticasone propionate 125 microgram)
    25/250 (salmeterol 25 microgram, fluticasone propionate 250 microgram)
    03.02 Fluticasone and salmeterol Seretide Evohalers® For existing patients
    For paediatric use ONLY (i.e. up to 18 years of age)
    Seretide Evohalers
    12.02.01 Fluticasone furoate Avamys ® Approved for use in children and adults.
    Previous APC decision reviewed in December 2015.
    03.02 Fluticasone furoate & vilanterol Relvar Ellipta®
    92mcg/22mcg - In line with COPD Guidance
    92mcg/22mcg & 184mcg/22mcg - In line with Asthma Guidance
    03.02 Fluticasone furoate, umeclidinium bromide and vilanterol combination Trelegy Ellipta®®

    TRIPLE COMBINATION INHALER

    Fluticasone furoate, umeclidinium bromide and vilanterol combination

    Trelegy Ellipta

    Use inline with COPD guidnace - Criteria for triple therapy and for triple inhaler use in COPD

    03.02 Fluticasone Inhaler Flixotide® For paediatric use ONLY
    Green Fluticasone Evohaler 50, Fluticasone Accuhaler 50,100
    Amber Formulary Status Fluticasone Evohaler 125, Fluticasone Accuhaler 250
    03.02 Fluticasone Nebulised Solution Flixotide®
    12.02.01 Fluticasone Propionate Nasal drops Flixonase Nasule® Specialist recommendation for Nasal polyps

    02.12 Fluvastatin Capsules 
    09.01.02 Folic Acid  Green Tablets
    Amber Formulary Status SF Solution - Lexpex
    02.08.01 Fondaparinux Arixtra® Hospital Use Only
    09.04 Food Boosting Dietary Measures   This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Not Present on this Formulary

    • The use of sip feeds should usually only be considered when food boosting dietary measures alone have failed to improve nutritional intake or status after 4 weeks.
    • The community nutritional screening tool should be used to identify patients who need food boosting dietary measures
    • ACBS. In certain clinical conditions some foods may have the characteristics of drugs and ACBS advises as to the circumstances in which such foods may be regarded as drugs and so can be prescribed in the NHS. Prescriptions should be endorsed ACBS. Refer to appendix 7 in the BNF.
    • The ACBS approved categories for prescribing sip feeds are; Shortbowel syndrome, Intractable malabsorption, Pre-operative preparation of patients who are malnourished, Proven inflammatory bowel disease, Total gastrectomy, Dysphagia and disease related malnutrition (this can incorporate a range of conditions and is open to interpretation)

    Not Present on this Formulary
    03.01.01.01 Formoterol  
    06.01.06 Freestyle Optium β-Ketone test strips 

    Ketone test strips to be used with the Freestyle Optium Neo meter

    Meter restricted for use on the advice of specialist care only

    06.01.06 Freestyle Optium test strips 

    Glucose test strips to be used with the Freestyle Optium Neo meter

    Meter restricted for use on the advice of specialist care only

    17.17 Fresenius Kabi 1 L Sodium chloride 
    02.11 Fresh Frozen Plasma  Hospital Use Only
    13.05.02 Fumaderm®  
    02.02.02 Furosemide  Tablets
    Oral solution
    Injection
    Monitor potassium level. Indicated in pulmonary oedema. Need large doses in renal failure
    11.03.01 Fusidic Acid 1% MR Eye Drops   NICU use as per guideline - 1st line
    Primary care antibiotic guidance - Bacterial conjunctivitis infection - 2nd line - £££
    13.10.01.02 Fusidic Acid 2% Fucidin® Cream
    Ointment
    04.07.03 Gabapentin   Second Line
    Please be aware of the abuse potential associated with this class of agent - See NHS England advise
    Capsules
    Tablets
    04.08.01 Gabapentin  CAPSULES
    Tablets - ££
    MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors
    04.11 Galantamine Reminyl® Tablets
    MR capsules
    Solution
    APC verdict - present status = RED
    Future status = AMBER with a framework in primary care before transfer - commissioning discussion
    16.05.01 Gamgee   UHB burns only
    Sterile or non sterile highly absorbent cotton wool enclosed in an absorbent cotton cover

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Full thickness burns
    Can be cut to required size
    Secondary dressing
    Duration dressing remains on wound before changing
    Dependent on exudate levels
    Frequency of dressing change
    Dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used as a primary dressing
    Only to be used in UHB burns unit
    Rationale for inclusion in formulary
    UHB burns unit only
    11.03.03 Ganciclovir 0.15% ophthalmic gel  Virgan® Specialist ophthalmologist recommendation
    08.01.05 Gefitinib Tablets 
    09.02.02.02 Gelatin Gelofusine®
    09.02.02.02 Gelatin Isoplex® For use in liver theatres only
    09.02.02.02 Gelatin Geloplasma®
    09.02.02.02 Gelatin Gelaspan®
    12.03.01 Gelclair®  Oncology & haematology use
    08.01.03 Gemcitabine Injection 
    07.01.01 Gemeprost 
    16.07.02 Generic Rx - Woven and fabric swabs  7.5cm x 7.5cm only
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Cleansing wounds via aseptic technique
    Duration dressing remains on wound before changing
    N/A
    Frequency of dressing change
    N/A
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be applied to a wound as a dressing
    Rationale for inclusion in formulary
    Necessity for wound cleansing
    Cost effective
    Included in Sterile wound packs or used to supplement sterile packs
    12.01.01 Gentamicin Genticin® Only with positive culture/sensitivity data
    11.03.01 Gentamicin 0.3% Drops  ophthalmic 2nd line after chloramphenicol - specialist ophthalmologist recommendation.
    03.12 Gentamicin nebulised  Hospital only
    06.01.02.01 Glibenclamide  For patients who do not want to move to insulin but not responding to metformin
    Use in pregnancy as per NICE
    06.01.02.01 Gliclazide 
    06.01.02.01 Gliclazide MR  2nd Line option
    06.01.02.01 Glimepiride 
    06.01.04 Glucagon GlucaGen® HypoKit
    06.01.04 GlucoGel®  Glucose 40% oral gel
    06.01.06 Glucomen Areo Ketone sensor 

    PREFERRED FIRST LINE

    Ketone test strips to be used with the GlucoMen Areo 2K

    06.01.06 Glucomen Areo Sensor glucose sensor 

    PREFERRED FIRST LINE

    Glucose test strips to be used with the GlucoMen Areo 2K

    09.02.02.01 Glucose Intravenous Infusion  
    13.07 Glutaraldehyde 10% solution Glutarol®
    02.06.01 Glyceryl Trinitrate Injection  Hospital Use Only
    02.06.01 Glyceryl Trinitrate MR Buccal Tablets  Hospital Use Only
    02.06.01 Glyceryl Trinitrate Patches 
    02.06.01 Glyceryl Trinitrate SL Spray & Tablets 
    07.04.04 Glycine 
    13.14.07 Glycopyrrolate 0.05% w/v in water  BAD recommended quantity = 250ml
    Use with an iontophoresis machine to treat hyperhidrosis.
    13.14.07 Glycopyrrolate 2% w/w in cetomacrogol cream  BAD recommended quantity = 100g
    Use to treat disabling facial hyperhidrosis. Apply to affected sites twice daily.
    03.01.02 Glycopyrronium Seebri breezhaler® For COPD only
    13.12 Glycopyrronium  Unlicensed
    For specialist initiation for hyperhidrosis
    15.01.03 Glycopyrronium Bromide 400mcg / ml oral solution (equivalent 320 micrograms/ml Glycopyrronium) 

    Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.

    15.01.03 Glycopyrronium Injection 
    10.01.03 Golimumab Simponi® Hospital Use Only
    06.05.01 Gonadorelin  Hospital use only
    06.07.02 Goserelin  For endometreosis or breast cancer
    06.07.02 Goserelin  For assisted conception
    08.03.04.02 Goserelin Zoladex® & Zoladex® LA
    16.09.01 Graduated compression hosiery  Based on assessment
    16.09.01 Graduated compression hosiery accessories  Based on assessment
    04.06 Granisetron  Granisetron tablets
    Granisetron patch - For use in oncology patients only
    Granisetron injection
    16.02.04 Granuflex  Specialist recommendation
    Hydrocolloid dressings
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Hyperkeratosis, granulating wounds, forms cohesive gel on contact with exudate
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    3-7 days
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to ingredients - contains pectin and gelatine
    Not for diabetic foot ulcers or ischaemic wounds
    Not for infected wounds
    Rationale for inclusion in formulary
    Comformable waterproof dressing, aids rehydration.
    Reduces and softens hyperkeratosis
    03.04.02 Grass and Tree Pollen Extract Pollinex® Hospital only
    03.04.02 Grass pollen extract Grazax® Supported by RICaD
    17.06 Great Bear Libra  Order code - 10540A
    Pack size - 5
    Usual quantity - 5 valves (1 pack) per month
    Review period – Weekly (at every catheter change)
    04.04 Guanfacine   Intuniv® 2nd line Atomoxetine, hospitals to manage/support patient
    For the treatment of ADHD in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.
    07.03.03 Gygel Contraceptive Jelly 
    16.18 Haelan Tape  Specialist recommendation
    Adhesive, waterproof, occlusive tape impregnated with 4mg/cm2 Fludroxycortide (topical steroid)
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Chronic over granulation, non acute or weeping.
    Duration dressing remains on wound before changing
    Cut the tape to size. Apply for 12 hours at a time, remove and discard. Apply to clean, dry skin that is shorn of any hair.
    Frequency of dressing change
    Apply daily for 12 hours at a time. Maximum treatment time 7 days.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Chicken pox
    Tuberculosis of the skin
    Hypersensitivity to any components in the tape (steroid fludroxycortide)
    Facial rosacea
    Acne vulgaris
    Perioral dermatitis
    Perianal and genital pruritis
    Dermatoses in infants
    Dermatitis napkin eruption
    Bacterial, viral and fungal infections
    Keep away from the eyes
    Avoid prolonged use on the face
    Not for untreated bacterial, fungal or viral skin lesions
    Rationale for inclusion in formulary
    Treatment of over granulation
    09.08.02 Haem Arginate Normasang® NHSE commissioned
    14.04 Haemophilus influenzae type B Combined Vaccine Menitorix®
    03.01.05 Haleraid® 
    04.02.01 Haloperidol  Supported by ESCA
    Tablets
    Capsules
    SF Liquid
    Injection - For rapid tranquilisation
    04.02.02 Haloperidol Haldol Decanoate®
    09.06.01 Healthy Start Vitamins  Available free of charge from designated centres
    02.08.01 Heparin sodium injection  Hospital Use Only
    13.13 Heparinoid 0.3% Hirudoid®
    14.04 Hepatitis A vaccine Single Component Avaxim®
    14.04 Hepatitis A vaccine Single Component Epaxal®
    14.04 Hepatitis A vaccine Single Component Havrix Monodose®
    14.04 Hepatitis A vaccine Single Component Vaqta® Paediatric
    14.04 Hepatitis A vaccine with Hepatitis B vaccine  Twinrix®
    14.05.02 Hepatitis B immunoglobulin 
    14.04 Hepatitis B vaccine Single Component Engerix B®
    14.04 Hepatitis B vaccine Single Component Fendrix®
    14.04 Hepatitis B vaccine Single Component HBvaxPRO®
    13.11.02 Hibitane Obstetric® 
    13.10.05 Histoacryl® 
    17.11 Hollister In-view Silicone self-adhesive sheath (Standard)  Special and Extra sizes also available
    Order code - 97225/29/32/36/41
    Gauge/CH size - 25/29/32/36/41mm
    Usual quantity - 30 every month
    Review period – Before each Rx or if more than 30 used per month
    17.05 Hollister VaPro  Gender - Male
    Order code - 72084 – 72164
    Gauge/CH size - 8 - 16
    Usual quantity - 30 every month (1 pack per month)
    Review period – Every 3 months
    Gender - Female
    Order code - 72082 - 72142
    Gauge/CH size - 8 - 14
    Usual quantity - 30 every month (1 pack per month)
    Review period – Every 3 months
    09.02.02.02 Human Albumin Solution 
    06.05.01 Human Menopausal Gonadotrophins  Menotrophin injection
    12.04 Human papilloma virus vaccine Gardasil®

    For use by ENT Specialists in recurrent respiratory papillomatosis (RRP)

    14.04 Human papilloma virus vaccine Gardasil®

    For use by ENT Specialists only in recurrent respiratory papillomatosis (RRP)

    14.04 Human papilloma virus vaccine Cervarix®
    14.04 Human papilloma virus vaccine Gardasil®

    For national immunisation campaign in adolescent girls ONLY 

    11.99.99.99 Hyaluronidase 1500 units 
    02.05.01 Hydralazine Hydrochloride Injection Apresoline® Hospital Use Only
    02.05.01 Hydralazine Tablets 
    06.03.02 Hydrocortisone  STANDARD RELEASE Tablets
    Injection
    13.04 Hydrocortisone  Potency: mild
    Hydrocortisone 0.5% Cream & Ointment
    Hydrocortisone 1% Cream & Ointment
    13.04 Hydrocortisone 0.25% Crotamiton 10% Eurax-Hydrocortisone® Steroid potency: mild
    Post scabies once infection cleared but itch still present
    13.04 Hydrocortisone 0.5%, Chlorhexidine HCl 1% & Nystatin  Nystaform-HC®

    Potency: Mild

    Cream, Ointment

    Paeds use only

    Replacement for discontinued Vioform HC 

    13.04 Hydrocortisone 1% with Clotrimazole 1% Canesten HC® Steroid potency: mild
    13.04 Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort® Steroid potency: mild
    12.03.01 Hydrocortisone 2.5mg lozenges  Specialist recommendations
    10.01.02.02 Hydrocortisone acetate Hydrocortistab®
    13.04 Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H® Steroid potency – mild
    12.01.01 Hydrocortisone Acetate 1% with Gentamicin 0.3% Gentisone® HC Only with positive culture/sensitivity data
    13.04 Hydrocortisone Butyrate Locoid® Potency: potent
    Cream
    Lipocream
    Ointment
    Scalp lotion
    06.03.02 Hydrocortisone sodium succinate Solu-Cortef®
    16.02.02 Hydrofilm  Vapour-permeable adhesive film
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Dry non infected wounds, retention of lines, fixation of secondary dressings, protection of intact skin, protection of skin against friction, protection of newly epithelialized wounds
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    Up to 7 days
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Clinically infected wounds, bleeding or exuding wounds
    Rationale for inclusion in formulary
    Retention of lines, protection of intact skin, fixation of other dressings. Cost effective
    Waterproof
    13.11.06 Hydrogen Peroxide Crystacide®
    12.03.04 Hydrogen Peroxide Mouthwash 
    13.11.06 Hydrogen Peroxide Solution BP  Hydrogen peroxide 3% solution (10 vols)
    Hydrogen peroxide 6% solution (20 vols)
    13.02.01 Hydromol Cream & Ointment® 
    13.02.01.01 Hydromol®  Bath and shower emollient
    13.14.07 Hydroquinone 5% w/w, hydrocortisone 1% w/w and tretinoin 0.1% w/w in a non-aqueous gel 0.3% w/v  BAD recommended quantity = 100g
    Use to treat melasma, in conjunction with a strong sunblock. Do not use for more than 6 months due to the risk of ochronosis. A commercially available similar preparation may be obtained called Pigmanorm® (Mawdsley Brooks £17.60).
    17.05 HydroSil gripper catheter  Gender - Male
    Order code - 73610-73618
    Gauge/CH size - 10 to 18
    Usual quantity - 30 every month (1 pack per month)
    Review period – Every 3 months
    17.05 HydroSil rose catheter  Gender - Female
    Order code - 71410-71418
    Gauge/CH size - 10 to 18
    Usual quantity - 30 every month (1 pack per month)
    Review period – Every 3 months
    13.02.01 Hydrous Ointment 
    09.01.02 Hydroxocobalamin 1mg/ml Injection 
    09.01.03 Hydroxycarbamide  For use in sickle cell
    13.05.03 Hydroxycarbamide 
    08.01.05 Hydroxycarbamide Capsules  For myeloproliferative disorders
    Supported with an ESCA (Under development)
    10.01.03 Hydroxychloroquine 
    13.05.03 Hydroxychloroquine  Specialist initiation and stabilisation
    13.05.02 Hydroxyurea  This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Amber Formulary Status
    Amber Formulary Status

    Not Present on this Formulary

    Not Present on this Formulary
    03.04.01 Hydroxyzine 
    15.01.03 Hyoscine Hydrobromide  Injection
    Patch
    04.06 Hyoscine Hydrobromide Patch  £££
    04.06 Hyoscine Hydrobromide tablets  300 microgram tablets
    11.08.01 Hypromellose 0.5% eye drops 
    06.06.02 Ibandronic Acid injection 
    06.06.02 Ibandronic Acid Tablets  Supported with an ESCA
    08.01.05 Ibrutinib Imbruvica®

    Use in line with NICE Hospital only- NHSE commissioned

    08.02.03 Ibrutinib Imbruvica® Use in line with NICE TA429
    07.01.01.01 Ibuprofen Pedea® injection
    10.01.01 Ibuprofen  Tablets
    Suspension - If swallowing difficulties and paediatrics use
    10.03.02 Ibuprofen gel 
    03.04.03 Icatibant Firazyr® Hospital only
    NHS England commissioned
    13.14.04 Ichthammol 1% w/w and zinc oxide 15% w/w in YSP  BAD recommended quantity = 100g
    Ichthammol is used to treat acutely inflamed atopic eczema. It is also used in paste bandages (Ichthopaste® £3.45) for chronic lichenified eczema.
    Treatment is often initiated at Dermatology day treatment centres but may be continued in the community. Apply twice daily until inflammation settled.
    16.08.09 Ichthopaste  Specialist recommendation
    Zinc and Ichthammol bandage.

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Venous leg ulcers
    Chronic eczema
    Dermatitis
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    Daily up to weekly dependant on skin and wound management.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use in any cases of sensitivity or allergy to ingredients
    Rationale for inclusion in formulary
    Zinc and ichthammol bandage. For treatment of dermatitis and chronic eczema when venous insufficiency is present.
    08.01.02 Idarubicin Hydrochloride  Red Capsules
    Red Hospital Only Injection
    08.01.05 Idelalisib  Zydelig® NHSE Commissioned
    Use in line with NICE TA 359
    09.08.01 Idursulfase concentrate for infusion  NHSE commissioned
    08.01.01 Ifosfamide infusion Mitoxana®
    02.05.01 Iloprost nebules Vantavis® Hospital Use Only
    NHS England commissioned
    08.01.05 Imatinib Tablets 
    09.08.01 Imiglucerase Injection Cerezyme® NHSE commissioned
    04.03.01 Imipramine 
    13.07 Imiquimod 3.75% Zyclara® £££
    For field changes >25cm2
    13.07 Imiquimod 5% Aldara® Actinic keratoses
    14.04 Inactivated Influenza Vaccine (Split Virion) 
    16.03.02 Inadine   Non-adherent dressing impregnated with povidone iodine (10%)
    Type of wound product is suitable for
    Mild local infection where there is low exudate levels, ischaemic wounds, dry, gangrenous digits with the aim to desiccate and auto-amputate.
    Dry-manage fixator sites
    Minor burns or skin trauma with local infection
    Duration dressing remains on wound before changing
    1-3 days depending on uptake of iodine from dressing
    Frequency of dressing change
    1-3 days depending on uptake of iodine from dressing
    Look at colour change of dressing (orange initially to white when all used)
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Iodine allergy or sensitivity
    Thyroid disorders
    Renal impairment
    Not suitable for children, pregnant or lactating women
    Rationale for inclusion in formulary
    Topical antimicrobial
    Non-adherent/pain free use
    No damage to granular or epithelial cells
    Easy application and removal
    Drying properties
    Efficacy against bacteria, fungi and viruses
    Cost effective.
    02.02.01 Indapamide  Use 2.5mg tablets only
    13.10.05 Indermil®  Indermil tissue adhesive
    07.01.01.01 Indometacin Indocid PDA®
    10.01.01 Indometacin  For gout and resistant cases
    Capsules
    M/R capsules
    Suspension
    14.04 Infanrix-IPV® 
    10.01.03 Infliximab Remicade® Hospital Use Only
    13.05.03 Infliximab Remicade® Use in line with NICE TA134
    14.04 Influenza vaccine   Brand as stated in Health Service circular, National Flu campaign
    13.08.01 Ingenol mebutate Picato® In line with treatment pathway provided (£)
    Approved at Feb 2015 APC.
    Please note that the dermatology section has not been reviewed by the APC.
    17.01 Instillagel  
  • To reduce injury to the urothenium and subsequent risk of possible urethral damage.
  • It can facilitate pain free insertion.
  • Help reduce the risk of associated infection.
  • One to be used at each catheter change.
  • For Community please prescribe on a ‘yellow card’
  • Order in singles.
  • For urethral catheter insertion. Volume is 6mls for females, and 11mls for males.
  • Licensed for supra pubic use where appropriate. 6ml to be used
  • 06.01.01.01 Insulin Actrapid® Prescribe by BRAND name
    06.01.01.01 Insulin Humulin® S Prescribe by BRAND name
    06.01.01.01 Insulin Insuman® Rapid Prescribe by BRAND name
    06.01.01.01 Insulin Aspart  NovoRapid® Prescribe by BRAND name
    06.01.01.01 Insulin Aspart  Fiasp®
    • Prescribe by BRAND name
    • For use only in gestational diabetes

    • Supported by RICaD (in development)

    06.01.01.02 Insulin degludec 100 units/mL Tresiba®

    Amber Traffic Light Type 1 Diabetes - Specialist Initiation.  Supported with a RICaD


    To avoid the use of an insulin pump in patients with Type 1 diabetes who have nocturnal/severe hypoglycaemia as defined in NICE TA 151 OR recurrent DKA despite good compliance with current insulin regime


    Prescribe by BRAND name

    Red Type 2 Diabetes. 

    Initiation and ongoing prescribing and supply.

    Patients with Type 2 diabetes who have nocturnal / severe hypoglycaemia or those with recurrent hypoglycaemic episodes requiring hospital admission.

    06.01.01.02 Insulin Detemir Levemir® Prescribe by BRAND name
    06.01.01.02 Insulin Glargine Lantus® ££
    Prescribe by BRAND name
    06.01.01.02 Insulin Glargine 100 units/ml  Abasaglar ®

    Prescribe by BRAND name

    First line for new patients initiated on insulin glargine 100 units/mL  

     

    06.01.01.02 Insulin Glargine 300 units/ml Toujeo® Reconsidered and approved in April 2017
    Specialist initiation
    For patients who require more than 80 units of insulin glargine per day and who are troubled by nocturnal hypos.
    Transfer to Primary Care should not happen until specialists can demonstrate reduction in nocturnal hypos (e.g. after 3-4 months).
    Supported with a RICaD (under development)
    06.01.01.01 Insulin Glulisine Apidra® Prescribe by BRAND name
    06.01.01.01 Insulin Lispro 100 units/mL  Humalog® Prescribe by BRAND name
    08.02.04 Interferon Alfa  Interferon alfa-2a
    Interferon alfa-2b
    08.02.04 Interferon Beta 
    08.02.04 Interferon Gamma Injection 
    14.05 INTERFERON GAMMA-1b Immukin®
    07.03.04 Intra-uterine Contraceptive Devices T-Safe® 380A QuickLoad® 380
    07.03.04 Intra-uterine Contraceptive Devices MiniTT® 380 Slimline® 380
    07.03.04 Intra-uterine Contraceptive Devices Nova-T® 380
    07.03.05 Intra-uterine Contraceptive Devices - Copper intra-uterine devices  Second line - Copper intra-uterine devices (72-120hrs)
    07.03.02.03 Intra-uterine Progestogen Only System Jaydess® Effective for 3 years
    07.03.02.03 Intra-uterine Progestogen Only System Mirena® Effective for 5 years
    06.02.02 Iodine and Iodide  Aqueous Iodine Oral Solution
    16.03.02 Iodoflex  Cadexomer dressing containing iodine
    Type of wound product is suitable for
    Iodine paste in mesh form for chronic infected, sloughy wounds with moderate exudate eg pressure ulcers, leg ulcers, diabetic foot ulcers
    Can be used under compression bandaging
    MAX Duration dressing remains on wound before changing
    Up to 3 days
    Frequency of dressing change
    Daily for acute infection
    Up to 3 days for chronic wounds and infection, depending on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or sensitivity to iodine
    Precaution with large wounds due to absorption. Do not use more than 50g in a single application and no more than 150g in 7 days
    Dry necrotic wounds
    Thyroid disorders
    Renal impairment
    Not suitable for children, pregnant or lactating mothers
    Concurrent Lithium therapy
    Rationale for inclusion in formulary
    Anti microbial, broad spectrum, long acting/high absorption capacity
    Removes slough and debris to clean the wound bed
    Can be moulded to shape of the wound
    Alternative to honey products if allergy to bees
    16.03.02 Iodosorb  Cadexomer powder or ointment with iodine
    Type of wound product is suitable for
    Chronic exuding sloughy wounds eg leg ulcers, pressure ulcers, diabetic foot ulcers. Can be used under compression bandaging
    Duration dressing remains on wound before changing
    Up to 3 days
    Frequency of dressing change
    Daily for acute infection
    Up to 3 days for chronic infection
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy to iodine products
    Dry necrotic tissue
    Not suitable for Children, pregnant or lactating mothers
    Thyroid disorders
    Renal impairment
    Needs at least twice weekly dressings for iodine to be effective
    Rationale for inclusion in formulary
    Antimicrobial, broad spectrum, long acting
    De-slough and cleans wound debris
    Non-adherant. Reduces trauma to wound and pain on dressing changes
    Easy application. Can fill cavities or awkward shaped wounds
    Alternative to honey based products if allergy to bees
    08.01.05 Ipilimumab Infusion 
    03.01.02 Ipratropium  Ipratropium Inhaler
    Ipratropium Nebulised Solution
    02.05.05.02 Irbesartan 
    08.01.05 Irinotecan Injection 
    09.01.01.01 Iron and Folic Acid Pregaday®
    09.01.01.02 Iron Dextran CosmoFer®
    09.01.01.02 Iron Isomaltoside Monofer®
    09.01.01.02 Iron Sucrose Venofer®
    16.12 Irripod  Sterile sodium chloride solution
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Wound cleansing, for topical irrigation of the eye
    Duration dressing remains on wound before changing
    As required
    Frequency of dressing change
    As required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Single use
    External use only
    Rationale for inclusion in formulary
    Cost effective
    Cleansing of wounds
    15.01.02 Isoflurane 
    06.01.01.02 Isophane Insulin Insulatard® Prescribe by BRAND name
    06.01.01.02 Isophane Insulin Humulin® I Prescribe by BRAND name
    06.01.01.02 Isophane Insulin Insuman® Basal Prescribe by BRAND name
    02.07.01 Isoprenaline  Hospital Use Only
    02.06.01 Isosorbide Dinitrate  Hospital Use Only
    02.06.01 Isosorbide mononitrate   Brand Rationalisation – APC preferred brands:-
    Chemydur XL Tablets
    Monomil XL Tablets
    13.06.02 Isotretinoin ORAL  Dermatologists only.
    Contraindicated in pregnancy
    16.02.02 IV 3000  Specialist recommendation
    Fixation dressing
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For fixation of intravenous and subcutaneous catheter sites
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    Up to 7 days or when wet/soiled
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Sensitivity to any of the product components
    Not for use on pressure ulcers, burns or donor sites
    Strips and documentation label are not to be used as suture replacements or primary wound closure methods
    Rationale for inclusion in formulary
    Fixation of intravenous and subcutaneous devices
    06.01.03 IV fluids 
    02.06.03 Ivabradine  Supported by RICaD
    13.06 Ivermectin 1% cream Soolantra® Alternative option to metronidazole / Azelaic acid.
    13.06.03 Ivermectin 1% cream  Soolantra®

    For topical treatment of inflammatory lesions of rosacea (papulopustular) in adults.

    Alternative treatment option to

    metronidazole 0.75% cream/gel (see section 13.10.1.2)

    or

    azelaic acid 15% gel (see section 13.6.1) 

    13.05.02 Ixekizumab Taltz® Use in line with NICE TA 442
    17.06 Jade Euro  Order code - JECV
    Pack size - 5
    Usual quantity - 5 valves (1 pack) per month
    Review period – Weekly (at every catheter change)
    17.14 Jade-Euro-Med Ltd   Dribbling bag
    Order code - Fig 18
    Usual quantity - May be re-used for at least a month
    Drip Male Urinal
    Order code - M 100
    Usual quantity - May be re-used for at least a month
    Replacement belt for M 100
    Order code - JB 100
    Usual quantity - May be re-used for at least a month
    14.04 Japanese Encephalitis Vaccine Ixiaro® Not NHS Not NHS
    Only available as private prescriptions for travel purposes
    16.22 Jelonet   Paraffin gauze dressing
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    As a primary layer for use with Flamazine or Flammercerium
    Duration dressing remains on wound before changing
    24 hours
    Frequency of dressing change
    Daily- occasionally alternate day
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy to any ingredients.
    Rationale for inclusion in formulary
    Cost effective primary layer
    09.05.02.01 Joulies phosphate solution   Paediatrics
    16.08.04 K lite  Lightweight knitted bandage

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Designed for use on sprains/strains
    Can be used to prevent oedema, would require a wadding bandage to be applied beneath
    It is the second layer of a four layer compression bandage kit
    Where there is open skin, a primary dressing must be used
    Duration dressing remains on wound before changing
    Change in line with primary dressing
    Frequency of dressing change
    1-7 days
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known allergy to any components
    Not suitable for application of pressure on its own and therefore should be used with other bandage components for the treatment of venous ulcers
    Caution over bony prominences where the bandage can cause pressure
    Rationale for inclusion in formulary
    Cost effective
    Essential for providing support to a limb and as part of a bandage compression therapy kit
    16.03.04 Kendall AMD  Specialist use - dressing for pin sites only.
    Absorbent, non adherent foam disc impregnated with PHMB. Double sided with a centre hole and radial slit
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For use on pin sites, drains and tubes.
    Duration dressing remains on wound before changing
    1-7 days
    Frequency of dressing change
    1-7 days dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not intended as a primary treatment for infection
    Do not use as a primary treatment for full thickness burns
    Not for patients sensitive to PHMB

    Rationale for inclusion in formulary
    Provides local exudate management and antimicrobial properties
    Absorbent
    Non adherent and semi occlusive
    16.22 Kerlix   Gauze roll containing 0.2% Polyhexamethylene Biguanide (PHMB)
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Colonised or infected wounds, with moderate to heavy exudate
    Duration dressing remains on wound before changing
    3 days
    Frequency of dressing change
    3 days
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy to PHMB
    Do not use with Sodium hypochlorite ( Eusol) solutions, as this will deactivate PHM
    Do not apply gauze circumferentially as it has no stretch, and can become tight restricting circulation
    Rationale for inclusion in formulary
    Broad-spectrum antimicrobial agent that reduces bacterial colonization within the dressing and bacterial penetration through the dressing.
    Can be used in conjunction with Renasys Negative Pressure Therapy
    13.08.02 Keromask®  Specialist recommendation
    FP10 prescriptions should be endorsed 'ACBS'
    16.17 Kerra Pro  Silicone pads designed to redistribute pressure from bony prominences.
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Prevention and treatment of category (Stage/Grade) 1 pressure ulcers
    Duration dressing remains on wound before changing
    As required. Check skin daily.
    Frequency of dressing change
    As required, check skin daily. Pads will last up to 3 months
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Must only be used as part of a pressure ulcer prevention programme
    Not to be used on a grade 2, 3 4, unstageable or deep tissue injury pressure ulcer unless directed by a clinical specialist
    Known sensitivity to silicone
    Do not use as a wound dressing
    Do not apply directly onto broken skin
    If skin macerates beneath, ensure the area is being checked and washed daily and consider utilising a cotton stockinette to reduce humidity
    Rationale for inclusion in formulary
    Cost effective
    Available in a large range of shapes and sizes
    Accessible pressure ulcer prevention medical device
    Reusable on the same patient for up to 3 months by washing with soap and water and thoroughly drying
    16.01.02 KerraMax  Rationale (developed by TV Team)
    Superabsorbent dressing
    Type of wound product is suitable for
    Highly exuding wounds as a primary or secondary dressing.
    Can be used under compression therapy
    Stackable as no backing present to hold exudate
    Duration dressing remains on wound before changing
    1-7 days.
    Frequency of dressing change
    Dependent on level of exudate, usually daily or more frequently
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not cut or tear
    Rationale for inclusion in formulary
    Required for heavily exuding wounds. Hospital Use Only
    16.16 Kerraped  A shoe to accommodate bandages and offload pressure from the front of the foot
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Neuropathic foot ulcers or patients with bulky bandages who cannot wear their own footwear
    Duration dressing remains on wound before changing
    As required
    Frequency of dressing change
    As required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Ensure correct size is selected
    Rationale for inclusion in formulary
    Only footwear available for patients with neuropathic ulcers or bulky bandages
    15.01.01 Ketamine Injection  Injection
    Preservative-Free Injection
    13.10.02 Ketoconazole 2% cream  ££
    13.09 Ketoconazole 2% shampoo  Primary care prescriptions must be endorsed SLS
    10.01.01 Ketoprofen Injection 
    11.08.02 Ketorolac Acular®
    15.01.04.02 Ketorolac Injection Toradol®
    06.01.06 KetoSens blood ketone test strips 

    Ketone test strips to be used with the CareSens Dual meter

    16.02.03 Kliniderm  Specialist recommendation
    Polyurethane foam with adhesive silicone wound contact layer
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Suitable for acute and chronic wounds including leg ulcers, pressure ulcers, superficial and partial thickness burns, donor sites, post operative wounds and skin abrasions. Suitable for low to moderately exuding wounds for patients with fragile skin
    Available in border and non border

    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    1-7 days – dependant on exudate level
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known product or component sensitivity eg Silicone
    Rationale for inclusion in formulary
    Wound contact surface is coated with a layer of soft silicone which reduces trauma to delicate tissue. Range of shapes and sizes available.
    16.08.01 Knit-Band  Cellulose contour bandage used for retention of non adhesive dressing products

    Rationale (developed by TV Team)
    Type of wound product is suitable for:
    Retention bandage
    Duration dressing remains on wound before changing
    Change in line with dressing change
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Take care to apply joint below to joint above.
    Always use a primary dressing
    Rationale for inclusion in formulary
    Most cost effective choice.
    16.08.06 Ko-flex  A water resistant vapour permeable cohesive bandage

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Venous ulceration, oedema, Managing sprains and strains and following orthopaedic surgery
    Forms part of the K four bandage system
    Duration dressing remains on wound before changing
    1 to 7 days
    Frequency of dressing change
    Dependant on exudate levels if wound present or oedema management .
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not recommended on those patients with an ABPI lower than 0.8.
    Contains latex
    Rationale for inclusion in formulary
    Cohesive bandage that can be used alongside other formulary products
    Forms the 4th layer of a four layer compression bandage system
    16.08.07 K-Soft  An absorbent non –woven, sub bandage wadding.

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Provides padding , shaping and protection of the limb prior to the application of compression bandage therapy.
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    Daily up to weekly dependant on exudate and oedema management.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Advised not to apply directly to skin as can cause irritation.
    Rationale for inclusion in formulary
    Essential for protecting a limb, padding and shaping
    Forms part of the compression bandage regime.
    Suitable for use with other formulary products.
    16.03.04 Kytocel  Absorbent gelling fibre wound dressing
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Moderate to heavily exuding chronic and acute wounds that are sloughy and clinically infected.
    Haemostatic properties for minor bleeds in superficial wounds
    Autolytic debridement properties

    Duration dressing remains on wound before changing
    1-3 days
    Frequency of dressing change
    1-3 days, dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy to Shellfish (Chitin)
    Full thickness burns
    Heavily bleeding wounds
    Dry wounds
    Rationale for inclusion in formulary
    Cost effective
    Alternative to available antimicrobials
    Can be used on heavily exuding wounds
    16.03.01 L- Mesitran hydro/border   UHB - specialist only
    A hydro active gel dressing containing medical grade honey available without or with an adhesive film border. L- Mesitran has anti bacterial properties and can debride and reduce malodour
    Type of wound product is suitable for
    Burns, chronic wounds, necrotic/sloughy wounds, surgical wounds, diabetic ulcers with caution, donor sites, fungating wounds.
    Max Duration dressing remains on wound before changing
    3-7 days
    Frequency of dressing change
    3- 7 days, dependent on exudate level
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to dressing and any of its components use with caution in patients with bee venom allergy
    Not suitable for full thickness burns/deep narrow cavities
    Caution must be exercised when applying to diabetic patients. Blood glucose levels must be monitored.
    Rationale for inclusion in formulary
    Desloughing, Antimicrobial, Deodorising
    17.06 L.IN.C Medical Care-Flo  Order code - CF1
    Pack size - 5
    Usual quantity - 5 valves (1 pack) per month
    Review period – Weekly (at every catheter change)
    17.09 L.IN.C Medical Systems Ltd bladder infusion kit  To maintain closed drainage system
    Order code - MCI/701
    Gauge/CH size - 10
    17.09 L.IN.C Medical Systems Ltd bladder infusion kit  To maintain closed drainage system
    Order code - MCI/701
    Gauge/CH size - 10
    02.04 Labetalol 100mg/20ml injection  Hospital Use Only
    02.04 Labetalol Tablets  Specific indication - Pregnancy
    04.08.01 Lacosamide  Vimpat ® Tablets & Syrup
    Supported with an ESCA
    MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors
    04.08.01 Lacosamide Injection Vimpat ® MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors
    04.08.01 Lamotrigine  Tablets
    Dispersible tablets
    MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history
    08.03.04.03 Lanreotide Somatuline Autogel® and Somatuline® LA®

    Amber Formulary Status Palliative care use only
    Red Oncology, Acromeagly

    09.05.02.02 Lanthanum Fosrenol ® Specialist recommendation
    08.01.05 Lapatinib Tablets 
    09.08.01 L-arginine   Red Capsules, Tablets, Oral solution
    Red Hospital Only Infusion
    09.08.01 Laronidase Infusion Aldurazyme®
    15.02 LAT gel (unlicensed product) 
    11.06 Latanoprost  Specialist Ophthalmologist Recommendation
    11.06 Latanoprost (Preservative Free)  Monopost® Specialist Ophthalmologist Recommendation
    1st line preservative free option
    For use within licence for those patients requiring a preservative free preparation
    11.06 Latanoprost 0.005% with Timolol 0.5% Eye Drops Xalacom® Specialist Ophthalmologist Recommendation
    17.15 LBF Barrier Cream  Order code - 3822
    Usual quantity - Start with 1 pack; check patient tolerance, usage and prescribe as appropriate.
    10.01.03 Leflunomide  Supported with an ESCA
    08.02.04 Lenalidomide 
    09.01.06 Lenograstim Injection Granocyte®
    08.01.05 Lenvatinib  Kisplyx®

    Use in line with NICE

    08.03.04.01 Letrozole 
    06.07.02 Leuprorelin  For endometreosis or breast cancer
    08.03.04.02 Leuprorelin Acetate (3.75mg and 11.25mg) 
    04.08.01 Levetiracetam  Tablets
    SF oral solution
    Coated granules in sachets (Desitrend®)
    Desitrend®
  • Paediatrician initiation.
  • For patients up to and including 16 years of age unable to swallow tablets and in whom the liquid formulation is not appropriate or tolerated.
    MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors
  • 04.08.01 Levetiracetam Infusion  MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors
    15.02 Levobupivacaine Injection Chirocaine®
    15.02 Levobupivacaine with Fentanyl  Levobupivacaine 0.1% with fentanyl 2mcg epidural
    Levobupivacaine 0.1% with fentanyl 4mcg/ml epidural
    11.03.01 Levofloxacin Oftaquix Eye drops - £££ - 2nd line
    Use SDU if using 1or 2 hourly or if significant OSD/toxicity.
    04.02.01 Levomepromazine Nozinan® Tablets - Supported by ESCA
    Injection
    04.06 Levomepromazine (Methotrimeprazine)  For palliative care only
    07.03.05 Levonorgestrel Levonelle® 1500 First Line - Levonorgestrel 1.5mg (Levonelle) - (0-72hrs)
    07.03.02.01 Levonorgestrel 30mcg Norgeston®
    02.07.01 Levosimendan  Hospital Use Only
    06.02.01 Levothyroxine 
    15.02 Lidocaine  GreenLidocaine injection
    Red Hospital OnlyLidocaine 10% spray
    Red Hospital OnlyLidocaine 4% topical solution
    GreenLidocaine 5% ointment
    15.02 Lidocaine  Versatis® Under review
    12.03.01 Lidocaine 10% spray 
    15.02 Lidocaine 2.5% with Prilocaine 2.5% EMLA®
    15.02 Lidocaine 4 % cream LMX 4 Paediatrics only
    15.02 Lidocaine 5% and Phenylephrine 0.5% 
    04.07.03 Lidocaine 5% patch  Versatis® patch Supported by RICaD (in development)
    02.03.02 Lidocaine hydrochloride 
    11.07 Lidocaine Hydrochloride with Fluorescein Minims®
    15.02 Lidocaine with Adrenaline Xylocaine® lidocaine 10% pump spray
    15.02 Lidocaine with Adrenaline  Lidocaine 1% adrenaline 1:200,000 injection
    Lidocaine 2% adrenaline 1:200,000 injection
    Lidocaine 2% adrenaline 1:80,000 cartridge
    15.02 Lidocaine with tetracaine Pliaglis®
    15.02 Lidocaine2% with Chlorhexidine 0.25% Instillagel®
    15.02 Lignocaine 
    16.11 LimbO Waterproof Protector  Waterproof protector, non slip latex free with a flexible seal at the opening
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Used to keep arm, PICC, leg and foot dressings dry, can be fully submerged in water.
    Duration dressing remains on wound before changing
    N/A
    Frequency of dressing change
    N/A
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    N/A
    Rationale for inclusion in formulary
    Multiple sizing for legs and arms
    06.01.02.03 Linagliptin Trajenta® To be used in line with NICE guidance
    06.02.01 Liothyronine  Tablets
    Injection
    16.19 Liquiband Optima   Tissue Adhesive
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Closure of minor skin wounds from surgical incisions and simple traumatic lacerations
    Duration dressing remains on wound before changing
    Single application should be sufficient to close the wound. If this does not maintain the wound edges, refer to a medic for consideration of other wound closure
    Frequency of dressing change
    As necessary
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    May cause skin sensitivities
    Do not use on any wound with evidence of active infection, gangrene or wounds of pressure aetiology
    Do not use on mucosal surfaces or on skin that may be regularly exposed to bodily fluids or with dense natural hair
    Do not use on patients with a known sensitivity to formaldehyde or cyanoacrylate
    Rationale for inclusion in formulary
    Necessary for closure of minor wounds
    13.02.01 Liquid and White Soft Paraffin Ointment (50:50) 
    11.08.01 Liquid Paraffin Xailin® Night First Line
    11.08.01 Liquid Paraffin VitA-POS® Second Line
    16.14 Liquid paraffin / white soft paraffin 50:50  Rationale to support use in the context of wound management
    Emollient ointment containing liquid paraffin and white soft paraffin
    To assist the skin in retaining moisture
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For use on all dry skin conditions including eczema and psoriasis
    Duration dressing remains on wound before changing
    NA
    Frequency of dressing change
    Daily or more frequently if required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or hypersensitivity to any of the ingredients
    Rationale for inclusion in formulary
    Treatment of dry skin conditions.
    Dermatology approved
    06.01.02.03 Liraglutide Victoza® To be used in line with NICE guidance
    04.04 Lisdexamfetamine Elvanse® Not routinely prescribed in primary care.
    Commissioning discussion pending.
    ESCA to be developed
    02.05.05.01 Lisinopril 
    04.02.03 Lithium  Must state brand as different formulations / salts are not interchangeable
    Supported by ESCA
    Regular review in secondary care - full discharge at 12 months
    APC preferred brand:- Priadel
    06.01.02.03 Lixisenatide Lyxumia® 1st line choice GLP1 for Co-prescribing with insulin.
    Supported with a RICaD.
    04.03.01 Lofepramine  Tablets
    Suspension
    04.10.03 Lofexidine Hydrochloride BritLofex®
    08.01.01 Lomustine Capsules 
    04.01.01 Loprazolam 
    04.01.01 Loprazolam Injection 
    03.04.01 Loratadine 
    04.01.02 Lorazepam Injection  
    04.08.02 Lorazepam Injection  
    15.01.04.01 Lorazepam Injection 
    04.01.02 Lorazepam Tablets 
    09.08.01 L-ornithine L-aspartate 5gm/10ml injection 
    02.05.05.02 Losartan 
    11.04.01 Loteprednol Lotemax®
    13.06.02 Lymecycline Tetralysal®300 In line with Antibiotic guide
    16.09.02 Lymphoedema garments  Based on specialest assessment
    17.06 MacGregor Qufora  Order code - 21104204
    Pack size - 5
    Usual quantity - 5 valves (1 pack) per month
    Review period – Weekly (at every catheter change)
    17.07 MacGregor Qufora sterile Q Flow   Lever Tap
    Order code - 12161704 - 12361504
    Pack size - 350/500/750ml X 10 per box
    Usual quantity - 10 every 2 months
    Review period – Before each Rx
    T-tap
    Order code - 12151704 - 12351504
    Pack size - 350/500/750ml X 10 per box
    Usual quantity - 10 every 2 months
    Review period – Before each Rx
    09.05.01.03 Magnesium Aspartate Dihydrate Sachet 
    09.05.01.03 Magnesium citrate 
    09.05.01.03 Magnesium Glycerophosphate  Unlicensed – specialist initiation and stabilisation
    09.05.01.03 Magnesium Sulphate Injection 
    13.10.05 Magnesium Sulphate Paste BP 
    16.11 Magnide (application aid for closed toe stockings)  Application aid for closed toe stockings
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Application of closed toe compression garments
    Duration dressing remains on wound before changing
    N/A
    Frequency of dressing change
    N/A
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    N/A
    Rationale for inclusion in formulary
    Effective applicator for closed toe hosiery
    13.10.04 Malathion 
    02.02.05 Mannitol  Hospital Only
    03.07 Mannitol inhalation Bronchitol ® Hospital only
    17.08 McGregor Qufora  Order code - 14851204
    Pack size - 2L x 10
    Usual quantity - 10 every 2 months (1 pack every 2 months)
    Review period – Before each Rx
    14.04 Measles, Mumps and Rubella Vaccine, Live (MMR) 
    06.07.04 Mecasermin Increlex® Hospital use only
    13.02.02 MediHoney Barrier cream  Specialist recommendation
    Barrier cream containing active Medihoney.
    Helps to reduce inflammation
    When used in the context of wound management
    Type of wound product is suitable for
    Treatment of incontinence related lesions
    Treats blistered skin
    Prevention and treatment of maceration and excoriation
    Treats candidiasis and intertrigo
    Duration dressing remains on wound before changing
    At each episode of hygiene
    Frequency of dressing change
    At each episode of hygiene
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Patch test before use
    Rationale for inclusion in formulary
    Suitable for neonates and children
    Treats fungal infections as well as incontinence associated lesions
    Reduces inflammation
    Can be applied to broken skin
    16.15 MediHoney Barrier cream   Specialist recommendation
    Barrier cream containing active Medihoney.
    Helps to reduce inflammation
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Treatment of incontinence related lesions
    Treats blistered skin
    Prevention and treatment of maceration and excoriation
    Treats candidiasis and intertrigo
    Duration dressing remains on wound before changing
    At each episode of hygiene
    Frequency of dressing change
    At each episode of hygiene
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Patch test before use
    Rationale for inclusion in formulary
    Suitable for neonates and children
    Treats fungal infections as well as incontinence associated lesions
    Reduces inflammation
    Can be applied to broken skin
    06.04.01.02 Medroxyprogesterone Acetate Provera®
    06.04.01.02 Medroxyprogesterone Acetate Climanor®
    07.03.02.02 Medroxyprogesterone Acetate Depo-Provera®
    07.03.02.02 Medroxyprogesterone acetate Sayana Press® Suitable for self-injection in patients who have had appropriate training
    08.03.02 Medroxyprogesterone Acetate 
    10.01.01 Mefenamic Acid  For dysmenorrhoea
    Tablets and Capsules
    16.07.03 Mefix  Permeable, aperture non woven, synthetic adhesive tape
    For securing dressings.
    Rationale (developed by TV Team)
    Frequency of dressing change
    Determined by wound type and dressing change
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None listed
    Rationale for inclusion in formulary
    Available on drug tariff. Different availability of sizes in comparison to Clinipore for difficult to dress areas. Some stretch and flexibility to improve conformity and adhesion. Can be used to secure dressings rather than bandages.
    08.03.02 Megestrol Acetate 
    04.01.01 Melatonin  Circadin ®
    04.01.01 Melatonin 
    08.01.01 Melphalan  Red Tablets
    Red Hospital Only Injection
    04.11 Memantine Ebixa® APC verdict - present status = RED
    Future status = AMBER with a framework in primary care before transfer - commissioning discussion
    09.06.06 Menadiol Sodium Phosphate 
    14.04 Meningococcal A, C, W135, and Y conjugate vaccine 
    14.04 Meningococcal group B Vaccine Bexsero®
    14.04 Meningococcal group C conjugate vaccine 
    13.03 Menthol 1% in aqueous cream  Dermacool - ££
    03.08 Menthol and Eucalyptus Inhalation BP 1980 
    13.14.07 Mepacrine Hydrochloride  

    For Discoid lupus erythematosus (DLE) See Chapter 5

    16.04.02 Mepiform  Specialist recommendation (burns)
    Silicone sheet for scar treatment
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Not for use on open wounds- to be applied on healed scar only.
    This is not a dressing but a scar treatment
    Duration dressing remains on wound before changing
    23 hours
    Frequency of dressing change
    Daily
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use on open or infected wounds
    Do not use on skin affected by acne
    Discontinue use if a rash or itching occur
    Rationale for inclusion in formulary
    Scar therapy
    Silicone sheets have been shown to soften, flatten scarring aiding movement, nerve sensations and function.
    Cost effective
    16.02.03 Mepitel  Specialist recommendation
    Soft polymer non adherent dressing without pad
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Primary wound contact layer, non adherent, traumatic and chronic wounds
    Requires secondary dressing
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    Up to 7 days
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Heavily bleeding wounds
    Any sensitivity to silicone
    Rationale for inclusion in formulary
    Non adherent primary wound contact layer to protect skin tears, fragile skin, primary contact layer for use under topical negative pressure
    15.02 Mepivacaine Scandonest Plain®
    03.04.03 Mepolizumab Nucala® Use in line with NICE TA431
    16.01.02 Mepore  Second line
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Post operative closed surgical wounds or simple wounds with up to light amounts of exudate.
    Can be used as a protective dressing for sutured post operative wounds. Can be used as a protective dressing for newly epithelialized wounds. Can be used for small traumatic wounds.
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    1-7 days. If daily change is required - review product choice
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known product or component sensitivity.
    Rationale for inclusion in formulary
    Sutured surgical wounds for protection. Can be used as a protective dressing for newly epithelialized wounds. Can be used for small traumatic wounds.
    04.07.02 Meptazinol Meptid®
    09.08.01 Mercaptamine Cystagon® NHSE commissioned
    08.01.03 Mercaptopurine Tablets 
    For Oncology
    03.12 Meropenem nebulised  Hospital only
    08.01 Mesna  This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Red Formulary Status
    Red Formulary Status

    Not Present on this Formulary

    Amber Formulary Status
    Amber Formulary Status
    07.03.01 Mestranol 50mcg / Norethisterone 1000mcg Norinyl-1® For patients who need high oestrogen
    For patients who are on anticonvulsant treatment
    16.15 Metanium ointment  Barrier cream
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For relief of the symptoms of nappy rash
    Frequency of dressing change
    Spread the ointment thinly so the skin texture can be clearly seen through it. Repeat at each nappy change.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used on adults in conjunction with containment products for incontinence due to the inclusion of light liquid and white paraffin in the ingredients, which will repel urine/faeces back onto the skin.
    Any allergy to the listed ingredients
    Overdose is unlikely when Metanium Nappy Rash Ointment is used as instructed for treating nappy rash. However, as this product contains titanium salicylate, accidental ingestion or excessive topical application could lead to symptoms of salicylate poisoning.
    Rationale for inclusion in formulary
    Dermatology approved
    13.02.02 Metanium® Cream  Specialist recommendation
    Barrier cream
    When used in the context of wound management
    Type of wound product is suitable for:
    For relief of the symptoms of nappy rash
    Frequency of change
    Spread the ointment thinly so the skin texture can be clearly seen through it. Repeat at each nappy change.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used on adults in conjunction with containment products for incontinence due to the inclusion of light liquid and white paraffin in the ingredients, which will repel urine/faeces back onto the skin.
    Any allergy to the listed ingredients
    Overdose is unlikely when Metanium Nappy Rash Ointment is used as instructed for treating nappy rash. However, as this product contains titanium salicylate, accidental ingestion or excessive topical application could lead to symptoms of salicylate poisoning.
    Rationale for inclusion in formulary
    Dermatology approved
    02.07.02 Metaraminol  Hospital Use Only
    06.01.02.02 Metformin 
    06.01.02.02 Metformin Hydrochloride MR  2nd line - ONLY for patients intolerant of slowly titrated standard release metformin
    BCC CCG preferred brand:- Sukkarto SR 500mg and 1000mg prolonged release tablets.
    06.01.02.02 Metformin oral solution SF 

    2nd line - For patients with swallowing difficulties £££

    04.10.03 Methadone   Injection
    Tablets
    03.09.01 Methadone Hydrochloride 2mg/5ml  Palliative care only
    04.10.03 Methadone mixture 1mg/ml  
    03.12 Methotrexate  Supported with a ESCA
    08.01.03 Methotrexate  Red Tablets for oncology
    Red Hospital Only Injection for oncology
    10.01.03 Methotrexate  Supported with an ESCA
    Methotrexate tablets - use 2.5mg strength ONLY
    Methotrexate Injection - Metoject is APC preferred brand.
    Check cytotoxic disposal arrangements locally
    13.05.03 Methotrexate  Specialist initiation and stabilisation
    Supported with an ESCA (under development)
    09.01.03 Methoxy Polyethylene Glycol-Epoetin Beta Mircera® NHSE commissioned Renal dialysis
    CCG Commissioned for use in cancer - NICE TA 323
    13.05.02 Methoxypsoralen  Methoxypsoralen 5 - 20mg tablets
    And
    8-methoxypsoralen 10mg tablets
    13.08.01 Methyl-5-Aminolevulinate Metvix®
    02.05.02 Methyldopa Tablets 
    04.04 Methylphenidate  Please note that Commissioning discussion are underway. However the present status is as follows:-
    Red Birmingham CrossCity CCG, Birmingham South Central CCG, Sandwell & West Birmingham CCG
    Amber Traffic Light Supported with an ESCA - Solihull CCG.
    04.04 Methylphenidate Hydrochloride MR  Please note that commissioning discussion is underway. However the present status is as follows:-
    Red Birmingham CrossCity CCG, Birmingham South Central CCG, Sandwell & West Birmingham CCG
    Amber Traffic Light Supported with an ESCA - Solihull CCG.

    BSMHT preferred brands:- Concerta XL, Equasym XL, Medikinet XL
    10.01.02.02 Methylprednisolone Acetate Depo-Medrone®
    10.01.02.02 Methylprednisolone Acetate Depo-Medrone® with Lidocaine
    06.03.02 Methylprednisolone acetate injection 
    06.03.02 Methylprednisolone sodium succinate injection 
    06.03.02 Methylprednisolone tablets 

    In line with NICE

    02.05.05 Metirosine  Hospital Use Only
    04.06 Metoclopramide  Tablets
    SF solution - £££ - swallowing difficulties only
    Not 1st choice in patients under 20 years of age
    04.06 Metoclopramide Injection  For hospital use only
    02.02.01 Metolazone  Specialist recommendation (unlicensed)
    Use with local trust approval.
    Available from ‘special-order’ manufacturers or specialist-importing companies.
    02.04 Metoprolol Tartrate  Tablets
    Modified Release Tablets
    02.04 Metoprolol Tartrate Injection Betaloc® Hospital Use Only
    13.10.01.02 Metronidazole 0.75%  Rosex ® - For acne rosacea. Not for infected wounds
    Acea® - For acne rosacea. Not for infected wounds
    Anabact ® gel - Malodorous tumours and skin ulcer. For wounds
    07.02.02 Metronidazole gel 0.75%  Zidoval®
    06.07.03 Metyrapone Metopirone®
    02.03.02 Mexiletine hydrochloride (unlicensed)  Use with local trust approval.
    Available from ‘special-order’ manufacturers or specialist importing companies
    12.03.02 Miconazole Daktarin®
    13.10.02 Miconazole  2% cream
    2% dusting powder
    11.03.02 Miconazole 1% eye drops 
    07.02.02 Miconazole 1.2g vaginal capsule  Gyno-Daktarin 1®
    07.02.02 Miconazole 2% intravaginal cream Gyno-Daktarin®
    04.08.02 Midazolam Buccolam®
    15.01.04.01 Midazolam Injection Hypnovel® For palliative care
    02.07 Midodrine Bramox® 3rd line after non-pharmacological intervention
    2nd line after pharmacological therapy
    Supported with an ESCA
    08.01.05 Midostaurin Rydapt®

    Use in line with NICE.

    08.02.04 Mifamurtide Infusion 
    07.01.02 Mifepristone Mifegyne®
    09.08.01 Miglustat Zavesca®
    04.07.04.01 Migraleve Pink ® 
    02.05.01 Minoxidil Loniten®
    07.04.02 Mirabegron Betmiga® Use in line with NICE
    04.03.04 Mirtazapine  Tablets
    Orodispersible tablets - £££
    07.01.01 Misoprostol  Unlicensed - oral or PV
    11.99.99.99 Mitomycin  

    Mitomycin drops - SPECIAL (unlicensed formulation)

    08.01.02 Mitomycin Injection 
    08.01.05 Mitotane Tablets Lysodren®
    08.01.02 Mitoxantrone Injection 
    15.01.05 Mivacurium Chloride Injection Mivacron®
    06.01.06 Mobile Cassette  

    Glucose test strips to be used with the Accu-Chek Mobile

    Restricted use: Meter restricted for use in patients with needle phobia, paediatrics, visual impairments, and physical impairments requiring single- handed use.

    04.03.02 Moclobemide 
    04.04 Modafinil  For treatment of narcolepsy only
    12.02.01 Mometasone Furoate  £££
    Second Line
    13.04 Mometasone Furoate 0.1% Elocon® Potency: potent
    Cream
    Ointment
    Scalp lotion
    03.03.02 Montelukast 
    04.07.02 Morphine  Suppositories
    100mg/100ml PCA
    5mg/5ml intrathecal injection
    Pre-filled syringes
    04.07.02 Morphine  Tablets
    MR tablets
    MR capsules
    Solution
    Injection
    15.01.04.02 Morphine Injection 
    02.05.02 Moxonidine 
    09.06.07 Multivitamins 
    13.10.01.01 Mupirocin Bactroban® Cream and Ointment
    12.02.03 Mupirocin 2% nasal ointment 
    13.05.03 Mycophenolate   Specialist initiation and stabilisation
    Supported with an ESCA (under development)
    08.02.01 Mycophenolate Mofetil  Red Tablets & Suspension - New post transplant
    Amber Formulary Status Tablets & Suspension - Post transplant pre 2013
    Red Hospital Only Injection
    10.02.01 Mycophenolate mofetil   Supported by ESCA
    For use in connective tissue diseases
    For specialist initiation and dose stabilisation.
    03.07 N - Acetylcysteine  Nebulised Solution
    16.01.01 N/A Ultra  Second Line
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For flat granulating and epithelising wound for non to heavy exudate levels where adherence may occur. To be used as a primary dressing with a secondary for absorption.
    Duration dressing remains on wound before changing
    7 days maximum
    Frequency of dressing change
    1-7 days, depending on levels of exudate
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known product or component sensitivity eg silicone
    Use with care if wound is bleeding heavily
    Rationale for inclusion in formulary
    To be used to reduce adherence to wound bed
    02.06.04 Naftidrofuryl 
    04.10.01 Nalmefene  Update following Jan 15 APC.
    Restricted to Specialist Substance Misuse Services only.
    Birmingham = Crime Reduction Initiatives (CRI) - Reach Out Recover. Single point of contact 24/7 Tel: 0121 227 5890
    Sandwell = Swanswell Tel: 0121 553 1333
    Solihull = Solihull Integrated Addiction Services (SIAS). Tel: 0121 301 3600
    04.10.03 Naloxone 

    Used to reverse opioid overdose.

    15.01.07 Naloxone Injection 
    04.10.01 Naltrexone 
    04.10.03 Naltrexone Nalorex®
    06.04.03 Nandrolone decanoate injection Deca-Durabolin® Hospital use only
    10.01.01 Naproxen 
    08.02.04 Natalizumab Tysabri®
    03.07 Nebulised Hypertonic sodium chloride Resp-Ease® Resp-Ease® (Sodium chloride 7% nebuliser solution) for CF patients
    08.01.03 Nelarabine vial 
    11.04.02 Neodocromil Rapitil®
    15.01.06 Neostigmine 
    10.02.01 Neostigmine Injection  Hospital only
    10.02.01 Neostigmine Tablets 
    02.06.03 Nicorandil  Specialist initiation
    09.06.02 Nicotinamide 
    13.06.01 Nicotinamide Nicam® 3rd line
    04.10.02 Nicotine replacement therapy 
    02.06.02 Nifedipine  Brand Rationalisation – APC preferred brands:-
    Adipine MR Tablets
    Adipine XL Tablets
    Coracten SR Capsules
    Coracten XL Capsules
    07.01.03 Nifedipine (unlicensed) 
    08.01.05 Nilotinib Capsules 
    02.06.02 Nimodipine Infusion Nimotop® Hospital Use Only
    02.06.02 Nimodipine Tablets Nimotop®
    08.01.05 Nintedanib Vargatef®

    Hospital only- NHSE commissioned

    Use in line with NICE

    03.12 Nintedanib (Ofev®) 

    Hospital only- NHSE commissioned

    Use in line with NICE and available from day 91 following publication of TA.

    09.08.01 Nitisinone capsules 
    15.01.02 Nitrous oxide 
    08.02.03 Nivolumab Opdivo®

    In line with NICE 

    02.07.02 Noradrenaline / Norepinephrine  Hospital Use Only
    06.04.01.02 Norethisterone 
    08.03.02 Norethisterone 
    07.03.02.01 Norethisterone 350mcg Noriday®

    Alternative to discontinued Micronor®

    14.05 Normal immunoglobulin Vivaglobin®
    14.05.01 Normal immunoglobulin for Intramuscular use 
    14.05.01 Normal immunoglobulin for Subcutaneous use 
    12.03.02 Nystatin 100,000units/ml suspension Nystan® Don not prescribe Sugar Free
    07.02.02 Nystatin pessaries (unlicensed) 
    16.05.02 Oakmed Option Wound Manager  Wound drainage system consisting of a hydrocolloid adhesive wafer and a drainable drainage bag
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Complex abdominal wounds, moderate to large fistula’s, orthopaedic wounds or fungating wounds with high levels of exudate, that are unmanaged with conventional dressings.
    Max Duration dressing remains on wound before changing
    Empty drainage bag as required. If no port for drainage, change as required.
    Frequency of dressing change
    As long as adhesive remains intact whilst being mindful of skin integrity
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known product component sensitivity to hydrocolloid (Gelatine and Pectin)
    Low to moderate exuding wounds
    Do not use if a conventional dressing can manage the exudate levels
    Rationale for inclusion in formulary
    Various size selection with drainage ports and windows
    For highly exuding wounds that conventional dressings cannot manage the exudate levels
    08.02.03 Obinutuzumab  Use in line with NICE
    NHS England funded
    11.08.02 Ocriplasmin Jetrea®

    Use in line with NICE

    13.11 Octenisan®   MRSA skin decolonisation, if chlorhexidine sensitivity is a problem.
    08.03.04.03 Octreotide Sandostatin® and Sandostatin Lar®

    Amber Formulary Status Palliative care use only
    Red Oncology, Acromeagly

    06.04.01.01 Oestrogen only HRT patch Estradot, Evorel, FemSeven, Estraderm MX, Elleste Solo MX, Progynova TS, Sandrena Gel This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Present on this Formulary
    But
    UHB does not commence oestrogens or HRT but will continue treatment for patients adimtted on these products in line with the Birmingham Women's Hospital Formulary.

    Amber Formulary Status
    Amber Formulary Status
    When oral therapy inappropriate
    Estradot, Evorel, FemSeven

    Amber Formulary Status
    Amber Formulary Status
    Evorel

     

    BWHFT Formulary

    GREENAMBER                                    RED                                                          
    Oestrogen Only Transdermal Preparations
    Evorel 25mcg, 50mcg, 75mcg & 100mcg Patches
    Oestrogel 0.06% - 1-4 strips daily
    Estraderm MX 25mcg, 50mcg, 75mcg & 100 mcg Patches
    Estradot 25mcg, 37.5mcg, 50mcg, 75mcg & 100mcg Patches 
    Elleste Solo MX 40mcg & 80mcg Patches
    Femseven 50mcg, 75mcg & 100mcg Patches
    Progynova TS 50mcg & 100mcg Patches
    Sandrena Gel 500mcg & 1mg sachets daily
     
    Prescribing Advice
    Alternatives to The Evorel Patches can be tried if patient unable to tolerate due to skin irritation or poor absorption or failure of patches to adhere to the skin. Gels may also provide an alternative in these circumstances or in patients with an allergy to plasters.
    Progestogens should also be prescribed for women with intact uterus.
    06.04.01.01 Oestrogen only HRT tablet Elleste-Solo, Premarin, Bedol, Climaval, Hormonin, Progynova, Zumenon This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Present on this Formulary
    But
    UHB does not commence oestrogens or HRT but will continue treatment for patients adimtted on these products in line with the Birmingham Women's Hospital Formulary.

    Green Formulary Status
    Green Formulary Status
    Conjugated oestrogens (Premarin ®), Estradiol (Elleste-Solo ®)

    Green Formulary Status
    Green Formulary Status
    Premarin ®

     

    BWHFT Formulary

    GREENAMBER                                    RED                                  
    Oestrogen Only Oral Preparations
    Premarin 300mcg & 0.625mg & 1.25mg
    Elleste Solo 1mg & 2mg
    Bedol 2mg
    Climaval 1mg & 2mg
    Hormonin
    Progynova 1mg & 2mg
    Zumenon 1mg & 2mg
     
    Prescribing Advice
    Progestogens should also be prescribed for women with intact uterus.
    06.04.01.01 Oestrogens for HRT Climagest® This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Not Present on this Formulary

    Not Present on this Formulary

    Green Formulary Status
    Green Formulary Status
    08.02.03 Ofatumumab Arzerra®
    11.03.01 Ofloxacin 0.3% Eye drops Exocin®
    04.02.01 Olanzapine  Supported by ESCA
    Tablets
    Orodispersible tablets
    04.02.02 Olanzapine Embonate ZypAdhera®
    08.01.05 Olaparib  Lynparza ®

    Hospital only- NHSE commissioned

    Use in line with NICE

    12.01.03 Olive Oil Ear Drops 
    11.04.02 Olopatadine Opatanol® 2nd line - £££
    03.04.02 Omalizumab Xolair® Hospital only
    13.05.03 Omalizumab   In line with NICE
    16.07.05 Omnistrip  Adhesive wound closure strip

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For atraumatic closure of minor wounds or surgical incisions
    Require a secondary dressing
    Duration dressing remains on wound before changing
    As necessary, up to 14 days
    Frequency of dressing change
    As necessary
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None
    Rationale for inclusion in formulary
    Cost effective
    Essential for closure of minor injuries
    04.06 Ondansetron  For Chemotherapy
    Tablets
    Melt tablets
    SF syrup - swallowing difficulties only
    Suppositories
    Injection
    04.06 Ondansetron  For hyperemesis in pregnancy (off label)
    and
    For use in palliative care (off label)
    Tablets
    Melt tablets
    SF syrup - swallowing difficulties only
    Suppositories
    Injection
    04.09.01 Opicapone  Ongentys ® Second-line therapy to entacapone, in patients who fail to respond to, or are intolerant of, entacapone, in situations where apomorphine therapy is being considered.
    Supported with and ESCA
    ESCA under development
    02.13 Optison®  Hospital Use Only
    09.02.01.02 Oral Rehydration Salts 
    04.05.01 Orlistat  o Suitable in patients with a BMI of over 30 or if BMI of 28 or more with other risk factors for cardiovascular disease
    o Only continue prescription beyond 3 months if the patient has lost at least 5% of body weight since starting drug.
    o Do not co-prescribe orlistat with other drugs aimed at weight loss.
    o The patient must keep to a low fat diet to reduce the potential for side effects and maximise likely weight loss
    o Consider administration of a multivitamin supplement.
    o All patients should have weight regularly monitored to assess response to treatment along with any other relevant physical monitoring associated
    with their physical health and/or medication.
    08.01.05 Osimertinib 

    Use in line with NICE

    08.01.05 Oxaliplatin 
    06.04.03 Oxandrolone Tablets 2.5 mg 
    04.01.02 Oxazepam 
    04.08.01 Oxcarbazepine Trileptal® Tablets
    Suspension
    MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history
    11.07 Oxybuprocaine Hydrochloride Minims®
    07.04.02 Oxybutynin 
    07.04.02 Oxybutynin Hydrochloride patch Kentera® If first line are not tolerated. Following specialist advise.
    13.12 Oxybutynin immediate release tablets  
  • For hyperhidrosis (off label use)
  • After trial of aluminium salts
  • 07.04.02 Oxybutynin MR 

    £££

    04.07.02 Oxycodone  Patients who do not tolerate morphine
    Capsules - BCC CCG preferred brand - Lynlor Capsules
    MR tablets - BCC CCG preferred brand - Reltebon MR Tablets
    SF Solution
    04.07.02 Oxycodone hydrochloride injection 
    03.06 Oxygen  Green Short term use in palliative care
    Amber Formulary Status Long term use- requires specialist assessment


    13.06.02 Oxytetracycline  In line with Antibiotic guide
    07.01.01 Oxytocin 
    08.01.05 Paclitaxel - Albumin Bound Formulation Abraxane®

    Use in line with NICE

    08.01.05 Paclitaxel Injection 
    08.01.05 Palbociclib Ibrance®

    Use in line with NICE

    Hospital only – NHSE commissioned

    08.01 Palifermin Kepivance® This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Red Formulary Status
    Red Formulary Status

    Not Present on this Formulary

    Not Present on this Formulary
    04.02.02 Paliperidone Xeplion® APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion)
    04.02.02 Paliperidone Long Acting Injection Trevicta®
  • Third line option
  • Patient has been stable mentally for at least 12 months and had a stable dose of paliperidone palmitate monthly injection and has not required a dosage adjustment in the last 6 months.
  • (12 months using the monthly injections and no dose adjustment for last 6 month before considering the 3-monthly injection)
  • APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion)
  • 04.06 Palonosetron Aloxi®
    15.01.05 Pancuronium Bromide Injection 
    08.01.05 Panitumumab Vectibix®
    08.01.05 Panobinostat Farydak®

    Hospital only- NHSE commissioned

    Use in line with NICE

    04.07.01 Paracetamol  Tablets
    Soluble tablets - high sodium content - Only if swallowing difficulties
    SF suspension
    04.07.01 Paracetamol and codeine Co-codamol ®15/500 £££
    Limited evidence.
    For elderly community who would not tolerate separate ingredients and to support a step down review.
    Where ever possible, avoid the use of combination products.
    Use paracetamol and codeine separately.
    All combination products of paracetamol and codeine / dihydrocodeine are deemed products less suitable for prescribing in the BNF
    04.07.01 Paracetamol and codeine Co-codamol® 30/500 Where ever possible, avoid the use of combination products.
    Use paracetamol and codeine separately.
    All combination products of paracetamol and codeine / dihydrocodeine are deemed products less suitable for prescribing in the BNF
    Tablets
    Capsules
    Effervescent tablets - £££ - sodium content. Only if swallowing difficulties
    04.07.01 Paracetamol IV Perfalgan®
    04.07.01 Paracetamol Suppositories 
    04.08.02 Paraldehyde rectal solution 50% in olive oil (10ml) 
    06.06.01 Parathyroid Hormone 
    15.01.04.02 Parecoxib Injection Dynastat®
    09.03 Parenteral Nutrition (TPN or PN) 
    Parenteral Nutrition (TPN or PN)
    TPN scratch bag
    • All patients who require parenteral nutrition must be referred to the Parenteral Nutrition Team.
    • For patients who require home care, arrangements for discharge must be made as early as possible.
    • Basic regimes are stocked for emergencies but wherever possible treatment must be tailored to the needs of the patient. These regimens are required to be ordered specially and may take a few days to arrive.
    09.06.04 Paricalcitol Zemplar®
    04.03.03 Paroxetine  Tier 2 - Tablets
    08.01.05 Pazopanib Tablets 
    03.01.05 Peak Flow Meter 
    14.04 Pediacel® 
    08.01.05 Pegaspargase Oncaspar®

    Hospital only- NHSE Commissioned

    Use in line with NICE.

    09.01.06 Pegfilgrastim 
    08.02.04 Peginterferon Alfa  Peginterferon alfa-2a
    Peginterferon alfa-2b prefilled pen
    08.01.05 Pembrolizumab Keytruda® NHSE Commissioned
    Use in line with NICE TA 357
    08.01.03 Pemetrexed Injection 
    04.02.01 Penfluridol (Oral) 
    09.08.01 Penicillamine  Specialist recommendation for Wilson disease
    Supported with and ESCA (in development)
    10.01.03 Penicillamine  Supported with an ESCA
    11.03.01 Penicillin 5000 units in 1ml eye drops  Unlicensed
    Ophthalmologists only
    08.01.05 Pentostatin Infusion Nipent®
    04.08.01 Perampanel Fycompa® Supported with a ESCA
    MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history
    02.06.03 Perhexiline 
    04.02.01 Pericyazine Neilactil® Supported by ESCA
    02.05.05.01 Perindopril erbumine 
    13.10.04 Permethrin  5% Lyclear® Dermal Cream
    04.02.01 Perphenazine Fentazin® Supported by ESCA
    08.01.05 Pertuzumab Injection 
    04.07.02 Pethidine Injection 
    15.01.04.02 Pethidine Injection 
    02.08.02 Phenindione tablets 
    04.08.01 Phenobarbital  Tablets
    Elixir
    MHRA Category 1 - Doctors are advised to ensure that their patient is maintained on a specific manufacturer’s product
    04.08.01 Phenobarbital Injection  MHRA Category 1 - Doctors are advised to ensure that their patient is maintained on a specific manufacturer’s product
    13.14.07 Phenol 2% w/w in compound zinc paste BP  BAD recommended quantity = 50g
    Used for intractable pruritus ani, unresponsive to moderate strength topical steroid and barrier preparations.
    02.05.04 Phenoxybenzamine Hydrochloride Capsules 
    02.07.02 Phenylephrine  Hospital Use Only
    11.05 Phenylephrine Hydrochloride Single Dose Units 
    04.08.01 Phenytoin  Capsules
    Suspension
    MHRA Category 1 - Doctors are advised to ensure that their patient is maintained on a specific manufacturer’s product
    04.08.01 Phenytoin Injection  MHRA Category 1 - Doctors are advised to ensure that their patient is maintained on a specific manufacturer’s product
    03.09.01 Pholcodine Linctus, BP 
    09.05.02.01 Phosphate Infusion Phosphate Polyfusor®
    09.05.02.01 Phosphate supplements Phosphate-Sandoz®
    09.06.06 Phytomenadione 1mg capsules 
    09.06.06 Phytomenadione Injection  Konakion® MM
    Konakion® MM Paediatric
    16.06.01 PICO products  Disposable and portable system designed to kick start wound healing. Required components: One PICO device, 2 dressings per kit.
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Acute, chronic, dehisced, partial thickness burns, flaps, grafts and traumatic wounds.
    Consider standard interactive dressings first.
    Duration dressing remains on wound before changing
    Twice a week dressing change, PICO device weekly change
    Frequency of dressing change
    Determined by exudate levels.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    It should not be used on:
    Confirmed and untreated osteomyelitis
    Malignancy in wound bed or wound margins
    Exposed blood vessels
    Organs
    Unexplored fistulae
    Necrotic wounds
    Anastomotic sites
    Emergency airway aspiration
    Pleural, mediastinal or chest tube drainage and surgical suction
    Rationale for inclusion in formulary
    These devices promote patient mobility at a cost effective price and is available on drug tariff which other comparable models are not.
    11.06 Pilocarpine  Amber <br>Formulary Status Specialist ophthalmologist recommendation - 1%, 2% & 4% eye drops
    Red Hospital Only Single dose units (SDU) - Specialist ophthalmologist use
    12.03.05 Pilocarpine Hydrochloride Tablets Salagen® Licensed for treatment of xerostomia following irradiation for head and neck cancer; dry mouth and dry eyes in Sjögren's syndrome.

    Effective only in patients who have residual salivary gland function.
    13.05.03 Pimecrolimus Elidel® Use in line with NICE TA82
    04.02.01 Pimozide Orap®
    06.01.02.03 Pioglitazone 
    04.09.03 Piracetam Nootropil® Tablets
    Solution
    03.12 Pirfenidone  Hospital only
    04.07.04.02 Pizotifen  Tablets
    Elixir
    09.01.07 Plerixafor Injection Mozobil® NHSE commissioned
    14.04 Pneumococcal polysaccharide conjugate vaccine (adsorbed) Prevenar 13®
    14.04 Pneumococcal polysaccharide conjugate vaccine (adsorbed) Synflorix®
    13.07 Podophyllotoxin  Condyline®
    Warticon®
    13.07 Podophyllum 
    14.04 Poliomyelitis Vaccine Inactivated (Salk)  The polio vaccine is only given as part of combined products
    16.22 Polyfax  Rationale (developed by TV Team)
    Type of wound product is suitable for
    Partial thickness facial burns & healing graft sites, infected/ colonised wounds
    Duration dressing remains on wound before changing
    2 days or 2-3 times/ day depending on injury site and type- as directed by Burns team
    Frequency of dressing change
    2 days or 2-3 times/ day
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy to Polymixin B Sulphate or Bacitracin Zinc
    No more than 200g of Polyfax ointment per day
    Rationale for inclusion in formulary
    Prevent and treat bacterial infections in burns
    16.07.01 Polyfield Nitrile Patient Pack  Primary care and BCHC
    Other trust - as per trust contract

    Sterile dressing pack
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    To be used on all wounds requiring aseptic dressing procedures
    Duration dressing remains on wound before changing
    Single use
    Frequency of dressing change
    Determined by wound type
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None listed
    Rationale for inclusion in formulary
    Available on drug tariff, cost effective and incorporates a measure guide which would be an additional cost with other packs
    16.02.05 PolyMem (excluding Silver)   Specialist recommendation
    Foam dressing that contains a cleansing agent and glycerol
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Low to moderately exuding wound including skin tears, and other traumatic wounds, superficial and partial thickness wounds, burns, donor and graft sites and radiotherapy induces reactions
    Duration dressing remains on wound before changing
    2-7 days
    Frequency of dressing change
    Up to 7 days dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Sensitivity to ingredients contained within the dressing
    Not for full thickness burns
    Not for ischaemic wounds
    Not for diabetic foot wounds
    Not in conjunction with solutions containing hypochlorite
    Rationale for inclusion in formulary
    Suitable for fragile and sensitive skin,
    Soft and comformable,
    Easy to redress awkward areas
    Wide range of sizes including digit shaped dressings
    14.04 Polysaccharide Typhoid Vaccine Typherix®
    14.04 Polysaccharide vaccine for injection Typhim Vi®
    09.02.01.01 Polystyrene Sulphonate Resins Resonium A®
    09.02.01.01 Polystyrene Sulphonate Resins Calcium Resonium®
    13.09 Polytar Plus®  Contains peanut oil
    13.09 Polytar®  Contains peanut oil
    08.01.05 Ponatinib Iclusig®

    Use in line with NICE

    03.05.02 Poractant Alfa Curosurf® Hospital only
    09.02.01.01 Potassium Chloride  Green MR tablets & Sando-k effervescent tablets
    Amber Formulary Status SF Syrup (Kay-Cee-L) - specialist recommendations
    09.02.02.01 Potassium Chloride and Glucose Intravenous Infusion  
    09.02.02.01 Potassium Chloride and Sodium Chloride Intravenous Infusion 
    09.02.02.01 Potassium Chloride Concentrate (Sterile)  This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Not Present on this Formulary

    Not Present on this Formulary

    Amber Formulary Status
    Amber Formulary Status
    09.02.02.01 Potassium chloride infusions 
    09.02.02.01 Potassium Chloride, Sodium Chloride and Glucose Intravenous Infusion 
    07.04.03 Potassium Citrate  Potassium Citrate mixture BP
    06.02.02 Potassium iodate 85mg 
    06.02.02 Potassium iodide 65mg tablets 
    13.11.06 Potassium Permanganate Tablets 
    13.11.04 Povidone-Iodine Preps  10% antiseptic solution
    10% ointment
    7.5% surgical scrub
    04.09.01 Pramipexole IR  Supported with a ESCA
    02.09 Prasugrel Efient® Supported by RICaD

    02.12 Pravastatin Tablets 
    03.12 Prednisolone  Plain tablets
    10.01.02.01 Prednisolone 
    • PLAIN Tablets (NOT enteric coated)

     

    • Dispersible tablets - Only for use in children or patients with swallowing difficulties 
    10.01.04 Prednisolone 
    • Second line gout treamtment 
    • PLAIN tablets - NOT enteric coated
    11.04.01 Prednisolone eye drops  Specialist ophthalmologist recommendation
    0.5% eye/ear drops
    1% eye drops - Drug of choice for Anterior Uveitis in A&E - unless the patient has a preference for dexamethasone 0.1%.
    0.5% Single Use Drops (minims) - Used in patients with severe Chronic Allergic Eye Disease who present to A&E with a flare up
    06.03.02 Prednisolone PLAIN Tablets 
    04.03.04 Pregabalin 

    ££

    Second Choice for generalised anxiety disorder

    04.07.03 Pregabalin  4th line after duloxetine
    Advice of specialist if duloxetine is unsuitable
    Please be aware of the abuse potential associated with this class of agent - See NHS England advice.
    Prescribers should prescribe generically
    04.08.01 Pregabalin  MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors
    Prescribers should prescribe generically
    15.02 Prilocaine Hydrochloride with Felypressin Citanest with Octapressin®
    15.02 Prilocaine Hydrochloride1% injection Citanest®
    04.08.01 Primidone Mysoline® MHRA Category 1 - Doctors are advised to ensure that their patient is maintained on a specific manufacturer’s product
    04.09.03 Primidone 
    10.01.04 Probenecid 
    15.02 Procaine Hydrochloride 
    08.01.05 Procarbazine Capsules 
    04.06 Prochlorperazine  Buccal tablets
    Tablets
    Syrup
    Injection
    04.09.02 Procyclidine  Tablets
    SF syrup
    04.09.02 Procyclidine Injection 
    13.10.05 Proflavine Cream, BPC  
    06.04.01.02 Progesterone Cyclogest® Fertilty
    06.04.01.02 Progesterone Cyclogest®

    Recurrent miscarriage

    06.04.01.02 Progesterone [micronised] -  Utrogestan® Supported with a RICaD
    06.04.01.02 Progesterone vaginal gel Crinone®
    03.04.01 Promethazine Phenergan®
    04.01.01 Promethazine Hydrochloride 
    04.06 Promethazine Hydrochloride Phenergan
    16.03.04 Prontosan Wound Gel 30ml  Specialist recommendation
    A gel containing betaine, a surfactant to remove biofilm and debris and PHMB to help control bacterial bioburden.
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Cleansing, decontamination and moisturising of acute and chronic wounds including 1st and 2nd degree burns.
    Duration dressing remains on wound before changing
    Apply at each dressing change
    Frequency of dressing change
    As determined by the wound and exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None
    Rationale for inclusion in formulary
    Gel to cleanse and decontaminate wounds
    Antimicrobial
    Breaks down biofilms in chronic wounds
    16.03.04 Prontosan Wound Irrigation Solution   Wound irrigation solution containing betaine a surfactant to remove biofilm and debris and PHMB to help control bacterial bioburden.
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Cleansing, decontamination and moisturising of acute and chronic wounds including 1st and 2nd degree burns.
    Duration dressing remains on wound before changing
    Apply at each dressing change
    Frequency of use
    As determined by the wound and exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None
    Rationale for inclusion in formulary
    Solution to cleanse and decontaminate wounds
    Antimicrobial
    Breaks down biofilms in chronic wounds
    Can be used as an irrigation fluid with VAC Veraflow
    02.03.02 Propafenone hydrochloride Tablets Arthmol®
    13.12 Propantheline  
  • For hyperhidrosis (licensed indication)
  • Specialist recommendation
  • 15.01.01 Propofol Injection 
    02.04 Propranolol  Tablets
    Modified Release Capsules
    04.07.04.02 Propranolol 
    04.09.03 Propranolol 
    13.14.01 Propylene glycol 20% w/w in aqueous cream  BAD recommended quantity = 100g
    As a moisturiser, to use on very dry skin conditions. Works well as a barrier, enhances penetration
    of other treatments like topical steroids. Use when urea-based preparations, e.g. Eucerin® and
    Aquadrate®, are ineffective, unsuitable or not tolerated.
    13.14.02 Propylene glycol 40% w/w in Dermovate® cream  BAD recommended quantity = 100g
    Very potent steroid.
    Use for severe inflammatory disease without hyperkeratosis, or at sensitive skin sites e.g. the vulva.
    06.02.02 Propylthiouracil 
    13.02.02 Prosheild plus  2nd line
    Skin protectant
    When used in the context of wound management
    Type of wound product is suitable for
    To treat injured skin associated with incontinence where a dressing seal cannot be achieved
    Duration dressing remains on wound before changing
    Apply at each episode of hygiene
    Frequency of dressing change
    Apply at each episode of hygiene
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    External use only
    Avoid contact with eyes
    Known allergic sensitivity to any of the components
    Keep out of reach of children
    Do not apply to pressure ulcers or leg ulcers
    Not to be used as a first line barrier cream
    Not to be used to protect peri wound
    Not to be used as an emollient
    Rationale for inclusion in formulary
    For treatment of incontinence lesions where a standard dressing seal cannot be achieved
    13.02.02 ProShield  Skin cleanser for use in patients with chronic diarrhoea or incontinence of urine.
    When used in the context of wound management
    Type of wound product is suitable for
    To cleanse intact or injured skin from contamination of urine or faeces
    Duration dressing remains on wound before changing
    Apply at each episode of hygiene
    Frequency of dressing change
    Apply at each episode of hygiene
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    External use only
    Avoid contact with eyes
    Known allergic sensitivity to any of the components
    Keep out of reach of children
    Rationale for inclusion in formulary
    For skin cleansing related to incontinence.
    Only skin cleanser available on drug tariff
    16.15 ProShield   Skin cleanser for use in patients with chronic diarrhoea or incontinence of urine.
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    To cleanse intact or injured skin from contamination of urine or faeces
    Duration dressing remains on wound before changing
    Apply at each episode of hygiene
    Frequency of dressing change
    Apply at each episode of hygiene
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    External use only
    Avoid contact with eyes
    Known allergic sensitivity to any of the components
    Keep out of reach of children
    Rationale for inclusion in formulary
    For skin cleansing related to incontinence.
    Only skin cleanser available on drug tarrif
    16.15 ProShield plus   Skin protectant
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    To treat injured skin associated with incontinence where a dressing seal cannot be achieved
    Duration dressing remains on wound before changing
    Apply at each episode of hygiene
    Frequency of dressing change
    Apply at each episode of hygiene
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    External use only
    Avoid contact with eyes
    Known allergic sensitivity to any of the components
    Keep out of reach of children
    Do not apply to pressure ulcers or leg ulcers
    Not to be used as a first line barrier cream
    Not to be used to protect peri wound
    Not to be used as an emollient
    Rationale for inclusion in formulary
    For treatment of incontinence lesions where a standard dressing seal cannot be achieved
    17.15 Proshield Plus skin protective  Order code - 8213 0300 04
    Usual quantity - Start with 1 pack; check patient tolerance, usage and prescribe as appropriate.
    17.07 Prosys Lever Tap   Short Tube
    Order code - P500S -LT
    Pack size - 500ml x 10 per box
    Usual quantity - 10 every 2 months
    Review period – Before each Rx
    Long Tube
    Order code - P500L -LT
    Pack size - 500ml x 10 per box
    Usual quantity - 10 every 2 months
    Review period – Before each Rx
    17.08 ProSys Non-sterile 2 litre night bag with single use drainable tap  Order code - PSU2
    Pack size - 10 per pack
    Usual quantity - 10 per month (1 pack per month Maximum 3 packs per month)
    Review period – Before each Rx
    17.08 ProSys Non-sterile 2 litre night bag with single use drainable tap  Order code - PSU2
    Pack size - 10 per pack
    Usual quantity - 10 per month (1 pack per month Maximum 3 packs per month)
    Review period – Before each Rx
    17.07 Prosys Slide Action Tap  Short Tube
    Order code - P500S
    Pack size - 500ml x 10 per box
    Usual quantity - 10 every 2 months
    Review period – Before each Rx
    Long Tube
    Order code - P500L
    Pack size - 500ml x 10 per box
    Usual quantity - 10 every 2 months
    Review period – Before each Rx
    17.08 ProSys Slide outlet tap  Order code - P2000
    Pack size - 2L x 10
    Usual quantity - 10 every 2 months (1 pack every 2 months)
    Review period – Before each Rx
    Order code - P2000-LT
    Pack size - 2L x 10
    Usual quantity - 10 every 2 months (1 pack every 2 months)
    Review period – Before each Rx
    17 Prosys Vesica Community catheterisation pack   Does not include catheter or anaesthetic gel
    Catheterisation pack
    Order code - Vescp-01
    Catheterisation pack LT
    Order code - Vescp-02
    02.08.03 Protamine sulphate injection  Hospital Use Only
    02.11 Prothrombin complex injection  Hospital Use Only
    06.05.01 Protirelin TRH
    11.07 Proxymetacaine Hydrochloride Minims®
    03.10 Pseudoephedrine Hydrochloride 
    13.09 Psoriderm® 
    10.02.01 Pyridostigmine Bromide Mestinon®
    09.06.02 Pyridoxine Hydrochloride 
    04.02.01 Quetiapine MR Tablets  Supported by ESCA
    The GP should be given a rationale for prescribing rather than first line antipsychotics
    Brand Rationalisation – APC preferred brands:-
    Biquelle XL, Sondate XL, Zaluron XL
    04.02.01 Quetiapine Tablets  Supported by ESCA
    06.07.01 Quinagolide Norprolac®
    02.03.02 Quinidine (unlicensed)  For hospital only use. All prescribing is retained by secondary care
    10.02.02 Quinine Sulphate 
    14.05 Rabies immunoglobulin 
    14.04 Rabies vaccine Rabipur® Not NHS Not NHS
    Only available as private prescriptions for travel purposes
    06.04.01.01 Raloxifene Hydrochloride Evista® This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Amber Formulary Status
    Amber Formulary Status

    Amber Formulary Status
    Amber Formulary Status
    Raloxifene is indicated as second line for secondary prevention of osteoporotic fractures

    Not Present on this Formulary
    08.01.03 Raltitrexed Injection 
    02.05.05.01 Ramipril Capsules  Ramipril (as capsules) has the most robust evidence base and is considered to be the first line agent of choice.
    11.08.02 Ranibizumab Lucentis®
    • Use in line with NICE 
    02.06.03 Ranolazine Ranexa® Supported by RICaD
    04.09.01 Rasagiline Azilect® Supported with a ESCA
    10.01.04 Rasburicase Fastertec® Hospital Use Only
    13.14.07 Reflectant (Dundee) sunscreens – coffee, coral pink, beige  BAD recommended quantity = 100g
    Used to treat photosensitivity disorders where the patient is sensitive to visible light, most commonly solar urticaria and porphyrias, particularly erythropoietic protoporphyria.
    08.01.05 Regorafenib Stivarga®

    Use in line with NICE

    NHS E commissioned

    15.01.04.03 Remifentanil Injection Ultiva®
    16.06.01 Renasys products  As for Topical Negative Pressure Therapy
    06.01.02.03 Repaglinide 
    14.04 Repevax® 
    03.04.02 Reslizumab (Cinqaero®)  

    For specialist use only in line with NICE.

    NHS England is the responsible commissioner for use in Asthma

    02.10.02 Reteplase  Hospital Use Only
    14.04 Revaxis® 
    08.01.05 Ribociclib Kisqali®

    Use in line with NICE

    Hospital only - NHSE commissioned

    09.06.02 Riboflavin  Specialist recommendation - inherited metabolic disease
    13.06.02 Rifampicin  Specialist initiation
    04.09.03 Riluzole Rilutek® Supported with a ESCA
    09.02.02.01 Ringer's Solution for Injection 
    06.06.02 Risedronate  
    04.02.01 Risperidone  Supported by ESCA
    Tablets
    Liquid
    04.02.02 Risperidone Risperdal Consta® APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion)
    08.02.03 Rituximab MabThera®
    10.01.03 Rituximab (rheumatology) MabThera® Hospital Use Only
    02.08.02 Rivaroxaban Xarelto® BSSE APC preferred agent
    This recommendation must only be taken into account after a patient and prescriber have discussed all treatment options (including warfarin) and only if they have no preference about which medicine they want to use.

    RedUse following Hip and Knee surgery – Full course of treatment supplied on discharge
    Amber Formulary StatusFollowing diagnosis of AF – use in line NICE and toolkit, initiation/recommendation by haematologist, transfer to GP with RICaD
    Amber Formulary StatusFor the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/recommendation by haematologist, transfer to GP with RICaD
    Amber Formulary StatusFor preventing adverse outcomes after acute management of ACS - use in line with NICE. Initiation/recommendation by haematologist, transfer to GP with RICaD. Supported with RICaD (in development).
    04.11 Rivastigmine Exelon® APC verdict - present status = RED
    Future status = AMBER with a framework in primary care before transfer - commissioning discussion
    04.07.04.01 Rizatriptan 

    Green Traffic Light Tablets

    Black  Wafer/oral lyophilisates SF £££ 

    04.07.04.01 Rizatriptan orodispersible tablets   Reserved for patient who are vomiting due to migraine
    17.11 Rochester Clear Advantage with Aloe silicone sheath Style 1   Other types available
    Order code - 1243/1283/1323/1363/1403
    Gauge/CH size - 24/28/32/36/40mm
    Usual quantity - 30 every month
    Review period – Before each Rx or if more than 30 used per month
    15.01.05 Rocuronium Bromide Injection Esmeron®
    03.03.03 Roflumilast Daxas®

    To be used in line with NICE
    Supported with a RICaD

    09.01.04 Romiplostim Injection Nplate®
    04.09.01 Ropinirole  Supported with ESCAs
    Tablets - Parkinsonism & Restless legs
    MR tablets - Parkinsonism
    15.02 Ropivacaine Hydrochloride  Ropivacaine 75mg/10ml injection
    02.12 Rosuvastatin 
    14.04 Rotavirus vaccine Rotarix®
    04.09.01 Rotigotine patch  Supported with a ESCA
    04.08.01 Rufinamide Inovelon® Supported with an ESCA
    MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history
    17.08 Rusch Belly Bags (Teleflex) with belt  Order code - B1000
    Usual quantity - Each bag can be used for 28 days
    Review period – Before each Rx
    17.03 Rusch Brilliant Aquaflate All Silicone catheter  Includes empty syringe for deflation of previous catheter, and syringe prefilled with sterile water for balloon inflation.
  • Standard/Male - Gauge/CH size 12/14/16/18
  • Order code - DA310112/4/6/8
  • Usual quantity - One every 12 weeks
  • Review period - Before each Rx or if catheter life less than 4 weeks
  • Female - Gauge/CH size 12/14/16
  • Order code - DA210112/4/6
  • Usual quantity - One every 12 weeks
  • Review period - Before each Rx or if catheter life less than 4 weeks
  • 17.04 Rusch PTFE coated Aquaflate latex foley catheter   Includes empty syringe for deflation of previous catheter and a syringe prefilled with sterile water.
    Gender - Standard/Male
    Order code - DP310112-310124
    Gauge/CH size - 12 to 24
    Usual quantity - 1 every month
    Review period – Before each Rx

    Gender - Female
    Order code - DP210112-210124
    Gauge/CH size - 12 to 24
    Usual quantity - 1 every month
    Review period – Before each Rx

    08.01.05 Ruxolitinib Jakavi®
    02.05.05.02 Sacubitril valsartan  In line with NICE TA388
    Supported by RICaD
    Transfer to Primary care at 3 months following initiation by Heart Failure specialist supported by a RICaD
    03.01.01.01 Salbutamol  Salbutamol Inhaler
    Salbutamol Oral (Salbutamol Tablets - £££)
    Salbutamol Nebulised Solution
    Salbutamol Injection
    07.01.03 Salbutamol 
    13.07 Salicylic Acid  Salactol
    Salatac
    Verrugon
    13.14.06 Salicylic acid 2% w/w and sulphur 2% w/w in aqueous cream  BAD recommended quantity = 100g
    Sulphur is antiseptic, anti-parasitic and anti seborrhoeic; salicylic acid at lower concentrations is mildly keratolytic. Use on scaly, inflamed conditions of the face or scalp, such as treatment resistant seborrhoeic dermatitis, once or twice daily.
    13.14.02 Salicylic acid 5% w/w / propylene glycol 47.5% w/w in Dermovate® cream  BAD recommended quantity = 100g
    Very potent steroid; propylene glycol increases penetration of Dermovate®.
    To use on the palms and/or soles for hyperkeratotic eczema, palmoplantar pustulosis and psoriasis
    where it is persistent, severe and not responding to Dermovate® and emollients alone. It can be used
    once daily under occlusion for short periods (a maximum of 2 weeks) and then without occlusion for
    a few weeks more. Keep the frequency of application to a minimum to reduce the risk of atrophy
    and tachyphylaxis. Please see NICE guidelines on psoriasis (all ages) and atopic eczema (children and young people) for advice on safe appropriate use of corticosteroids. http://guidance.nice.org.uk/
    13.14.06 Salicylic acid in emulsifying ointment  BAD recommended quantity = 100g
  • Salicylic acid 2% w/w in emulsifying ointment
  • Salicylic acid 5% w/w in emulsifying ointment
  • Salicylic acid 10% w/w in emulsifying ointment
  • Salicylic acid 20% w/w in emulsifying ointment
    Salicylic acid softens keratin and makes scales easier to remove; the effects are concentration dependent.
    Higher concentrations can irritate or burn normal skin.
    Use for hyperkeratotic psoriasis, hyperkeratotic eczema, viral warts, lichen simplex, ichthyosis, keratodermas, callus, keratosis pilaris and other hyperkeratotic conditions where emollients and commercial preparations are ineffective.
    Commercial preparations are urea-based (e.g. Calmurid® £5.70) or salicylic-acid based (e.g. SalactolTM paint (16.7% salicylic acid with 16.7% lactic acid; 10 ml, £1.71) or Verrugon® ointment (50% salicylic acid; 6 g, £3.12)).
  • 12.03.05 Saliveze®  Approved for ACBS condition
    Dry mouth (xerostomia)
    For patients suffering from dry mouth as a result of having (or having undergone) radiotherapy, or sicca syndrome.
    Palliative Care
    Dental practitioners
    12.03.05 Salivix®pastilles   Only useful in patients who have residual salivary gland function.
    Approved for ACBS condition
    Dry mouth (xerostomia)
    For patients suffering from dry mouth as a result of having (or having undergone) radiotherapy, or sicca syndrome.
    Palliative Care
    Dental practitioners
    03.01.01.01 Salmeterol Inhaler 
  • Prescribe by brand to ensure patients receive the device they are used to.
  • Check licensed indication (differences among brands).
  • Be aware of differences in excipients among the different brands.
  • 09.05.01.01 Sandocal-1000® 
    09.04.01 Sapropterin Dihydrochloride  Kuvan®
    08.02.04 Sarilumab Kevzara®

    In line with NICE Commissioned by CCGs.

    16.11 Seal-Tight Woundcare Protector  Waterproof protector, non slip latex free
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Used to keep leg and foot dressings dry, can be fully submerged in water.
    Duration dressing remains on wound before changing
    N/A
    Frequency of dressing change
    N/A
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    N/A
    Rationale for inclusion in formulary
    Multiple sizing for leg including extra large limb
    No adjustments required
    13.05.02 Sebco® 
    13.05.03 Secukinumab  Use in line with NICE TA350
    04.09.01 Selegiline Hydrochloride 

    Supported with a ESCA
    Tablets
    Liquid

    Oral Lyophilisate - patients with swallowing difficulties

    09.05.05 Selenium  Specialist recommendation
    Amber Formulary Status Tablets and Capsules
    Red Hospital Only Selenium Injection
    13.09 Selenium Sulphide Selsun®
    04.03.03 Sertraline  Tier 1 - Tablets
    09.05.02.02 Sevelamer  Specialist recommendation
    15.01.02 Sevoflurane 
    07.04.05 Sildenafil  Sildenafil tablets generic
    02.05.01 Sildenafil (Revatio®)  Hospital Use Only
    NHS England commissioned
    Tablets
    Injection
    10.04 Sildenafil tablets GENERIC 

    Use in digital ulceration is commissioned by NHS England

    All prescribing retained in Secondary Care

    Off label use 

    07.03.04 Silicone contraceptive diaphragms - Type C Arcing Spring Diaphragm  Arcing spring diaphragm sizes 60–95mm (rising in 5mm)
    13.07 Silver Nitrate  Silver nitrate applicators (40%,75% and 95%)
    Silver nitrate 95% caustic applicator
    16.18 Silver nitrate   Specialist recommendation
    Caustic pencil
    NOT 1ST LINE TREATMENT
    ONLY TO BE USED IN A CLINIC SETTING OR BY A CLINICAL SPECIALIST
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For treatment of chronic over granulation, non acute or weeping.

    Duration dressing remains on wound before changing
    Apply moistened caustic pencil tip for 1-2 mins, whilst protecting the surrounding skin with soft paraffin.
    Frequency of dressing change
    Maximum treatment: 3 applications
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Keep away from the eyes
    Not suitable for use on the face, ano-genital region or large areas
    Not for untreated bacterial, fungal or viral skin lesions
    Can cause chemical burns
    Rationale for inclusion in formulary
    Treatment of over granulation
    13.07 Silver Nitrate 95% with Potassium Nitrate 5% AVOCA®
    13.10.01.01 Silver Sulfadiazine Flamazine®
    17.08 Simpla 2 litre S2 urine drainage bag with non-return valve  Order code - 320902
    Pack size - 10 per pack
    Usual quantity - 10 per month (1 pack per month. Maximum 3 packs per month)
    Review period – Before each Rx
    17.09 Simpla G strap (Coloplast)  Order code - 383001
    Gauge/CH size - 5
    Usual quantity - 5 every 6 months (1 pack per 6 months)
    Review period – Before each Rx
    17.08 Simpla Plus with anti-kink tubing  Order code - 21576
    Pack size - 2L x 10
    Usual quantity - 10 every 2 months (1 pack every 2 months)
    Review period – Before each Rx
    17.07 Simpla Profile  Short Tube
    Order code - 21573
    Pack size - 500 ml short tube (6 cm) x 10 per box
    Usual quantity - 10 every 2 months
    Review period – Before each Rx
    Long Tube
    Order code - 21574
    Pack size - 500 ml long tube (25 cm) x 10 per box
    Usual quantity - 10 every 2 months
    Review period – Before each Rx
    03.09.02 Simple Linctus, BP 
    03.09.02 Simple Linctus, Paediatric BP 
    02.12 Simvastatin  MHRA advice regarding high dose simvastatin (May 2010)
    • Simvastatin 80 mg should be considered only in patients with severe hypercholesterolaemia and high risk of cardiovascular complications who have not
    achieved their treatment goals on lower doses, when the benefits are expected to outweigh the potential risks
    • Prescribers treating patients who are taking simvastatin 80 mg or who are being considered for an up-titration to that dose may need to review their
    treatment during their next visit, to take into account the new evidence
    • Patients who are currently taking simvastatin 80 mg should not stop taking their medicine. However, they should be advised to contact their doctor
    immediately if they experience unexplained muscle pain, tenderness, or weakness
    • Please report suspected adverse reactions with medicines, including statins, to us via the Yellow Card Scheme (www.yellowcard.gov.uk)
    08.02.02 Sirolimus   Red Tablets & Solution - New post transplant
    Amber Formulary Status Tablets & Solution - Post transplant pre 2013
    06.01.02.03 Sitagliptin Januvia® To be used in line with NICE guidance
    03.04 Skin Prick Test  Hospital only
    13.10.05 Skin tissue adhesive Dermabond ProPen®
    10.01.03 Sodium aurothiomalate  Myocrisin® Supported with an ESCA
    09.08.01 Sodium Benzoate   Red Tablets & SF Liquid
    Red Hospital Only Injection
    07.04.03 Sodium Bicarbonate 
    12.01.03 Sodium Bicarbonate 
    09.02.01.03 Sodium bicarbonate capsules  Specialist recommendations
    09.02.02.01 Sodium Bicarbonate Infusion 
    03.01.05 Sodium Chloride 
    09.02.01.02 Sodium Chloride  Green Sodium Chloride M/R tablets
    Red Sodium chloride 5mmol solution
    Red Sodium chloride 1mmol/l oral solution
    11.08.01 Sodium Chloride  Amber Formulary Status Specialist ophthalmologist recommendation - Sodium chloride PF 5% drops (Moorfields)
    Amber Formulary Status Specialist ophthalmologist recommendation - Sodium chloride 5% eye ointment
    Red Hospital Only Sodium chloride 0.9% minims - Dilutant for impregnated vital dye strips
    13.11.01 Sodium Chloride Irriclens®
    13.11.01 Sodium Chloride Normasol® Sodium chloride 0.9% irrigation sachets
    13.11.01 Sodium Chloride Steripod®
    12.02.02 Sodium chloride 0.9% drops 
    09.02.02.01 Sodium Chloride and Glucose Intravenous Infusion 
    09.02.01.02 Sodium chloride infusion 
    07.04.04 Sodium Citrate 
    06.06.02 Sodium Clodronate  Supported with an ESCA
    11.04.02 Sodium Cromoglicate 2% eye drops  
    11.04.02 Sodium Cromoglicate 2% preservative free eye drops   Specialist Ophthalmologist recommendation as Catacrom
    09.01.01.01 Sodium Feredetate Sytron®
    07.04.04 Sodium hyaluronate Cystistat®
    11.08.01 Sodium Hyaluronate   Amber Formulary Status - Specialist ophthalmologist recommendation - Sodium Hyaluronate 0.15% MULTI (Hyabak®)
    Amber Formulary Status - Specialist ophthalmologist recommendation - Sodium Hyaluronate 0.2% PF MULTI (HyloForte®)
    Amber Formulary Status - Specialist ophthalmologist recommendation - Sodium Hyaluronate 0.4% unit dose (SDU) (Clinitas) - Each unit is re sealable and may be used for up to 12 hrs
    Red Hospital Only Sodium Hyaluronate Viscoelastic (CIMA OCU+1.4% (OcuPlus ®)
    02.05.01 Sodium Nitroprusside Injection  Hospital Use Only
    09.08.01 Sodium Phenybutyrate Ammonaps® NHSE commissioned
    Tablets & Injection
    02.13 Sodium Tetradecyl Sulphate Fibro-Vein® Hospital Use Only
    04.08.01 Sodium Valproate  EC tablets
    MR tablets
    Crushable tablets
    SF liquid
    M/R granules (prolonged release capsules and sachets) (Episenta®)
    Episenta®
  • Paediatrician initiation.
  • For patients with epilepsy aged up to and including 16 years of age unable to swallow tablets and who require a modified release formulation in whom other formulations are more expensive or not appropriate.

    MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history
  • 04.08.01 Sodium Valproate Injection  MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history
    16.01.02 Softpore   Frist line
    Alternative to Cosmopore
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Low to moderately exuding wounds, superficial wounds (closed), light amounts of exudate.
    Use alone without other products, also can be used as a protective dressing for sutured post operative wounds. Can be used as a protective dressing for newly epithelialised wounds. Can be used for minor traumatic wounds
    Duration dressing remains on wound before changing
    Maximum 7 days, dependent on exudate levels
    Frequency of dressing change
    If daily change is required; review dressing type
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known product or component sensitivity
    Rationale for inclusion in formulary
    Sutured/Post-surgical wound for protection . Most cost effective option.
    Can be used as a protective dressing for newly epithelialized wounds.
    Can be used for minor traumatic wounds
    07.04.02 Solifenacin Vesicare®

    £££

    Place in therapy is after agents that have effectiveness at lower costs 

    06.01.03 Soluble Insulin 
    06.05.01 Somatropin 
    08.01.05 Sorafenib Tablets 
    16.02.06 Sorbsan range (excluding Silver)   Calcium alginate dressing
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Use in moderate to highly exuding wounds with a sloughy or granulating wound bed. Also helps with haemostasis in wounds with minor bleeding or where blood is present in the exudate.
    Available in flat and rope dressing
    Primary dressing only. Secondary dressing will be required.
    Duration dressing remains on wound before changing
    Can be left in place for approximately 4 days
    Frequency of dressing change
    1-4 days dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use in individuals with a known sensitivity to any of the components of the dressing
    Do no use on dry or lightly exuding wounds as adherence is an issue
    Extreme caution if used for tumours with friable tissue
    Rationale for inclusion in formulary
    Sorbsan can facilitate debridement, absorb exudate and is a haemostat
    Cost effective.
    Biodegradable
    02.04 Sotalol 
    03.01.05 Spacers Device  Able Spacer® - For use with all pressurised (aerosol) inhalers
    AeroChamber® Plus - For use with all pressurised (aerosol) inhalers
    Volumatic® - For use with Clenil Modulite®, Flixotide®, Seretide®, Serevent®, and Ventolin® inhalers
    13.11 Spiriclens pump spray 
    02.02.03 Spironolactone  Retains potassium
    Useful in liver cirrhosis and congestive heart failure usually with loop diuretic. Monitor potassium levels carefully
    16.05.01 Sterile Gauze / swabs/ non woven   7.5cm x 7.5cm only

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Cleansing wounds via aseptic technique
    Duration dressing remains on wound before changing
    N/A
    Frequency of dressing change
    N/A
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be applied to a wound as a dressing
    Rationale for inclusion in formulary
    Necessity for wound cleansing
    Cost effective
    Included in Sterile wound packs or used to supplement sterile packs
    13.11.07 Sterile Larvae (Maggots) LarvE® Specialist recommendation only
    Free range: Biomonde Larvae 100/200 or BioBag
    Biosurgical treatment for the debridement and cleansing of wounds consisting of aseptically produced living larvae.
    The BioBag is presented in the five (5) configurations listed below. The larvae are Lucilia sericata contained in a sterile polyester net bag with a sterile PVA spacer cube, presented in a sterile transport container.
    BioBag 50 at least 50 larvae 25 x 40mm 1 8x8x10
    BioBag 100 at least 100 larvae 50 x 40mm 1 12x12x10
    BioBag 200 at least 200 larvae 60 x 50mm 1 25x10x10
    BioBag 300 at least 300 larvae 120 x 60mm 2 25x10x10
    BioBag 400 at least 400 larvae 100 x 100mm 2 25x10x10
    Free range larvae, larvae and 30 x 30 flat retention net plus kit pack, larvae and 40 x 60cm boot retention net plus kit pack. Additional 100 or 200 larvae available.
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    The BioMonde Larval Debridement Therapy Products are indicated for debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, venous stasis ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds.
    Duration dressing remains on wound before changing
    and
    Frequency of dressing change
    An application of BioBag can be left in place for up to 4 days, dependent on the condition of the wound. If the wound is not sufficiently debrided after 4 days, the treatment can be repeated with a fresh application of BioBag. The treatment should be stopped as soon as the wound is sufficiently debrided or if no improvement is observed after 3 or more applications. The total number of treatment cycles will depend on the characteristics of the wound, the response of the patient to LDT and the aim of the therapy. Most ulcers are completely debrided within 1 to 6 treatment cycles. If exudate production is excessive, the secondary dressing may be changed as required while leaving the BioBag undisturbed. Frequent removal of the outer dressing will also help to control the odour associated with the liquefied necrotic tissue
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Larvae should not be used in patients with known hypersensitivities to fly larvae, polyester, PVA (polyvinyl alcohol) or the components of the media on which the larvae are raised (including soya protein, yeast protein, potato starch and bovine protein) as this may result in dermatitis or more severe immunological reactions in susceptible individuals. If treatment is undertaken then these patients should be under strict medical supervision for the duration of the treatment with immediate access to care.
    Patients with life or limb-threatening, rapidly advancing infections should not be treated with as LDT may interfere with the close and frequent observation that these patients require.
    Should not be used as first line therapy of infected tendon and bone. These wounds should be treated surgically and/or with antibiotics before using LDT.
    Should not be used to treat wounds which are not directly exposed to the outside. Wounds should never be allowed to close over the larvae either intentionally or unintentionally.
    Should not be used on wounds with an inadequate blood supply as this ultimately reduces the ability of the wound to heal. LDT will enlarge the wound as necrotic tissue is debrided but the resulting clean wound is at risk from re-infection.
    Although some mild bleeding is common during LDT, larvae should not be used on wounds that have a tendency to bleed or wounds close to an exposed major blood vessel, especially if considered to be necrotic as this can lead to rupture of the blood vessels which could be life-threatening. If LDT is attempted, the patient must remain under strict medical supervision for the duration of the treatment.
    Should not be used on patients with an inborn or medication-induced coagulopathy or in patients being treated with anticoagulants. If these patients are treated with LDT, they should remain under strict medical supervision for the duration of the treatment.
    Should never be used in sterile body cavities.
    Should be used with caution on wounds over adjacent exposed organs or leading to a body cavity, and only under close medical supervision for the duration of the treatment.
    Data are not available concerning the antibiotic / antiseptic activity of maggots and therefore any infected wound should receive standard antibiotic care.
    Rationale for inclusion in formulary
    Only available larval therapy on prescription.
    Rapid debridement of chronic wounds
    Can be utilised in the community
    04.08.01 Stiripentol  Diacomit® APC supports the continuation treatment in adults for those started as children (off label use).
    Inheriting BCH RAG status.
    02.10.02 Streptokinase  Hospital Use Only
    09.05.02.02 Sucroferric oxyhydroxide 
    • 2nd or 3rd line agent
    • Specialist use
    16.15 Sudocrem cream   Barrier cream
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Intact skin, not to be applied to a wound.
    To protect the skin from moisture, irritation and chafing.
    To protect the peri wound when utilising free range larvae
    Frequency of dressing change
    Application at every episode of hygiene. Apply a thin layer sparingly. Remove with olive oil.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used in conjunction with containment products for incontinence due to the inclusion of lanolin in the ingredients, this will repel urine/faeces back onto the skin.
    Any allergy to the listed ingredients
    Rationale for inclusion in formulary
    Dermatology approved
    13.02.02 Sudocrem® Cream  Barrier cream
    When used in the context of wound management
    Type of wound product is suitable for:
    Intact skin, not to be applied to a wound.
    To protect the skin from moisture, irritation and chafing.
    To protect the peri wound when utilising free range larvae
    Frequency of change
    Application at every episode of hygiene. Apply a thin layer sparingly. Remove with olive oil.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used in conjunction with containment products for incontinence due to the inclusion of lanolin in the ingredients, which will repel urine/faeces back onto the skin.
    Any allergy to the listed ingredients
    Rationale for inclusion in formulary
    Dermatology approved
    15.01.06 Sugammadex Bridion® For use within the terms of its licence when
    Approved by a Consultant Anaesthetist either at the time of the emergency or as soon as practical post emergency
    Suxamethonium is contraindicated
    10.01.03 Sulfasalazine EC  Supported with an ESCA
    10.01.01 Sulindac  Polyhydramnios (women only)
    04.02.01 Sulpiride  Supported by ESCA
    04.07.04.01 Sumatriptan  Tablets
    Nasal Spray - £££
    Injection - should only be used if oral treatments are not effective
    08.01.05 Sunitinib Capsules Sutent®
    13.08.01 Sunsense® Ultra 

    SPF 50

    ACBS Criteria:
    Protection from UV radiation in abnormal cutaneous photosensitivity resulting from genetic disorders or photodermatoses, including those resulting from radiotherapy and chronic or recurrent herpes simplex labialis. 

    Preparations with SPF less than 30 should not normally be prescribed.

    09.03 Supplementary Preparations Addiphos®
    09.03 Supplementary Preparations Additrace®
    09.03 Supplementary Preparations Peditrace®
    09.03 Supplementary Preparations Solivito N®
    09.03 Supplementary Preparations Vitlipid N®
    16.02.03 Suprasorb X  Specialist recommendation
    Biocellulose gel sheet dressing

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Light to moderately, non infected exuding wounds
    Duration dressing remains on wound before changing
    1-7 days
    Frequency of dressing change
    1-7 days, dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to any components of the dressing
    Rationale for inclusion in formulary
    Light to moderate exudate. Specialist use only
    16.03.04 Suprasorb X + PHMB  Specialist recommendation
    Biocellulose gel sheet dressing with PHMB antimicrobial properties
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Light to moderately, critically colonised or infected exuding wounds
    Can be used on all wound types at all stages of wound healing
    Can be cut or folded to wound shape size
    Duration dressing remains on wound before changing
    1-3 days
    Frequency of dressing change
    1-3 days, dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to PHMB or any components of the dressing
    Heavily exuding wounds
    Rationale for inclusion in formulary
    Light to moderate exudate in clinically infected wounds.
    Suitable for all wounds at all stages of wound healing
    Doesn’t affect healthy cells, suitable for long term use when necessary
    15.01.05 Suxamethonium Chloride Injection 
    08.02.02 Tacrolimus  Red Prograf Capsules, Advagraf Modified release Capsules- New post transplant
    Amber Formulary Status Prograf Capsules, Advagraf Modified release Capsules - Post transplant pre 2013
    13.05.03 Tacrolimus Protopic® Use in line with NICE TA82
    0.03% & 0.1% Ointment
    13.14.07 Tacrolimus in OrabaseTM  BAD recommended quantity = 50g

    Tacrolimus 0.1% w/w in OrabaseTM
    Tacrolimus 0.3% w/w in OrabaseTM
    07.04.05 Tadalafil Cialis® £££
    In line with SLS criteria
    4 tab per month - on demand
    11.06 Tafluprost (Preservative Free) 15micrograms/ml Saflutan® Specialist Ophthalmologist Recommendation
    2nd line preservative free option
    For use within licence for those patients requiring a preservative free preparation
    08.01.05 Talimogene laherparepvec Imlygic®

    Hospital only- NHS E commissioned

    Use in line with NICE

    08.03.04.01 Tamoxifen 
    07.04.01 Tamsulosin MR Capsules 
    04.07.02 Tapentadol SR Palexia SR®
    02.08 TauroLock  Hospital Use Only
    02.08 TauroLock HEP 500  Hospital Use Only
    06.01.06 Tee2 Blood glucose strips  

    Glucose test strips to be used with the Tee2+ meter

    16.02.04 Tegadem Hydrocolloid Range   Hydrocolloid Range with film border
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Low to moderate exuding, granulating or epithelising wounds
    Inner layer of hydrocolloid adhesive absorbs exudate providing higher absorbency
    Maintains odour control
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    3-7 days
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not suitable for infected wounds, full thickness burns or wounds with exposed bone, muscle or tendon, wounds at risk of maceration.
    Not for diabetic foot ulcers or ischaemic wounds
    Known product or component sensitivity
    Rationale for inclusion in formulary
    Outer barrier film protects the wound and
    Peri-wound skin from contaminants, body fluids, bacteria and viruses
    Does not contain gelatine or pectin
    Film border prevents creasing of the dressing
    Tegaderm hydrocolloid thin allows for observation of the wound
    16.02.05 Tegaderm Foam Adhesive  Foam dressing
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Wound management by secondary intention on acute, chronic, full thickness or partial thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds, surgical wounds, donor sites and fungating ulcers
    Can be used as a primary or secondary dressing
    Film border increases adherence
    Duration dressing remains on wound before changing
    Can stay in place up to 3-7 days
    Frequency of dressing change
    Dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Care with fragile skin
    Rationale for inclusion in formulary
    Can be used for low to moderate exudate levels
    Different sizes and shapes available
    Conformability around difficult areas such as heels and elbows
    Can be used on sacral and buttock wounds where incontinence is an issue due to film backing and border.
    08.01.03 Tegafur with Uracil Uftoral® This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Not Present on this Formulary

    Red Formulary Status
    Red Formulary Status

    Not Present on this Formulary
    16.01.02 Telfa (podiatry only)  Rationale (developed by TV Team)
    Thin absorbent cotton pad with non adherent film

    Type of wound product is suitable for
    Dry or lightly exuding wounds
    Duration dressing remains on wound before changing
    1-7 days
    Frequency of dressing change
    As exudate levels determines
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None
    Rationale for inclusion in formulary
    Cost effective. Non adherent dressing for dry or lightly exuding wounds
    04.01.01 Temazepam  Tablets - £££££
    SF Solution
    15.01.04.01 Temazepam Injection 
    08.01.05 Temoporfin Injection 
    08.01.05 Temozolomide Capsules 
    08.01.05 Temsirolimus Infusion Torisel®
    02.10.02 Tenecteplase  Hospital Use Only
    15.01.04.02 Tenoxicam Injection 
    13.10.02 Terbinafine 1% cream  ££
    07.01.03 Terbutaline 
    03.01.01.01 Terbutaline Inhaler 
    03.01.01.01 Terbutaline Nebulised Solution 
    08.02.04 Teriflunomide Aubagio®

    In line with NICE

    06.06.01 Teriparatide Forsteo® £££ - Use in line with NICE
    06.05.02 Terlipressin Glypressin® Hospital use only
    06.04.02 Testosterone gel   Testim
    Testogel
    Tostran
    Please note:- Unlicensed use in women. Birmingham Women's Hospital to issue the first supply
    06.04.02 Testosterone implant  Hospital use only - menapausal clinic
    06.04.02 Testosterone injection Sustanon 250®
    06.04.02 Testosterone undecanoate 250 mg/mL Nebido®
    06.04.02 Testosterone undecanoate oral  Restandol Testocaps®

    For paediatric directorate only

    For induction of puberty

    14.05.02 Tetanus immunoglobulin 
    04.09.03 Tetrabenazine Xenazine® 25
    15.02 Tetracaine  Tetracaine 4% gel (Ametop)
    First line for Birmingham Children's Hospital
    11.07 Tetracaine Hydrochloride Minims® Amethocaine Hydrochloride Update following APC
    06.05.01 Tetracosactide Synacthen®
    08.02.04 Thalidomide Pharmion®
    13.05.02 Thalidomide  NHS E Commissioned
    13.05.03 Thalidomide 
    03.01.03 Theophylline Uniphyllin Continus® Please refer to the current British National Formulary for advice on monitoring plasma-theophylline level.
    Theophylline levels may rise when patient stops smoking.
    09.06.02 Thiamine Pabrinex®
    09.06.02 Thiamine 
    15.01.01 Thiopental Injection 
    08.01.01 Thiotepa 
    06.04.01.01 Tibolone Livial® This medicine falls into several categories
    UHBHEFTCITY/SANDWELL

    Amber Formulary Status
    Amber Formulary Status

    Amber Formulary Status
    Amber Formulary Status

    Amber Formulary Status
    Amber Formulary Status

     

    BWHFT Formulary

    GREEN                                        AMBER                             RED                                    
    Tibolone  
    Prescribing Advice
    Tibolone may be used in postmenopausal women and may have an advantage if women are suffering from decreased libido or there are concerns re: bone density
    02.09 Ticagrelor Brilique® Supported by RICaD - ACS
    Supported by RICaD - Post MI

    14.04 Tick-borne encephalitis vaccine  Not NHS Not NHS
    Only available as private prescriptions for travel purposes
    13.04 Timodine®  Steroid potency – mild
    11.06 Timolol  Specialist ophthalmologist recommendation
    0.25% eye drops
    0.25% LA eye drops
    0.1% unit dose eye gel (Tiopex)
    02.08.01 Tinzaparin 

    Single use in DVT

    02.08.01 Tinzaparin 

    For all other indications.

    The APC's view is that on clinical grounds, the status for certain indications approved by APC should be amber, supported by an ESCA.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.(ESCAs to be developed).

    08.01.03 Tioguanine Tablets Lanvis®
    03.01.02 Tiotropium Spiriva Respimat® Amber Traffic Light For Asthma
    Green Traffic Light For COPD
    03.01.02 Tiotropium and Olodaterol Spiolto® Respimat® In line with COPD Guidance
    02.09 Tirofiban Aggrastat® Hospital Use Only
    02.11 Tisseel  Hospital Use Only
    08.01.05 Tivozanib Fotivda®

    In line with NICE

    10.02.02 Tizanidine 
    03.12 Tobramycin nebulised  NHS England Commissioned for Cystic Fibrosis only
    Red New Patients

    Amber Formulary Status Existing patients (initiated prior to April 2013)
    10.01.03 Tocilizumab RoActemra® Hospital Use Only
    10.02.01 Tofacitinib Xeljanz®

    Use in line with NICE

    07.04.02 Tolterodine 
    07.04.02 Tolterodine MR Capsules 

    £££
    2nd Line

    06.05.02 Tolvaptan  NICE TA358 - Tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease
    Tolvaptan (Samsca) for the treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH).
    16.06.01 Topical negative pressure therapy  Dependent on Trust contract
    Specialist recommendation
    The use of sub atmospheric pressure to promote or assist wound healing or to remove fluids from a site. Required components: Pump, Dressings foam or gauze, tubing and canister.
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Acute, chronic and traumatic wounds. Can be used as a adjunct to surgery and for salvage procedures such as wound dehiscence. Benefits are that it removes excess fluid that may contain bacterial pathogens, reduces soft tissue oedema, promotes granulation and provides a moist wound healing environment.
    Consider standard interactive dressings first.
    Duration dressing remains on wound before changing
    Every three days
    Frequency of dressing change
    Determined by exudate levels. Different canister sizes available
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    It should not be used on: Grossly infected or bleeding wounds
    Malignancy
    Exposed blood vessels
    Organs
    Unexplored fistulae
    Extensive necrotic wounds
    Caution with foam, document the number inserted, ensure all pieces are retrieved.
    Rationale for inclusion in formulary
    It removes excess fluid that may contain bacterial pathogens, reduces soft tissue oedema, promotes granulation and provides a moist wound healing environment.
    Both companies products are included due to different contracting arrangements.
    Can be used on large open wounds to increase speed of wound healing
    04.08.01 Topiramate  MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history
    08.01.05 Topotecan Hycamtin®
    08.01.05 Trabectedin Injection 
    04.07.02 Tramadol  Second line after morphine and codeine
    Capsules
    Soluble tablets - £££ - patients with swallowing difficulties
    15.01.04.02 Tramadol Injection 
    02.11 Tranexamic Acid 5% mouthwash  Palliative Use Only
    02.11 Tranexamic Acid 500mg Tablets 
    02.11 Tranexamic Acid Injection  Hospital Use Only
    08.01.05 Trastuzumab emtansine Kadcyla®

    Use in line with NICE

    08.01.05 Trastuzumab Infusion 
    04.03.01 Trazodone  Tablets
    Capsules
    SF liquid
    06.01.04 Treatment of hypoglycaemia Rapilose® gel
    08.01.01 Treosulfan  Red Capsules
    Red Hospital Only Injection
    08.01.05 Tretinoin Capsules 
    10.01.02.02 Triamcinolone Acetonide 
    13.14.07 Triamcinolone acetonide 0.1% w/w in OrabaseTM  BAD recommended quantity = 50g
    Used for ulcerative and erosive inflammatory skin disease including around stomas.
    06.03.02 Triamcinolone Injection Kenalog®
    13.14.07 Trichloroacetic acid 90% w/v  BAD recommended quantity = 10ml
    Used to destroy facial xanthelasmata; highly irritant.
    09.08.01 Trientine Dihydrochloride  Specialist recommendation
    04.02.01 Trifluoperazine  Supported by ESCA
    Tablets
    SF liquid
    11.03.03 Trifluorothymidine eye drops 
    08.01.03 Trifluridine-tipiracil Tablets Lonsurf®

    Use in line with NICE

    Hospital only- NHSE commissioned

    04.09.02 Trihexyphenidyl Hydrochloride Broflex®
    02.05.05 Trimetaphan camsilate  Hospital Use Only
    13.06.02 Trimethoprim  Specialist initiation “off label use”
    13.04 Trimovate®  Potency: moderate
    06.07.02 Triptorelin 
    08.03.04.02 Triptorelin SR Decapeptyl®
    09.08.02 Trometamol 7% injection  NHSE commissioned
    11.05 Tropicamide Mydriacyl® 0.5% & 1% eye drops
    0.5% & 1% Single Dose Units
    07.04.02 Trospium  For the over 65 yr old
    07.04.02 Trospium XL  For the over 65 yr old
    04.03.04 Tryptophan  Hospital use only
    16.08.03 Tubegauz tubular bandage  Podiatry only
    Non-prescribable on NHS
    Surgical stockinette. 100% cotton

    Rationale (developed by TV Team)
    Type of wound product is suitable for:
    PODIATRY ONLY for digital dressings
    Duration dressing remains on wound before changing
    As required
    Frequency of dressing change
    As required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None listed
    Rationale for inclusion in formulary
    Only product that has finger and toe sizes in 100% cotton
    14.04 Typhoid Live Oral vaccine Vivotif®
    09.08.01 Ubidecarenone  
    16.05 UCS® Debridement  

    Specialist recommendation

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Chronic/acute wounds for wound debridement and cleansing of surrounding area.  Also removes keratosis.
    Duration dressing remains on wound before changing
    N/A – may need to be used daily until wound bed preparation complete.
    Frequency of dressing change
    N/A
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None
    Rationale for inclusion in formulary
    Currently only Debrisoft available but UCS more cost effective and evaluated well in the community.

    17.09 Ugofix catheter straps   Order code - 3001/2/3/9/10
    Gauge/CH size - 5
    Usual quantity - 5 every 6 months (1 pack per 6 months)
    Review period – Before each Rx
    07.03.05 Ulipristal EllaOne® If copper IUD is not preferred/appropriate Ulipristal 30mg (EllaOne®) - (72-120hrs)
    06.04.01.02 Ulipristal acetate  Esmya ®

    Updated June 2018.

    Change of status in light of MHRA Drug Saftey information - March 2018 - Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users.

    ESCA removed - June 2018

    03.01.02 Ultibro Breezhaler  Indacaterol maleate and Glycopyrronium bromide
    To be used in line with COPD guidance
    03.01.02 Umeclidinium bromide Incruse Ellipta® In line with COPD Guidance
    17.06 Unomedical Careline  Lever Tap
    Order code - 90 821 1S-20
    Pack size - 5
    Usual quantity - 5 valves (1 pack) per month
    Review period – Weekly (at every catheter change)
    T Tap
    Order code - 90 805 1S-20
    Pack size - 5
    Usual quantity - 5 valves (1 pack) per month
    Review period – Weekly (at every catheter change)
    07.04.04 Uracyst 
    16.08.08 Urgo K TWO range (previously known as K-Two)  Two layer bandage system consisting of elastic and inelastic components that provide a sustained graduated compression,.
    Available in K two reduced.

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Treatment of venous leg ulcers, venous oedema and lymphoedema
    Duration dressing remains on wound before changing
    1 to 7 days
    Frequency of dressing change
    Daily up to weekly dependant on exudate and oedema management.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Arterial disease
    Diabetic Microangiplathy
    Ischaemic Phlebitis
    Septic thrombosis
    Allergy to any components in particular latex (available in latex free )
    Rationale for inclusion in formulary
    Two layer compression kit.
    Essential for treating venous leg ulceration
    2 layer less bulky for community use and enabling patients to wear foot wear
    Available in latex free option and reduced compression option
    16.08.08 Urgo K-Four range (previously known as K-Four)  Multi layer compression system

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Venous and mixed aetiology leg ulcers and associated conditions
    Duration dressing remains on wound before changing
    1 to 7 days
    Frequency of dressing change
    Daily up to weekly dependant on exudate and oedema management.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not recommended for patients with a ABPI of less than 0.8
    Contains latex
    Kit size determined by measuring the ankle after padding with the tape measure pulled taught
    Rationale for inclusion in formulary
    Compression system consisting of k-soft , k-lite, k plus 3a or K three c (dependent on ankle size) and Ko flex
    Component bandages available in longer lengths for larger limbs
    16.02.06 Urgosorb (excluding Silver)  Specialist recommendation
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Management of moderate to heavily exuding wounds. Absorbs and gels on contact with
    wound exudate which facilitates debridement of devitalised tissue.
    Dressing has haemostatic properties
    Duration dressing remains on wound before changing
    1-7 days dependent on exudate levels
    Frequency of dressing change
    1-7 days dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to any of the dressing components
    Contraindicated in 3rd degree burns, dry necrotic eschar
    Low exudate or dry wounds
    Rationale for inclusion in formulary
    Can be used for moderate to heavily exuding wounds
    Can be used for debriding sloughy and wet necrotic wounds
    Haemostatic
    16.03.03 Urgosorb Silver range   Specialist recommendation
    Alginate and hydrocolloid dressings containing silver
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Management of moderate to heavily exuding wounds that are clinically infected Absorbs and gels on contact with wound exudate which facilitates debridement of devitalised tissue.
    Dressing has haemostatic properties
    Duration dressing remains on wound before changing
    1-3 days dependent on exudate levels
    Frequency of dressing change
    1-3 days dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to any of the dressing components
    Contraindicated in 3rd degree burns, dry necrotic eschar
    Low exudate or dry wounds
    Removal on those undergoing MRI scans
    Avoid contact with electrodes or conductive gels during electronic measurement procedures
    Rationale for inclusion in formulary
    Can be used for moderate to heavily exuding clinically infected wounds
    Can be used for debriding sloughy and wet necrotic wounds
    Haemostatic
    Specialist Use only
    16.04.01 UrgoSTART range  A non adherent foam and contact layer impregnated with TLC-NOSF healing matrix to promote healing and prevent the detrimental effects of MMPs.
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Low to moderately exuding chronic wounds
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    1-7 days dependent on exudate levels.
    Treatment must be a minimum duration of 4-5 weeks
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use on infected or critically colonised wounds
    Known sensitivities to dressing components
    Rationale for inclusion in formulary
    Various sizes available including a shaped heel dressing in the foam range
    Pain free dressing changes
    Promotes wound healing
    Interacts with the wound bed to prevent the detrimental effects of MMPs on wound healing
    16.02.03 Urgotul  A non adherent flexible wound contact layer containing TLC Healing Matrix.
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Non to low exuding wounds, dermabrasions, traumatic, superficial, blistering. Can be used as a
    contact layer in cavity wounds with secondary absorbent dressing. Difficult to dress areas – fingers and toes.
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    Depends on clinical needs up to 7 days
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to any components
    Rationale for inclusion in formulary
    Pain free dressing changes. Promotes healing, interactive. Cost effective. Large range of sizes available
    02.10.02 Urokinase  Hospital Use Only
    17.10 Uro-Tainer Sodium chloride 0.9%  For mechanical flush of debris
    Order code - FB99849
    17.10 Uro-Tainer Twin Solution R (6.0% Citric Acid)  Order code - 9746625
    Usual quantity - Only if clinical rationale for use – SHORT TERM USE ONLY
    Review period – Before each Rx
    17.10 Uro-Tainer Twin Suby G (3.23% Citric Acid)  Order code - 9746609
    Usual quantity - Only if clinical rationale for use – SHORT TERM USE ONLY
    Review period – Before each Rx
    13.05.03 Ustekinumab  Use in line with NICE TA180
    10.01.03 Ustekinumab (rheumatology) Stelara® Hospital Use Only
    16.06.01 V.A.C. products  As for Topical Negative Pressure Therapy
    07.04.05 Vacuum pumps   Green if in line with SLS criteria
    Red if NOT in line with SLS criteria
    04.02.03 Valproic Acid Depakote®
    02.05.05.02 Valsartan 

    08.01.05 Vandetanib Tablets 
    04.10.02 Varenicline Champix® Tier 2
    14.04 Varicella Zoster vaccine Zostavax®
    14.05.02 Varicella-Zoster immunoglobulin 
    06.05.02 Vasopressin - Argipressin  Hospital use only
    09.08.01 Velaglucerase alfa injection  NHSE commissioned
    08.01.05 Vemurafenib Tablets 
    08.01.05 Venetoclax Venclyxto®

    Use in line with NICE

    04.03.04 Venlafaxine 
    04.03.04 Venlafaxine MR/XL  1st choice Vensir XL caps
    2nd choice Venlalic XL tabs
    02.06.02 Verapamil  Brand Rationalisation – APC preferred brands:-
    Univer Capsules
    Securon SR Tablets
    11.08.02 Verteporfin Visudyne®
    04.08.01 Vigabatrin Sabril® Supported with a ESCA
    MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors
    08.01.04 Vinblastine Injection 
    08.01.04 Vincristine Injection 
    08.01.04 Vinorelbine  Red Capsules
    Red Hospital Only Injection
    16.08.09 Viscopaste  Specialist recommendation
    Zinc paste bandage.

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Venous leg ulcers. Where venous insufficiency exists, the paste bandage should be used under graduated compression bandaging.
    Chronic eczema
    Dermatitis
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    Daily, up to weekly dependant on skin and wound management.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use in any cases of sensitivity or allergy to ingredients
    Rationale for inclusion in formulary
    For treatment of dermatitis and chronic eczema when venous insufficiency is present.
    09.06.01 Vitamin A   Vitamin A 150,000units oral drops
    Vitamin A drops paediatric directorate only (unlicensed)
    09.06.07 Vitamin and mineral supplements Forceval Soluble® Specialist recommendation
    Soluble is a food supplement
    09.06.07 Vitamin and mineral supplements Ketovite® Tablets & Liquid
    09.06.07 Vitamin and mineral supplements Renavit® Dietary management of water-soluble vitamin deficiency in adults with renal failure on dialysis.
    09.06.07 Vitamin and mineral supplements Forceval® Specialist recommendation
    Capsules are a licensed medicine
    09.06.02 Vitamin B Tablets, Compound Strong  Do not use vitamin B compound tablets
    09.06.01 Vitamins A and D  Specialist recommendation
    09.06.07 Vitamins A C and D  Abidec drops (25ml)
    Contains arachis (peanut) oil.
    09.06.07 Vitamins A C and D  Dalivit® drops
    04.03.03 Vortioxetine 
    • In line with NICE
    • Specialist initiation and stabilisation before transfer to Primary Care 
    17.14 Ward Surgical Appliance Co Male Dribbling bag  Order code - WM60
    Usual quantity - May be re-used for at least a month
    02.08.02 Warfarin  First Choice
    BSSE APC preferred agent
    This recommendation must only be taken into account after a patient and prescriber have discussed all treatment options (including warfarin) and only if they have no preference about which medicine they want to use.
    To be initiated by those who have the appropriate skills and experience.
    Use should be in line with local commissioning arrangements - For BCC CCG - Anticoagulation AQP
    Ensure that patients prescribed anticoagulants receive appropriate verbal and written information at the start of therapy, at hospital discharge, on the first anticoagulant clinic appointment, and when necessary throughout the course of their treatment. (NPSA Alert 18)
    09.02.02.01 Water for Injection 
    06.01.06 Wavesense Jazz Duo testing strips  

    Glucose test strips to be used with the Wavesense Jazz Wireless meter

    2 x 25 pack for less frequent users

    06.01.06 Wavesense Jazz testing strips 

    Glucose test strips to be used with the Wavesense Jazz Wireless meter

    17.05 Wellspect Healthcare Lofric Origo Male  Gender - Standard/Male
    Order code - 4431025 - 4431825
    Gauge/CH size - 10 to 18
    Usual quantity - 30 every month (1 pack per month)
    Review period – Every 3 months
    17.05 Wellspect Healthcare Lofric Sense Sterile Polyvinyl  Gender - Female 15cm
    Order code - 4160825 to 4161425
    Gauge/CH size - 8 to 14
    Usual quantity - 30 every month (1 pack per month)
    Review period – Every 3 months
    13.02.01 White Soft Paraffin BP 
    16.05.01 Xupad range  Latex free absorbent dressing pad

    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Low exuding closed surgical wounds only
    Duration dressing remains on wound before changing
    1 – 7 days depending on exudate
    Frequency of dressing change
    1 – 7 days depending on exudate
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not for moderate or highly exuding wounds. Always consider an interactive dressing.
    Not suitable for any wound type except for closed surgical wounds
    Rationale for inclusion in formulary
    Cost effective
    Various sizes available
    12.02.02 Xylometazoline  Short term use only
    Xylometazoline nose drops
    Xylometazoline nasal spray
    14.04 Yellow fever vaccine (Live)  Not NHS Not NHS
    Only available as private prescriptions for travel purposes
    03.03.02 Zafirlukast Accolate® For rare cases where montelukast is inappropriate.
    16.14 ZeroAQS cream  Rationale to support use in the context of wound management
    Emollient cream that occludes and moisturises the skin.
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For external application for use a s an emollient and as a skin cleanser/soap substitute in the management for dry skin conditions.
    Duration dressing remains on wound before changing
    NA
    Frequency of dressing change
    Daily or more frequently if required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or hypersensitivity to any of the ingredients
    Rationale for inclusion in formulary
    Dermatology approved
    Does not contain sodium lauryl sulphate (SLS)
    13.02.01 ZeroAQS®  SLS free
    16.14 Zerobase  Rationale to support use in the context of wound management
    Emollient cream containing liquid paraffin and soft white paraffin, to moisturise dry skin
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Symptomatic treatment of flaking, dry skin, sunburn, dry eczema and dry cases of psoriasis
    Duration dressing remains on wound before changing
    NA
    Frequency of dressing change
    Daily or more frequently if required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or hypersensitivity to any of the ingredients
    Frequency of dressing change
    Dermatology approved
    13.02.01 Zerobase® 
    13.02.01 Zerocream® 
    16.14 Zeroderm cream  Rationale to support use in the context of wound management
    Emollient ointment containing liquid paraffin, to moisturise dry or chapped skin
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    Symptomatic treatment of dry or chapped skin
    Can be used as a pre bathing emollient for dry skin to alleviate drying effects
    Duration dressing remains on wound before changing
    NA
    Frequency of dressing change
    Daily or more frequently if required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or hypersensitivity to any of the ingredients
    Rationale for inclusion in formulary
    Dermatology approved
    16.14 Zeroderm ointment  Rationale to support use in the context of wound management
    Rich emollient ointment containing light liquid paraffin, white soft paraffin and soya bean oil
    To assist the skin in retaining moisture
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For use as a barrier and moisturiser for symptomatic treatment of dermatitis, ichthyosis, eczema and psoriasis
    Can be used as a pre bathing emollient for dry skin to alleviate drying effects
    Duration dressing remains on wound before changing
    NA
    Frequency of dressing change
    Daily or more frequently if required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or hypersensitivity to any of the ingredients
    Rationale for inclusion in formulary
    Dermatology approved
    13.02.01 Zeroderm Ointment® 
    13.02.01 Zeroguent 
    16.01.02 Zetuvit E (sterile and non sterile)  Rationale (developed by TV Team)
    Absorbent cellulose pad with fluid repellent backing
    Type of wound product is suitable for
    Moderate exuding wounds . Secondary dressing.
    Available in non sterile and sterile.
    Only sterile to be used for wound care.
    Duration dressing remains on wound before changing
    1-7 days
    Frequency of dressing change
    Usually 1-2 days or when wet. If using daily consider Zetuvit Plus
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known product or component sensitivity
    Do not cut or tear
    Rationale for inclusion in formulary
    Required for absorbency, for moderately exuding wounds
    Step down from Zetuvit Plus
    16.01.02 Zetuvit PLUS  Rationale (developed by TV Team)
    Super absorbent dressing
    Type of wound product is suitable for
    Moderate to heavily exuding acute and chronic wounds. Secondary dressing only.
    Duration dressing remains on wound before changing
    1-7 days
    Frequency of dressing change
    1-3 days, if changing daily, review if needs more highly absorbent dressing, if lasting 7 days step down to Zetuvit E
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use if sensitivity to dressing or components
    Do not cut or tear
    Rationale for inclusion in formulary
    Moderate to heavily exuding wounds, higher absorbency than Zetuvit E. Cost effective.
    Step down from Zetuvit Plus
    13.02.02 Zinc and Caster Oil Ointment BP  Contains peanut oil
    Barrier cream
    When used in the context of wound management
    Type of wound product is suitable for:
    For relief of the symptoms of nappy rash and as a protective water resistant cream for dry, chapped skin
    Frequency of change
    As required, up to four times daily or at each nappy change.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used on adults in conjunction with containment products for incontinence due to the inclusion of peanut oil in the ingredients, which will repel urine/faeces back onto the skin.
    Any allergy to the listed ingredients
    May mask x-ray images
    Rationale for inclusion in formulary
    Dermatology approved
    16.15 Zinc and castor oil ointment  Barrier cream
    Rationale (developed by TV Team)
    Type of wound product is suitable for
    For relief of the symptoms of nappy rash and as a protective water resistant cream for dry, chapped skin
    Frequency of dressing change
    As required, up to four times daily or at each nappy change.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used on adults in conjunction with containment products for incontinence due to the inclusion of peanut oil in the ingredients, this will repel urine/faeces back onto the skin.
    Any allergy to the listed ingredients
    May mask x-ray images
    Rationale for inclusion in formulary
    Dermatology approved
    13.14.06 Zinc and salicylic acid paste (Lassar’s paste) half-strength  BAD recommended quantity = 100g
    Half-strength Lassar’s paste is used to prevent and treat irritant and/or flexural dermatitis where other barrier preparations such as Metanium® ointment (£2.01) have been ineffective. It has a skin barrier and mild anti-bacterial effect.
    It can be useful when applied to fissures in hand dermatitis or applied with bandages in exudative eczematous conditions.
    09.05.04 Zinc Sulphate 
    06.06.02 Zoledronic Acid 
    04.07.04.01 Zolmitriptan 

    Tablets

    04.01.01 Zolpidem 
    04.08.01 Zonisamide Zonegran® Supported with a ESCA
    MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history
    04.01.01 Zopiclone  Tier 1
    04.02.02 Zuclopenthixol Decanoate Injection (oily) Clopixol® APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion)
    04.02.01 Zuclopenthixol Tablets Clopixol® Supported by ESCA
    NHS Birmingham and Solihull
    Clinical Commissioning Group